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ABSTRACT 
 
Human papillomaviruses (HPV) are double-stranded, DNA, epitheliotropic viruses that infect skin 
and mucosal membranes. Over 200 types of HPV have been identified and classified into alpha (α), beta 
(β), gamma (γ), mu (µ), and nu (ν) genera. HPV in the genus α mainly infect mucosal membranes, cause 
the majority of the ano-genital cancers, and are widely studied. However, epidemiology of HPV in the other 
genera, which mainly infect skin, is poorly understood. Few studies have reported the seroprevalence of 
cutaneous HPV among healthy individuals, and to date, no study has prospectively examined the 
association between cutaneous HPV seropositivity and development of external genital lesions (EGLs) in 
men. The objectives of this study were to estimate the seroprevalence of cutaneous HPV types and 
investigate factors associated with the seropositivity, and evaluate the association between seropositivity to 
cutaneous HPV types and the risk of development of EGLs. Several studies have reported the 
seroprevalence of mucosal HPV types (6, 11, 16 and 18) in the 4-valent HPV vaccine among men. However, 
few studies have reported the seroprevalence of the five additional HPV types (31, 33, 45, 52 and 58) in the 
recently approved 9-valent HPV (9vHPV) vaccine specifically among men across a broad age range. 
Baseline data on seroprevalence prior to vaccine introduction and dissemination are needed to establish the 
effectiveness of vaccines over time. Also, this study estimated the seroprevalence of 9vHPV vaccine types 
and investigated factors associated with the seropositivity among men residing in Brazil, Mexico, and the 
United States (U.S.). 
To estimate the seroprevalence of cutaneous HPV types and 9vHPV vaccine types, 600 men were 
randomly selected from the HPV Infection in Men (HIM) Study. To examine the association between 
seropositivity to cutaneous HPV types and development of EGLs, a case-control study of 163 incident EGL 
cases and 352 EGL-free controls nested in the HIM cohort was conducted. Cases were ascertained through 
visual inspection at each of up to 10 biannual clinical visits, confirmed through biopsy, and categorized into 
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condyloma, suggestive of condyloma, penile intraepithelial neoplasia (PeIN) and other EGLs. Archived 
serum specimens were tested for antibodies against 14 cutaneous HPV types, β types (5, 8, 12, 14, 17, 22, 
23, 24, 38 and 47), α type 27, γ type 4, µ type1 and ν type 41, and 9vHP types (6, 11, 16, 18, 31, 33, 45, 52 
and 58) using a glutathione S-transferase (GST) L1-based multiplex serology assay. Socio-demographic 
and sexual behavior data were collected through a questionnaire. Binomial proportions were used to 
estimate seroprevalence, and logistic regression was used to examine factors associated with seropositivity. 
Overall, seroprevalence of ≥1 cutaneous HPV types was 65.4%, 1≥ β-HPV types was 39.0%, α-
HPV 27 was 8.9%, γ-HPV 4 was 30.9%, µ-HPV 1 was 28.6%, and ν-HPV 41was 9.4%. Higher educational 
attainment was significantly associated with seropositivity to ≥1 cutaneous HPV types (adjusted odds ratio 
[AOR] 1.75 for ≥16 years of education vs. ≤12 years of education, 95% confidence interval [CI] 1.08-2.83), 
and seropositivity of ≥1 β-HPV types was significantly associated with increasing age (AOR 1.72 for men 
aged 31-44 years vs. men aged 18-30 years, 95% CI: 1.12–2.63,). Country of residence, circumcision status, 
and lifetime number of male anal sex partners were other factors significantly associated with various type-
specific cutaneous HPV seropositivity. No statistically significant association was observed between 
grouped or individual cutaneous HPV seropositivity and the risk of development of EGLs across all 
pathological diagnoses. The seroprevalence of grouped and individual cutaneous HPV types was similar 
across different EGL categories and controls, with the most frequent types being ɤ-HPV 4, µ-HPV 1, and 
β-HPV 8. The seroprevalence of ≥1 9vHPV vaccine types was 28.3%, ≥1 high-risk types was 14.0%, five 
additional high-risk types was 11.2%, and low-risk types (6/11) was 17.4%. Compared to men with no male 
anal sex partners, men with ≥2 partners were two times more likely to be seropositive for grouped 9vHPV 
vaccine types, ≥1 high-risk types and ≥1 low-risk types, in addition to individual HPV types 6, 16, 33, and 
58, with AORs ranging from 2.19 to 7.36. Older age, current smoking, and being single were other factors 
significantly positively associated with different grouped and type-specific seropositivity. 
In conclusion, our data show that exposure to cutaneous HPV was common in men although 
different risk factors were independently associated with grouped and type-specific cutaneous HPV 
seropositivity. It appears that exposure to cutaneous HPV is not likely to increase the risk of EGLs among 
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men. Similarly, exposure to 9vHPV vaccine types was also common in men and seropositivity to 9vHPV 
vaccine types was positively associated with older age and lifetime number male anal sex partners. 
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CHAPTER ONE: 
 
INTRODUCTION 
 
Human papillomavirus (HPV) is one of the most common sexually transmitted infections 
worldwide.1 In the U.S., the annual direct medical cost associated with the treatment and prevention of HPV 
related diseases is estimated at $5 billion.2 Nearly all sexually active adults will get HPV at some point in 
their lives.3,4 The prevalence of HPV among women differs markedly across different countries and 
populations. For example, one multinational study reported an age-adjusted prevalence of overall HPV 
infection of 1.5% in Spain and 25.6% in Nigeria.5 The prevalence of HPV among men also varies from 
1.3% to 72.9% in different areas of the world.6 Although the human body clears most of the HPV infections 
without causing any clinical manifestations, a small proportion of HPV infections with certain types such 
as HPV 16 and 18 can persist and cause benign and malignant diseases such as genital warts and cancers.4 
To date, more than 200 types of HPV have been identified and fully sequenced and the majority of 
these types are placed into three genera, alpha (α) predominantly found on mucosal surfaces, beta (β) and 
gamma (γ) which are found on skin and in hair follicles.7-9 Over 40 types of HPV can infect cervix, linings 
of the vagina, vulva, penis, anus, rectum, mouth, throat, and other cutaneous epithelium.10,11 Often HPV are 
classified into low-risk and high-risk based on their potential for causing cancer.3,10 The International 
Agency for Research on Cancer (IARC) has categorized 13 types of HPV as carcinogens.11 Nearly all 
cervical cancers are caused by the high-risk HPV, specifically types 16 and 18, and nearly all genital warts 
are caused by low-risk HPV, specifically HPV types 6 and 11.4,11  
Emerging evidence shows that cutaneous HPV infection may increase the risk for squamous cell 
carcinoma (SCC) of the skin.12-14 Each year about 3.5 million new cases of basal cell carcinoma (BCC) and 
SCC of the skin are diagnosed in the U.S.,15 costing approximately half a billion in medical costs.15-17 
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Several studies have reported a positive association between anti cutaneous HPV serum antibodies and the 
risk of skin cancer.12,18-20 Commonly reported types of HPV that infect skin cells are from beta (β), gamma 
(γ), mu (µ) and nu (ν) genera.8 While the exact mechanism of the cutaneous HPV and SCC association is 
not clear, it is hypothesized that cutaneous HPV infection might modify the effect of ultra-violet (UV)-
induced DNA damage, leading to apoptosis, accumulation of mutations, and eventually to SCC.19  
Cutaneous HPV DNA has also been detected on the surfaces of penile intraepithelial neoplasia 
(PeIN),21,22 penile cancer,23,24 genital warts, other EGLs on UV-unexposed skin,25 and on cutaneous warts.26 
Two hospital-based case-control studies reported the presence of cutaneous HPV types in nearly all PeIN 
cases.21,22 PeIN are precursors of penile cancer.27 Less prevalent in the U.S.,28 penile carcinoma constitutes 
up to 10% of all cancers among men in the developing world,29 and its incidence is on the rise in some 
European countries.30-32 Although benign, genital warts (condyloma acuminata) are highly contagious and 
cause considerable amount of psychological discomfort and treatment related burden to patients. Both 
genital warts and PeIN (low and high-grade) are associated with an increased risk for carcinoma of the 
penis.33,34  
The emerging role of cutaneous HPV in the etiology of SCC of the skin and the detection of β-
cutaneous HPV in EGLs, strongly suggest a role for cutaneous HPV in the carcinogenesis of squamous 
epithelium both in the UV exposed and unexposed areas of the body. However, little data exist on the 
epidemiology and serology of cutaneous HPV, and their etiologic role in the development of SCC of the 
skin, EGLs, and penile cancer. HPV related lesions on male genitalia create reservoirs of infection and 
facilitate HPV transmission from men to women. Therefore, understanding the epidemiology of HPV 
infection among men is not only important for prevention of HPV related diseases in men, but also equally 
important in reducing the transmission of HPV infection from men to women.  
In the U.S., the bivalent and 4-valent HPV vaccines are recommended for routine vaccination for 
girls at age 11 or 12 years, females age 13 through 26 years, and males age 13 through 21 years if they have 
not received the vaccine before.35 Recently, the Advisory Committee on Immunization Practices (ACIP) 
added 9-valent HPV (9vHPV) vaccine to its recommendations.36 Information on the epidemiology and 
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serology of HPV infections among men is needed for vaccine recommendations in other countries, 
monitoring the effectiveness of vaccines over time, and strategic planning for immunizations of high-risk 
groups. Although a number of studies have reported the seroprevalence of HPV types (6, 11, 16 and 18) 
among men in different countries,37-42 few studies have examined other HPV types (i.e. 31, 33, 45, 52 and 
58) in 9vHPV vaccine among men across the entire adult lifespan and old age.  
 
SPECIFIC AIMS  
The goal of this research was to estimate exposure to a wide array of cutaneous HPV and 9vHPV 
vaccine types in a large multinational cohort of men from three countries (Brazil, Mexico, and the U.S.) 
and to explore the etiologic role of cutaneous HPV types independently and jointly with mucosal HPV in 
the development of EGLs. The specific aims of this research were: 
1) To estimate the seroprevalence of cutaneous HPV types in a sub-cohort of 600 men selected 
randomly from the HPV infection in men (HIM) Study participants at baseline and to investigate 
factors associated with the seropositivity.  
2) To examine the association between seropositivity to cutaneous HPV types and the risk for 
subsequent development of EGLs and assess for interaction by serostatus to 9vHPV vaccine types 
in a case- control study nested in the HIM cohort. 
3) To estimate the seroprevalence of 9vHPV vaccine types in a sub-cohort of 600 men selected 
randomly from the HIM Study participants at baseline and investigate factors associated with the 
seropositivity.  
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CHAPTER TWO: 
 
MANUSCRIPT 1: SEROPREVALENCE OF CUTANEOUS HUMAN PAPILLOMAVIRUSES 
(HPV) AMONG MEN IN THE MULTINATIONAL HIM STUDY 
 
ABSTRACT 
Little is known about the seroprevalence of cutaneous HPV infection and associated factors among 
men. Data on cutaneous HPV seroprevalence is primarily derived from skin cancer case-controls studies. 
Few studies have reported the seroprevalence of cutaneous HPV among healthy individuals. This study 
investigated the seroprevalence of cutaneous HPV types and associated factors among men residing in 
Brazil, Mexico, and the U.S. Six hundred men were randomly selected from the HPV Infection in Men 
(HIM) Study. Archived serum specimens collected at enrollment were tested for antibodies against 14 
cutaneous HPV types, β-HPV types (5, 8, 12, 14, 17, 22, 23, 24, 38 and 48), α-HPV 27, γ-HPV 4, µ-HPV1, 
ν-HPV 41 using a GST L1-based multiplex serology assay. Socio-demographic and sexual behavior data 
were collected by a questionnaire. Binomial proportions were used to estimate seroprevalence, and logistic 
regression was used to examine factors associated with seropositivity.  
Overall, 65.4% of men were seropositive to ≥1 of the 14 cutaneous HPV types, and 39.0% were 
seropositive for ≥1 β-HPV types. Seroprevalence was 8.9%, 30.9%, 28.6%, and 9.4% for α-HPV 27, γ-
HPV 4, µ-HPV 1, and ν-HPV 41, respectively. In multivariate analyses, seropositivity of any cutaneous 
HPV type was associated with higher education (adjusted odds ratio [AOR] 1.75; 95% CI: 1.08–2.83), and 
seropositivity of any β-HPV type was significantly associated with increasing age (AOR 1.72; 95% CI: 
1.12– 2.63, for men aged 31-44 years vs. aged 18-30 years). Other factors associated with various type-
specific cutaneous HPV seropositivity included country, circumcision, and lifetime number of male sexual 
partners. In conclusion, these data indicate that exposure to cutaneous HPV is common. Different risk 
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factors were independently associated with grouped and type-specific seropositivity. Future studies are 
needed to assess associations between seropositivity to cutaneous HPV types and the development of 
genital lesions among men.  
 
INTRODUCTION 
Human papillomavirus (HPV) is a non-enveloped double-stranded DNA virus that infects epithelial 
cells of the skin and mucus membranes.43 HPV is one of the most common sexually transmitted infections 
(STIs) worldwide, and nearly all sexually active men and women acquire HPV at some point in their lives.44 
HPV infection can cause a wide range of benign and malignant diseases, such as anogenital warts, recurrent 
respiratory papillomatosis, and cancers of the cervix, anal canal, penis, and a subset of head and neck 
cancers.45,46 To date, more than 200 types of HPV have been recognized and fully sequenced, and the 
majority of these types fall within three genera: alpha (α), predominantly found on mucosal surfaces, and 
beta (β) and gamma (γ), which are commonly found on skin and in hair follicles.7,8  
Mucosal HPV types have been studied extensively with respect to their etiologic role in the 
development of genital warts45,47 and several cancers.14,46  However, emerging evidence suggests that 
cutaneous HPV infection may increase the risk for squamous cell carcinoma (SCC) of the skin.19,20,48-50 
Several studies have reported associations between cutaneous HPV serum antibodies and higher risk for 
SCC.18-20,51 Commonly reported HPV types that infect cutaneous skin cells are from the, β, γ, µ, and ν 
genera.8 While the exact mechanism of the cutaneous HPV and SCC association is unclear, it is 
hypothesized that cutaneous HPV infection might modify the effect of UV-induced DNA damage and 
apoptosis, leading to accumulation of mutations and SCC.19  Furthermore, cutaneous HPV types have also 
been detected on the surface of external genital lesions25 and penile cancer precursors in non-UV-exposed 
regions of the genital skin. Two hospital-based case-control studies have reported the presence of cutaneous 
HPV types in nearly all penile intraepithelial neoplasia (PeIN) cases.21,22  
Despite its potential role in the development of SCC and PeIN, very little is known about the 
seroprevalence, associated factors, and natural history of cutaneous HPV infection among men. Previously, 
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we reported cutaneous HPV DNA prevalence detected on eyebrow hairs and skin swabs among U.S. men 
from the HIM Study.52 The objective of the current study was to estimate the seroprevalence of cutaneous 
HPV types, including β (types 5, 8, 12, 14, 17, 22, 23, 24, 38 and 47), α (type 27), γ (type 4), µ (type 1), 
and ν (type 41) in a sub-cohort of healthy men from the HIM Study and to investigate factors associated 
with cutaneous HPV seropositivity.  
 
METHODS 
 
Study Population 
This study included a sub-cohort of 600 men randomly selected from the HIM Study, a prospective 
cohort of the natural history of HPV infections in men. Simple random sampling method was used to select 
the sub-cohort because performing serology testing for the entire parent cohort was not viable and cost-
effective. The HIM Study population and methods have been described previously53,54 and a detailed 
description of the study population and recruitment strategies is also given in Appendix A1.7. Briefly, 
between July 2005 and September 2009, the HIM Study enrolled over 4000 men in the U.S., Brazil, and 
Mexico. Participants were eligible if they were: male, aged 18-70 years at baseline, and reported no previous 
diagnosis of penile or anal cancer, no previous diagnoses of anogenital warts, no current history or treatment 
for sexually transmitted infections including HIV, and no current discharges from the penis or burning 
sensation during urination. Participants were followed every six months for a median of four years of 
follow-up. At each study visit, participants completed a computer-assisted self-interviewed questionnaire 
(CASI), provided urine and blood samples, and underwent a clinical examination. A total of 3,695 HIM 
Study participants who provided a serum sample and completed the questionnaire at baseline were eligible 
for the current study.  The study was approved by the Institutional Review Boards of the University of 
South Florida (Tampa, FL, U.S.), the Ludwig Institute for Cancer Research (Sao Paulo, Brazil), the Centro 
de Referencia e Treinamento em Doencas Sexualmente Transmissiveis e AIDS (Sao Paulo, Brazil), and the 
Instituto Nacional de Salud Publica de Mexico (Cuernavaca, Mexico).  
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Specimens and Data Collection 
At the baseline visit, HIM Study participants provided detailed information on demographics (age, 
race, ethnicity, education, and marital status), socioeconomic status, medical history, smoking habits, 
alcohol consumption, and sexual history. Archived baseline serum samples from 600 participants were 
tested for seroreactivity to the L1 protein of 14 cutaneous HPV types, including β-types (5, 8, 12, 14, 17, 
22, 23, 24, 38 and 47), α-type 27, γ-type 4, µ-type 1, and ν-type 41. Only 14 types were tested due to limited 
funds, and were carefully selected based on previous reports of their association with cutaneous SCC19,48 
and their detection on the surface of EGLs.25 The antibody detection method was based on a glutathione S-
transferase (GST) capture enzyme-linked immunosorbent assay (ELISA), in combination with fluorescent 
bead technology previously described.55,56 To define type-specific HPV seropositivity, cut-off values (200 
median fluorescence intensity [MFI] units) were applied, as previously described,57,58 to allow for direct 
comparison with other studies using the same serologic assay.57,58 Serology results for two subjects were 
inadequate and were therefore excluded from analysis, resulting in a final sample size of 598 men. 
 
Statistical Analysis  
Baseline participant characteristics, including demographic, lifestyle, and sexual behavior factors 
were compared between participants from Brazil, Mexico, and the U.S. using the Chi-square and Fisher 
exact tests for categorical variables (Table 2.1). Participants in the randomly selected sub-cohort (n=600) 
were also compared to the full HIM cohort (>4,000 men) on all baseline socio-demographic and sexual 
behavioral characteristics listed in Table 2.1. Seropositivity to any cutaneous HPV (any HPV) was defined 
as the proportion of men who were seropositive to at least one of the 14 types of HPV included in this study, 
and seropositivity to any β-HPV was defined as the proportion of men who were seropositive to at least one 
of the 10 β-HPV types. Type-specific and grouped seroprevalence was calculated for the overall study 
population and by country. Holms-Bonferroni correction of p-values was used to account for multiple 
comparisons.59 Seropositivity to one, two, and three or more of the 14 cutaneous types was also estimated. 
To assess factors associated with seroprevalence of type-specific, any β-HPV, and any HPV in univariate 
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analyses, logistic regression was used to estimate odds ratios (ORs) and their 95% confidence intervals 
(CI). As seroprevalence was low (<10%) for some HPV types, type-specific logistic regression models 
were reported only for those types with seroprevalence of 10% or higher.  To assess factors associated with 
cutaneous HPV seroprevalence, a number of factors listed in Table 1 were considered in modeling 
associations with any HPV and any β-HPV seroprevalence in multivariate models. A backward stepwise 
elimination logistic regression procedure was conducted, using significance at p≤0.1 for retention. Country 
and age were forced into the model due to study design. The final multivariable model included country, 
age, race, education, circumcision, number of lifetime female sex partners, and number of lifetime male sex 
partners. Using these adjustment factors, separate multivariable models were estimated for seroprevalence 
to any HPV, any β-HPV, and type-specific HPV. All analyses were performed using SAS 9.3. 
 
RESULTS 
Significant differences in socio-demographic and behavioral characteristics were observed by 
country for all listed variables (p-values < 0.05) except the number of male anal sex partners in the past six 
months among those reporting ever having had a male sex partner (Table 2.1). Participants in the randomly 
selected sub-cohort (n=600) were similar (p>0.05) to the full HIM cohort (>4,000 men) on all baseline 
socio-demographic and sexual behavioral characteristics (Table A2.1 in Appendices). 
Overall, 65.4% participants were seropositive to one or more cutaneous HPV types (Table 2.1).  
Seroprevalence was 39.0% for at least one β-cutaneous HPV type, 8.9% for α-cutaneous type 27, 30.9% 
for γ-HPV type 4, 28.6% for µ-HPV type 1, and 9.4% for ν-HPV type 41 (Table 2.1, and Figures A2.1-2.4 
in Appendices). The highest overall type-specific seroprevalence was observed for γ-HPV type 4 (30.9%), 
µ-HPV type 1 (28.6%) and β-HPV type 8 (20.4%). No significant difference (p-value=0.140) in the 
seroprevalence of any HPV was observed by country (Brazil [70.0%], U.S. [65.4%], and Mexico [60.7%]). 
Significant differences in cutaneous HPV seroprevalence by country were observed for any-β HPV, as well 
as for each HPV type-specific seroprevalence listed, with the exceptions of HPV 27 and HPV 41 (Table 
2.1). Using the Holm-Bonferroni method, we observed significantly higher grouped β–HPV seroprevalence 
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among men in Brazil compared to Mexico (p-value<0.001). Table A2.2 in Appendices shows Wald’s 95% 
confidence intervals for the seroprevalence estimates.  
Figure 2.1 and 2.2 shows seropositivity to multiple HPV types. Averaged across all three countries, 
approximately 21.2% of men had antibodies to ≥3 HPV types, 14.4% to two HPV types, 29.8% to only one 
HPV type and 34.6% did not have antibodies against any type. Seropositivity to multiple HPV infections 
was statistically different by country (overall p-value<0.001) and remained significant after adjusting for 
multiple comparisons (p<0.05). Men in Brazil were more likely to be seropositive to ≥3 HPV types (34.0%) 
compared to men from the U.S. (22.3%) and Mexico (8.4%). 
Factors associated with seroprevalence of cutaneous HPV types (any-HPV, any β-HPV, ɤ-HPV4, 
µ-HPV, β-HPV 8, β-HPV17, β-HPV 23, β-HPV 38, and β-HPV 47) are presented in Tables 2.3, Table 2.4, 
and for HPV types with <10% seroprevalence in Table A2.3 in Appendices. In the multivariate model, 
adjusting for all variables listed in Table 2.3, country was significantly associated with seropositivity of β-
HPV 47 (AOR 2.67; 95% CI: 1.19 - 5.99), with men from Brazil more likely to be seropositive compared 
to men from the U.S. Compared to the youngest age group (18-30 years), mid-adult aged men (31-44 years) 
were significantly more likely to be seropositive for any-β HPV (AOR 1.72; 95% CI: 1.12 - 2.63), β-HPV 
8 (AOR 2.28; 95% CI: 1.33 - 3.91), β-HPV 38 (AOR 2.01; 95% CI 1.09 - 3.72), and β-HPV 47 (AOR 2.00; 
95% CI: 1.03 - 3.88), and men in the oldest age group (45-73 years) were more likely to be seropositive for 
β-HPV 8 and β-HPV 47. Higher educational attainment was significantly associated with any-HPV (AOR 
1.75 for ≥16 years of education compared to ≤ 12 years of education, 95% CI: 1.08 - 2.83) and ɤ-HPV 4 
(AOR 1.77 for ≥16 years of education compared to ≤ 12 years of education, 95% CI: 1.10 - 2.82). 
Circumcised men were more likely to be seropositive for ɤ-HPV 4 (AOR 1.72; 95%CI: 1.02 - 2.89) and β-
HPV 47 (AOR 2.37; 95%CI: 1.21 - 4.67). Similarly, having ≥ 2 lifetime male sex partners was significantly 
independently associated with seropositivity of β-HPV 17 (AOR 2.22; 95% CI: 1.06 - 4.62) and β-HPV 23 
(AOR 2.39; 95% CI: 1.07 - 5.33).  
Figure 2.3 summarizes the results of multivariate analyses for any HPV, any β-HPV, and individual 
HPV types. Men from Brazil were consistently more likely than men from the U.S. to be seropositive to 
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cutaneous HPV types. Mid-adult and older aged men (31-44 and 45-73 years), men with ≥16 years of 
education, circumcised men, and men with ≥2 lifetime male sex partners were more likely to be seropositive 
to cutaneous HPV.  
 
DISCUSSION 
This is the first study to estimate cutaneous HPV seroprevalence in a healthy population of men 
from three countries. We reported seroprevalence of 14 cutaneous HPV types and factors associated with 
grouped and individual HPV seroprevalence in 600 men from the HIM Study residing in the U.S., Mexico 
and Brazil. More than 65% of men were seropositive for one or more cutaneous HPV infection types, and 
more than 39% to one or more beta HPV types. Elevated risk of cutaneous HPV seropositivity was observed 
among men who were mid-adult and older ages, from Brazil, attained ≥16 years of education, circumcised, 
and reported ≥ 2 lifetime male sex partners.  
Previous to our population-based study, other estimates of cutaneous HPV seroprevalence were 
available only from control series of case-control studies of skin cancer. Due to differences in populations 
studied, age distribution, and the number of HPV types assessed, a direct comparison to the published 
literature is not possible. A cross-sectional study60 of cutaneous HPV seroprevalence among men and 
women undergoing a routine skin cancer screening in Tampa, Florida reported an overall seroprevalence 
for any HPV of 96.0% and 76.0% for any β HPV in men, which is higher than what we observed at 65.4% 
and 39.0%, respectively. Differences between this  and the cross-sectional study60 may be due to older age 
of the study population in  the cross-sectional study , recruited from a skin cancer screening clinic, and that 
analysis of the overall seroprevalence included 36 types of HPV compared to 14 types in our study. Type-
specific seroprevalence estimates in the cross-sectional study60 were also slightly higher for γ-HPV 4 
(46.0% vs. 39.0% in our study), µ-HPV 1 (37.0% vs. 28.6% in our study), and ν-HPV 41 (14.0% vs. 9.4% 
in our study).  The ubiquity of the cutaneous HPV suggests that cutaneous HPV might be a commensal 
component of the microbiological flora of the skin.61,62 One case-control study of SCC18 from Sweden and 
Austria reported seroprevalence estimates for controls that were comparable to those in our study for any 
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β-HPV (42.0%) and slightly higher seroprevalence estimates for type-specific HPV; however, the study 
population in that case-control study was older, and the number of β-HPV tested were 8 compared to 10 in 
our study. Some of the type-specific seroprevalence estimates in our study were also comparable with 
seroprevalence estimates reported from the control group of a systematic review63 of 15 studies examining 
the associations between cutaneous HPV and skin cancer, β-HPV 8 (22.8% vs. 20.4% in our study), β-HPV 
23 (12.4% vs. 12.2%), α-HPV 27 (12.5% vs. 8.9), γ-HPV 4 (33.7% vs. 30.9%), µ-HPV 1 (27.1% vs. 28.6%), 
and ν-HPV 41 (11.8% vs.9.4%) respectively.  
The increase in seroprevalence with increasing age observed in our study is consistent with studies 
of cutaneous HPV DNA detection conducted in the general population.64,65 Boxman and colleagues64 found  
strong associations between increasing age and cutaneous HPV DNA prevalence in the general population, 
with 29% DNA prevalence of any cutaneous HPV among 25-39-year-olds, 42% in 40-59-year-olds, and 
65% in 60-79-year-olds. A study by De-Koning et al.65 demonstrated a marginally significant association 
between increasing age and DNA prevalence of grouped beta HPV in the general population in Italy and 
Australia. However, neither study assessed associations between age and individual HPV types. 
Furthermore, few skin cancer case-control studies have assessed factors associated with cutaneous HPV 
seroprevalence in controls. Stujik et al. and Hampras et al. reported a significant association between 
increasing age and cutaneous HPV DNA prevalence.12,52 However, Iannacone and colleagues did not report 
an association between age and seropositivity to cutaneous HPV.60 In multiple studies of mucosal HPV 
seroprevalence, seroprevalence has been shown to increase significantly with age.39  
Cutaneous HPV seroprevalence in the current study also varied across geographical regions, with 
men in Brazil having the highest seroprevalence and men in Mexico the lowest for certain β HPV types. 
This is consistent with our previous findings where we reported higher seroprevalence among Brazilian 
men for mucosal HPV genotypes.39 Other multi-center studies have also reported geographic variation of 
cutaneous HPV DNA prevalence.7,65,66 It is possible that the observed geographical variation is reflective 
of the differences in individual immune response, environmental factors, sexual behaviors, and other 
unobserved factors. The observed difference in our study is unlikely due to specimen collection or antibody 
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testing techniques as study protocols were uniformly applied across the three study centers, and the serum 
specimens were tested using the same assay in a single laboratory.  
A pattern of elevated risk of cutaneous HPV seroprevalence among circumcised men was observed, 
specifically for γ-HPV 4, and β types 5, 14, 24 and 47.  To our knowledge this is the first study to compare 
seroprevalence of cutaneous HPV between circumcised and uncircumcised men. In a previous study of the 
HIM study population, Sichero et al. did not find cutaneous HPV DNA to be associated with circumcision.7 
Similarly, Albero et al. did not find an association between circumcision and DNA prevalence of any 
mucosal HPV, oncogenic HPV, and unclassified HPV types, but found a weak inverse association for non-
oncogenic HPV types.67 However, Lu et al. reported an association between seroprevalence of mucosal 
HPV type 11 and circumcision with lower seroprevalence among circumcised men.39 These findings 
suggest that the role of circumcision and HPV prevalence is complex and may depend on HPV type 
(cutaneous or mucosal), anatomic site of infection, and whether prevalence is based on DNA detection or 
antibody response. Although the inverse association of circumcision with mucosal HPV prevalence has 
been reported in other populations,68,69 the role of circumcision and cutaneous HPV prevalence is largely 
unknown. One possible explanation for this positive association could be the keratinization of the glans 
penis after circumcision. At birth, the glans is covered by the foreskin or prepuce, which is often removed 
from infants by circumcision.70 The glans is non-keratinized before circumcision and becomes keratinized 
after circumcision.70,71 In contrast to mucosal HPV, cutaneous HPV mainly infect skin and keratinized 
epithelium. Alternatively, it is also possible that circumcised penile tissues might have different 
immunogenic response to HPV than uncircumcised penile tissues. However, men in Brazil were mostly 
uncircumcised but had higher seroprevalence estimates. Cutaneous HPV DNA has been commonly detected 
on the normal skin,65 skin tumors,72 oral cavity,73 and anogenital tract.7 Given that the vast majority of 
studies have examined cutaneous HPV from non-genital anatomic sites, other modes of transmission 
besides skin to skin contact, might warrant further investigations.  
Education was significantly associated with any HPV, γ-HPV type 4, and β-HPV type 24. Men 
with higher education were more likely to be seropositive, an association also observed in the study of 
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Farzan et al. for some types of cutaneous HPV74 and in the study of Molano et al. for mucosal HPV types.75 
It is likely that education functions as a marker of lifestyle characteristics that may influence cutaneous 
HPV acquisition and natural history. It is possible that men with higher education have more opportunities 
for meeting new partners76 and increased skin to skin contact, which could result in a higher level of 
exposure to HPV. Seroprevalence to beta types 17, 23 and 24 were positively associated with the number 
of lifetime male sexual partners. This finding is consistent with previous studies of mucosal HPV,39,77,78 and 
could be explained that a higher number of sexual partners increases the probability of viral exposure, 
transmission, and risk of infection.  
The major strengths of this study are its large sample size, estimation of prevalence based on 
antibodies against L1 HPV capsid protein in a single laboratory simultaneously by multiplex serology, and 
the availability of detailed demographic and sexual behavior data. We also acknowledge some limitations. 
Considering the cross-sectional nature of current study, causal associations could not be determined. 
Another limitation is that measurement of antibodies against L1 viral protein do not necessarily represent 
current infection with HPV. Furthermore, due to lack of information of the serodynamics of cutaneous 
HPV, the impact of seroconversion, clearance of infections, and waning of antibodies with time could not 
be assessed; however, these are limitations inherent to all seroprevalence studies. Despite its limitations, 
the current study provides important data and contributes to the understanding of the distribution and 
associated factors of cutaneous HPV, which is largely unknown. 
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Table 2.1. Participant characteristics by country of residence (the U.S. Brazil, Mexico) 
Characteristic 
  Country  
Overall 
(N=598) 
U.S. 
(N=184) 
Brazil 
(N=200) 
Mexico 
(N=214) 
 
n % n % n % n % pa 
Age, Years          
  18-30 259 43.3 113 61.4 74 37.0 72 33.6 <.001 
  31-44 256 42.8 50 27.2 99 49.5 107 50.0  
  45-70 83 13.9 21 11.4 27 13.5 35 16.4  
Race          
  White                            269 45.0 111 60.3 146 73.0 12 5.6 <.001 
  Black                            78 13.0 40 21.7 38 19.0 0 0.0  
  Asian                            17 2.8 15 8.2 2 1.0 0 0.0  
  American Indian/Alaska Native    9 1.5 0 0.0 9 4.5 0 0.0  
  Other                            218 36.5 17 9.2 4 2.0 197 92.1  
  Not reported                     7 1.2 1 0.5 1 0.5 5 2.3  
Ethnicity          
  Hispanic     282 47.2 22 12.0 49 24.5 211 98.6 <.001 
  Non-Hispanic 305 51.0 162 88.0 143 71.5 0 0.0  
  Not reported 11 1.8 0 0.0 8 4.0 3 1.4  
Education, Years          
  ≤12        287 48.0 44 23.9 112 56.0 131 61.2 <.001 
  13-15        159 26.6 94 51.1 45 22.5 20 9.3  
  ≥16        149 24.9 45 24.5 43 21.5 61 28.5  
  Not reported 3 0.5 1 0.5 0 0.0 2 0.9  
Marital Status          
  Single/never married       259 43.3 125 67.9 89 44.5 45 21.0 <.001 
  Married/cohabitating       278 46.5 37 20.1 84 42.0 157 73.4  
  Divorced/separated/widowed 58 9.7 21 11.4 25 12.5 12 5.6  
  Not reported               3 0.5 1 0.5 2 1.0 0 0.0  
Smoking Status          
  Never   339 56.7 111 60.3 129 64.5 99 46.3 0.003 
  Former  113 18.9 30 16.3 32 16.0 51 23.8  
  Current 146 24.4 43 23.4 39 19.5 64 29.9  
Alcohol, No. Drinks/Month          
  0           141 23.6 29 15.8 55 27.5 57 26.6 0.016 
  1–30        279 46.7 82 44.6 89 44.5 108 50.5  
  31-60       58 9.7 22 12.0 18 9.0 18 8.4  
  ≥61        110 18.4 48 26.1 34 17.0 28 13.1  
 Not reported 10 1.7 3 1.6 4 2.0 3 1.4  
Circumcision          
  No  389 65.1 32 17.4 165 82.5 192 89.7 <.001 
  Yes 209 34.9 152 82.6 35 17.5 22 10.3  
Sexual Orientationb          
  MSW          524 87.6 167 90.8 154 77.0 203 94.9 <.001 
  MSM          51 8.5 6 3.3 37 18.5 8 3.7  
  MSWM         15 2.5 4 2.2 9 4.5 2 0.9  
Missing 8 1.3 7 3.8 0 0.0 1 0.5  
No. of Female LTPc          
  0           60 10.0 29 15.8 15 7.5 16 7.5 <.001 
  1-3         126 21.1 42 22.8 26 13.0 58 27.1  
  4-18        246 41.1 63 34.2 74 37.0 109 50.9  
  >=19        126 21.1 41 22.3 65 32.5 20 9.3  
 Not reported 40 6.7 9 4.9 20 10.0 11 5.1  
No. of Male Anal LTPc          
  0            507 84.8 176 95.7 135 67.5 196 91.6 <.001 
  1            28 4.7 1 0.5 17 8.5 10 4.7  
  2 or more    58 9.7 7 3.8 43 21.5 8 3.7  
  Not reported 5 0.8 0 0.0 5 2.5 0 0.0  
No. of female sex partners in the past 6 monthsd           
  0            115 21.4 26 16.8 34 18.4 55 27.8 <.001 
  1            241 44.8 80 51.6 74 40.0 87 43.9  
  ≥2          162 30.1 49 31.6 72 38.9 41 20.7  
  Not reported 20 3.7 0 0.0 5 7.6 15 7.6  
(Continued on next page) 
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Table 2.1. (Continued) 
   Country  
Characteristic 
Overall  
(598) 
U.S. 
(N=184) 
Brazil 
(N=200) 
Mexico 
(N=214) 
 
 n % n % n % n % pa 
No. of male sex partners in the past 6 monthsd           
  0             55 60.4 2 25.0 39 60.0 14 77.8 0.133 
  1             13 14.3 2 25.0 9 13.9 2 11.1  
  ≥2           21 23.1 4 50.0 16 24.6 1 5.6  
   Not reported 2 2.2 0 0.0 1 1.5 1 5.6  
a. Chi-square and Fisher’s exact tests were used to calculate p values. 
b. MSW=men having sex with women, MSM=men having sex with men, MSWM=men having sex with women and men. 
c. LTP = Life time partners  
d. Among those reporting ever having a female sex partner 
Note: Significant p-value highlighted  in bold 
 
 
 
 
Table 2.2. Type-specific cutaneous HPV seroprevalence among men residing in the U.S., Brazil, and Mexicoa,b    
Type of HPV 
Overall (N=598) U.S. (n=184) Brazil (n=200) Mexico (n=214) 
Seroprevalence  % Seroprevalence  % Seroprevalence  % Seroprevalence  % 
Any HPV 65.4 65.8 70.0 60.7 
Any β 39.0 39.1 48.5 29.9 
β-HPV 5 7.7 6.5 15.0 1.9 
β-HPV 8 20.4 21.2 29.5 11.2 
β-HPV 12 6.0 3.3 13.0 1.9 
β-HPV 14 5.7 3.8 11.0 2.3 
β-HPV 17 13.0 10.9 19.5 8.9 
β-HPV 22 6.9 6.5 11.0 3.3 
β-HPV 23 12.2 12.0 19.5 5.6 
β-HPV 24 7.7 7.1 12.5 3.7 
β-HPV 38 13.9 14.1 21.0 7.0 
β-HPV 47 12.4 13.0 16.5 7.9 
α-HPV 27 8.9 9.2 11.5 6.1 
γ-HPV 4 30.9 33.2 37.5 22.9 
µ-HPV 1 28.6 37.5 34.5 15.4 
ν-HPV 41 9.4 7.6 12.0 8.4 
a. 600 subjects were randomly selected at baseline from the HIM Study to participate in the cutaneous HPV seroprevalence study. 
Seroprevalence data for 2 subjects were not available; therefore, they were excluded from analysis. 
b. Chi-square and fisher exact tests were used to calculate p-values; Except Any-HPV, α-HPV 27, and ν-HPV 41, all other HPV types differ 
by country (p-value <0.05) 
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Table 2.3. Factors independently associated with any cutaneous HPV, β, γ, and µ HPV seroprevalence among men residing in the U.S., Brazil and Mexicoa 
Characteristics 
Any-HPVb Any β-HPVb γ-HPV 4 µ-HPV 1 
OR AOR (95%CI) OR AOR (95%CI) OR AOR (95%CI) OR AOR (95%CI) 
Country          
   U.S. 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   Brazil 1.21 1.41 (0.76 - 2.63) 1.46 1.44 (0.80 - 2.61) 1.21 1.76 (0.95 - 3.26) 0.88 1.17 (0.63 - 2.17) 
   Mexico 0.81 0.75 (0.31 - 1.85) 0.66 0.40 (0.16 - 0.99) 0.60 0.81 (0.31 - 2.17) 0.30 0.47 (0.17 - 1.29) 
Age, Years         
  18-30 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
  31-44 1.07 1.20 (0.79 - 1.83) 1.54 1.72 (1.12 - 2.63) 1.04 1.09 (0.70 - 1.71) 0.87 1.12 (0.70 - 1.79) 
  45-70 1.08 1.04 (0.58 - 1.85) 1.54 1.63 (0.91 - 2.92) 1.51 1.39 (0.77 - 2.53) 1.02 1.33 (0.71 - 2.49) 
Race         
  White                               1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
  Black                               0.63 0.56 (0.32 - 0.98) 0.80 0.72 (0.41 - 1.28) 0.59 0.58 (0.31 - 1.06) 0.69 0.64 (0.35 - 1.17) 
  Asian/American Indian/Alaska 
Native 
1.46 1.70 (0.59 - 4.88) 1.28 1.47 (0.60 - 3.59) 0.85 1.06 (0.42 - 2.68) 2.38 2.78 (1.12 - 6.89) 
  Other 0.70 1.01 (0.44 - 2.30) 0.58 1.53 (0.65 - 3.60) 0.50 0.86 (0.35 - 2.14) 0.35 0.70 (0.27 - 1.80) 
Education         
   ≤12        1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   13-15        1.08 0.89 (0.55 - 1.44) 1.26 1.19 (0.74 - 1.93) 1.22 1.06 (0.64 - 1.76) 1.63 0.91 (0.54 - 1.53) 
   ≥16        1.75 1.75 (1.08 - 2.83) 1.53 1.46 (0.93 - 2.30) 1.91 1.77 (1.10 - 2.82) 1.50 1.41 (0.86 - 2.32) 
Circumcision         
  No  1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
  Yes 1.15 1.36 (0.80 - 2.30) 1.12 1.23 (0.74 - 2.04) 1.57 1.72 (1.02 - 2.89) 1.96 1.50 (0.88 - 2.56) 
No. of Female Sex Lifetime 
Partners 
        
  0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
  1-3 0.69 0.69 (0.34 - 1.40) 0.73 0.90 (0.46 - 1.79) 0.98 0.94 (0.45 - 1.98) 1.10 1.24 (0.59 - 2.62) 
  4-18         0.79 0.79 (0.41 - 1.55) 0.93 1.03 (0.54 - 1.94) 1.30 1.26 (0.63 - 2.49) 1.12 1.25 (0.62 - 2.52) 
  ≥19       0.69 0.56 (0.27 - 1.15) 0.98 0.77 (0.38 - 1.54) 1.48 1.03 (0.49 - 2.18) 1.10 0.85 (0.39 - 1.84) 
No. of Male Sex Lifetime Partners          
   0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   1 0.86 0.86 (0.36 - 2.09) 1.77 1.91 (0.80 - 4.56) 0.76 0.69 (0.26 - 1.84) 0.69 0.69 (0.24 - 1.97) 
  ≥2 1.74 1.27 (0.63 - 2.54) 2.34 1.81 (0.97 - 3.38) 1.40 1.05 (0.55 - 2.02) 1.23 0.85 (0.43 - 1.68) 
a. Final model was selected through backward stepwise elimination with significance level of p≤0.1 for retention in the model. Country, age, race, marital status, education, smoking alcohol consumption, 
circumcision, # of female LTP, and # of male LTP were loaded to the model while forcing country and age (design factors) to stay in the model 
b. 'Any-HPV' category included men seropositive for at least one HPV types, and 'Any β HPV' category included men seropositive for at least one β HPV types. 
Note: OR= unadjusted OR; AOR = adjusted odds ratio; CI = confidence interval; LTP = lifetime sex partners; significant results are marked in bold 
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Table 2.4. Factors independently associated with any cutaneous HPV, β, γ, and µ HPV seroprevalence among men residing in the U.S., Brazil and Mexicoa 
Characteristics 
β-HPV 8 β-HPV 17 β-HPV 23 β-HPV 38 β-HPV 47 
OR AOR (95%CI) OR AOR (95%CI) OR AOR (95%CI) OR AOR (95%CI) OR AOR (95%CI) 
Country            
   U.S. 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   Brazil 1.56 1.24 (0.62 - 2.48) 1.99 1.98 (0.87 - 4.55) 1.78 1.37 (0.58 - 3.26) 1.62 1.10 (0.49 - 2.44) 1.32 2.67 (1.19 - 5.99) 
   Mexico 0.47 0.52 (0.16 - 1.71) 0.80 0.81 (0.19 - 3.53) 0.44 0.28 (0.06 - 1.26) 0.46 0.20 (0.06 - 0.75) 0.58 0.42 (0.11 - 1.64) 
Age, Years           
  18-30 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
  31-44 2.13 2.28 (1.33 - 3.91) 1.68 1.86 (0.98 - 3.51) 1.81 1.79 (0.90 - 3.53) 1.86 2.01 (1.09 - 3.72) 1.34 2.00 (1.03 - 3.88) 
  45-73 2.45 2.83 (1.41 - 5.65) 1.90 1.95 (0.85 - 4.48) 1.19 1.23 (0.47 - 3.26) 1.66 1.77 (0.77 - 4.05) 2.41 3.16 (1.41 - 7.06) 
Race           
  White                               1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
  Black                               0.73 0.64 (0.33 - 1.25) 0.91 0.83 (0.38 - 1.83) 0.65 0.68 (0.28 - 1.66) 0.78 0.80 (0.37 - 1.73) 0.84 0.85 (0.38 - 1.89) 
  Asian/American Indian/Alaska 
Native 
0.79 1.02 (0.35 - 3.01) 1.32 1.40 (0.43 - 4.56) 3.58 4.75 (1.71 - 13.14) 1.42 2.23 (0.77 - 6.44) 1.04 1.04 (0.28 - 3.83) 
  Other 0.33 0.57 (0.19 - 1.71) 0.53 0.93 (0.24 - 3.65) 0.36 1.25 (0.31 - 5.12) 0.43 1.48 (0.44 - 5.02) 0.55 2.29 (0.63 - 8.25) 
Education           
   ≤12        1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   13-15        0.90 0.82 (0.45 - 1.51) 1.10 1.32 (0.66 - 2.62) 1.53 1.25 (0.58 - 2.69) 1.07 0.99 (0.50 - 1.96) 1.43 1.63 (0.82 - 3.26) 
   ≥16        1.50 1.28 (0.74 - 2.21) 1.25 1.17 (0.61 - 2.28) 2.02 2.02 (1.00 - 4.07) 1.80 1.56 (0.83 - 2.92) 1.54 1.36 (0.69 - 2.66) 
Circumcision           
  No  1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
  Yes 1.21 1.09 (0.60 - 1.98) 1.05 1.38 (0.68 - 2.77) 1.03 1.24 (0.59 - 2.59) 0.94 0.81 (0.40 - 1.63) 1.70 2.37 (1.21 - 4.67) 
No. of Female LTP           
  0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
  1-3 0.55 0.69 (0.30 - 1.60) 0.78 1.10 (0.43 - 2.80) 0.80 1.13 (0.37 - 3.47) 1.02 1.74 (0.60 - 5.02) 0.88 1.02 (0.38 - 2.73) 
  4-18         0.88 0.90 (0.42 - 1.91) 0.69 0.83 (0.34 - 2.01) 1.05 1.53 (0.55 - 4.23) 1.34 2.02 (0.75 - 5.40) 1.01 0.94 (0.38 - 2.31) 
  ≥19       1.07 0.63 (0.28 - 1.45) 0.78 0.63 (0.24 - 1.67) 1.26 1.10 (0.37 - 3.33) 1.43 1.23 (0.43 - 3.56) 0.95 0.58 (0.21 - 1.59) 
No. of Male LTP           
   0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   1 0.98 0.86 (0.29 - 2.52) 0.95 0.61 (0.13 - 2.77) 2.39 2.43 (0.80 - 7.45) 1.24 1.14 (0.35 - 3.68) 0.56 0.58 (0.13 - 2.69) 
  ≥2 2.96 1.80 (0.92 - 3.51) 3.27 2.22 (1.06 - 4.62) 2.78 2.39 (1.07 - 5.33) 2.84 1.97 (0.94 - 4.16) 1.52 0.95 (0.41 - 2.24) 
a. Final model was selected through backward stepwise elimination with significance level of p≤0.1 for retention in the model . Country, age, race, marital status, education, smoking alcohol consumption, 
circumcision, # of female LTP, and # of male LTP were loaded to the model while forcing country and age (design factors) to stay in the model 
b. 'Any-HPV' category included men seropositive for at least one HPV genotype, and 'Any β HPV' category included men seropositive for at least one β HPV types. 
Note: OR= unadjusted OR; AOR = adjusted odds ratio; CI = confidence interval; LTP = lifetime sex partners; significant results are marked in bold 
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Figure 2.1. Seropositivity for 0, 1, 2, and ≥3 cutaneous HPV types by country 
If a person was seronegative for all 14 HPV types, he was categorized in the seropositivity to ‘0 HPV’ group. If a 
person was seropositive for only 1 HPV type out of the 14 types, he was categorized in the seropositivity to ‘1 HPV’ 
group. If a person was seropositive for 2 HPV types, he was categorized in the ‘2 HPV’ group, and if a person was 
seropositive for 3 or more types, he was categorized in the ‘≥ 3’ group. Chi-square p-value represents differences in 
each category by country. Distributions of seropositivity to 0, 1, 2, ≥3 HPV types significantly differed by country in 
all categories (Overall p-value <0.05). * Highlights significant p-values.  
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Figure 2.2. Seropositivity for 0, 1, 2, and ≥3 β HPV types by country 
If a person was seronegative for all 10 β types, he was categorized in the seropositivity to ‘0 HPV’ group. If a person 
was seropositive for only 1 type out of the 10 β types, he was categorized in the seropositivity to ‘1 HPV’ group. If a 
person was seropositive for 2 β types, he was categorized in the ‘2 HPV’ group, and if a person was seropositive for 
3 or more β types, he was categorized in the ‘≥ 3’ group. Chi-square p-value represents differences in each category 
by country. Distributions of seropositivity to 0, 1, 2, ≥3 β HPV types significantly differed by country in all categories 
(Overall p-value <0.05). * Highlights significant p-values. 
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Figure 2.3. Factors independently associated with cutaneous HPV seroprevalence among men residing in the U.S., Brazil, and Mexico –graphical 
representation of the multivariate models 
Blue color represents the reference categories, white color represents not estimated, green color represents adjusted odds ratio (AOR) and 95% confidence 
interval (CI) with protective effect for non-significant associations, dark red color represents AOR and 95% CI with increased risk for significant associations, 
and light red color represents AOR and 95% CI with increased risk for non-significant associations. a. Any-HPV = seropositivity to ≥1 HPV types; b. Any-β 
HPV =seropositivity to ≥1 β  HPV types; c. LTP = lifetime sex partners  
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CHAPTER THREE: 
 
MANUSCRIPT 2: SEROPREVALENCE OF CUTANEOUS HUMAN PAPILLOMAVIRUSES 
(HPV) AND THE RISK OF EXTERNAL GENITAL LESIONS (EGLS) IN MEN - A NESTED 
CASE CONTROL STUDY 
 
ABSTRACT 
A variety of cutaneous human papillomaviruses (HPV) are detectable in genital epithelial lesions 
in men and non-melanoma skin cancer patients. It remains unclear whether these viruses are associated 
causally with disease.  To date, no study has prospectively examined the association between cutaneous 
HPV seropositivity and development of external genital lesions (EGLs) in men. The objective of this study 
mine the association between seropositivity to cutaneous HPV types and the risk of subsequent 
development of EGLs. A nested case-control study including 163 incident EGL cases and 352 EGL-free 
controls in the HPV Infection in Men (HIM) Study cohort was conducted. Cases were ascertained at each 
of up to 10 biannual clinical visits and verified through biopsy and pathological diagnoses.  EGLs were 
categorized as condyloma, suggestive of condyloma, penile intraepithelial neoplasia (PeIN), and other 
EGLs. Archived serum specimens collected at baseline were tested for antibodies against 14 cutaneous 
HPV types (β types [5, 8, 12, 14, 17, 22, 23, 24, 38, and 47], α type 27, γ type 4, µ type 1, and ν type 41) 
using a GST L1-based multiplex serology assay. Socio-demographic and sexual behavior data were 
collected through a questionnaire. Using logistic regression, adjusted odds ratios (AOR) and 95% 
confidence intervals (CI) were estimated.  
Overall, seropositivity to ≥ 1 cutaneous HPV type (any-HPV) and ≥1 β types (any-β) was 58.3% 
and 37.5% among other EGL cases, 71.6% and 46.8% among condyloma, 66.8% and 50.0% among PeIN, 
and 71.9% and 38.4% among controls, respectively. Type-specific seropositivity was most common for ɤ-
HPV 4, µ-HPV 1, and β-HPV 8. No statistically significant association was observed between any-HPV, 
any-β, and type-specific HPV seropositivity and subsequent development of EGLs across all pathological 
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diagnoses.  In conclusion, overall, seropositivity to cutaneous HPV was common among men; however, it 
appears that cutaneous HPV is not associated with the development of genital lesions in men. 
 
INTRODUCTION 
Over 200 types of human papillomaviruses (HPV) have been identified,79 and classified into five 
genera: alpha (α), beta (β), gamma (γ) mu (µ) and nu (ν).8,80 The majority of HPV in the genus α infect 
mucosal membranes but some types are also detected in cutaneous skin.18,81 HPV with cutaneous tropism 
are categorized into genus β, including some types initially referred to as epidermodysplasia verruciformis 
(EV) types, which have been associated with skin lesions, particularly in immune-suppressed individuals.  
Genus γ infects cutaneous skin and creates intra-cytoplasmic inclusion bodies. Finally, genera µ and ν are 
also associated with skin lesions.18,81  
Emerging evidence shows that cutaneous HPV infection may increase the risk of squamous cell 
carcinoma (SCC) of the skin.49,82 Several studies have reported a positive association between cutaneous 
HPV seropositivity and DNA detection and the risk of SCC.18-20,48,83 It is hypothesized that cutaneous HPV 
infection might modify the effect of ultraviolet (UV) radiation induced DNA damage and apoptosis leading 
to accumulation of mutations and SCC.84  Cutaneous HPV DNA has also been detected on the surfaces of 
penile intraepithelial neoplasia (PeIN),21,22 penile cancer,23,24 genital warts and other EGLs,25 and skin 
warts.26 Some EGLs such as PeIN are precursors of penile cancer.85 Less prevalent in the United States,28 
penile carcinoma constitutes up to 10% of all cancers among men in low-resource countries,29 and its 
incidence is on the rise in some European countries.30,31,86 Genital warts (condyloma acuminata) are a 
common sexually transmitted infection (STI). Although, benign lesions, genital warts cause considerable 
psychological discomfort and treatment related burden to patients.87. Both genital warts and PeIN (low-
grade and high-grade) are associated with an increased risk for carcinoma of the penis.33,34  
The role of cutaneous HPV in the etiology of SCC of the skin and the detection of cutaneous HPV 
DNA on the surfaces of EGLs suggest a role in the pathogenesis of the squamous epithelium lesions both 
in the UV exposed and unexposed areas of the body. However, little data exist on the epidemiology and 
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serology of cutaneous HPV and their distributions and etiologic role in the development of EGLs. 
Previously we detected β-HPV DNA on 61.1% of all EGLs.25 Subsequently, in a nested case-control study 
(Campbell et al. under review) we detected a lower prevalence of β-HPV DNA on EGLs compared to 
controls, and found that some β types were negatively associated with condyloma. To our knowledge, no 
study has yet prospectively examined the association of seropositivity to cutaneous HPV types and the risk 
of EGLs in men. The purpose of this study was to examine the association between seropositivity to 
cutaneous HPV types and the risk of subsequent development of EGLs among men in a case-control study 
nested in the HIM cohort.  
 
METHODS  
 
Study Population  
This nested case-control study evaluated 163 incident EGL cases and 352 EGL-free controls in the 
HIM cohort, a multinational prospective study of the natural history of HPV infection in men. Study 
population and methods have been described previously in detail.53,54 Briefly, between July 2005 and 
September 2009, the HIM Study enrolled over 4000 men in Brazil, Mexico and the U.S. Participants were 
eligible if they were: male, aged 18-70 years at baseline, reported no previous diagnosis of penile or anal 
cancer, had no previous diagnoses of ano-genital warts, no current history or treatment for sexually 
transmitted infections including HIV, and no current discharges from the penis or burning sensation during 
urination. Participants were followed every six months for a median of four years. At each study visit, 
participants completed a computer-assisted self-interviewed questionnaire provided urine and blood 
samples, and underwent a clinical examination.  
Cases included pathologically confirmed incident EGLs ascertained through visual inspection and 
confirmed with pathology following biopsy. The HIM Study pathology protocol was implemented between 
February 2009 and May 2013. Approximately 2,754 men, who had ≥2 study visits approximately six 
months apart were included in the biopsy sub-cohort, described previously in detail.88,89 Briefly, at each 
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visit, a trained clinician examined men under 3x light magnification for EGLs. Using shave excision, a 
tissue specimen was collected from each lesion. Excised tissues were placed in 10% buffered formalin, sent 
to the University of South Florida Dermatopathology Laboratory and evaluated by two independent 
pathologists. Discrepant diagnoses were adjudicated by a panel of three independent pathologists and 
quality control was conducted on 10% of all biopsy specimens.88 Based on previously described criteria,88,90 
EGLs were categorized as ‘condyloma’, ‘suggestive of condyloma’, ‘PeIN’ and ‘EGLs other than 
condyloma, suggestive of condyloma and PeIN’ (i.e. the other EGL cases). A lesion with koilocytes, 
papillomatosis, hypergranulosis, parakeratosis and dilated blood vessels was diagnosed as ‘condyloma’, 
and a lesion without koilocytes but with one or two of the other features associated with a condyloma was 
considered ‘suggestive of condyloma’. These lesions were most likely early condyloma that did not 
manifest complete histological features of a fully developed condyloma. ‘Condyloma’ and ‘suggestive of 
condyloma’ were therefore combined in the statistical analyses (i.e. the combined condyloma group). 
Lesions such as molluscum contagiosum, intradermal nevus, fibroepithelial polyp (skin tag), chronic 
balanitis, genital melanotic macule, psoriasiform dermatitis, lichenoid tissue reaction, and acute mucositis, 
which had unknown etiology on gross examination, but presented definite histology on pathologic review, 
were categorized into the ‘other EGL cases’ group. Finally, lesions with pre-neoplastic or neoplastic cells 
were categorized as ‘PeIN’. Additionally, all four categories of pathological diagnoses were combined into 
one group ‘all EGL cases’ to achieve a large sample size during multivariate modeling.  
Controls included the HIM Study participants who did not develop an EGL throughout the entire 
four years of follow-up. Two controls, frequency matched on the length of follow up, were selected per 
case. All study procedures were approved by the Institutional Review Boards of the University of South 
Florida (Tampa, FL, U.S.), the Ludwig Institute for Cancer Research (Sao Paulo, Brazil), the Centro de 
Referencia e Terinamento em Doencas Sexualmente Transmissiveis e AIDS (Sao Paulo, Brazil), and the 
Instituto Nacional de Salud Publica de Mexico (Cuernavaca, Mexico). 
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Specimens and Data Collection  
At each study visit, HIM Study participants provided detailed information on demographics (age, 
race, ethnicity, education and marital status), socioeconomic status, medical history, smoking habits, 
alcohol consumption, and sexual history.  Archived biopsy cohort baseline serum specimens among both 
cases and controls were tested for seroreactivity to the L1 protein of 14 cutaneous HPV types including β 
types (5, 8, 12, 14, 17, 22, 23, 24, 38, and 47), α type 27, γ type 4, µ type 1, and ν type 41. Only 14 types 
were tested due to limited funds, and were carefully selected based on previous reports of their association 
with cutaneous SCC19,48 and detection on the surface of EGLs.25 The antibody detection method was based 
on a glutathione S-transferase capture enzyme-linked immunosorbent assay (ELISA), in combination with 
fluorescent bead technology (Luminex) as previously described.55,56,91 To define type-specific HPV 
seropositivity, standard cut-off values (200 median fluorescence intensity [MFI]) were applied, as 
previously described.57,58  
 
Statistical Analysis 
Demographic, lifestyle and sexual behavior characteristics were compared between cases and 
controls using Fisher’s exact tests for categorical variables (Table 3.1). Type-specific seroprevalence was 
defined as the proportion of men who tested seropositive for antibodies to a given HPV type. 
Seroprevalence to any cutaneous HPV (any-HPV) was defined as the proportion of men who were 
seropositive to at least one of the 14 types of HPV included in this study, and seroprevalence to any-β HPV 
was defined as the proportion of men who were seropositive to at least one of the 10 β-HPV types. Type-
specific and grouped seroprevalence was calculated for different diagnostic categories of EGLs and 
controls. Seropositivity to one type, two types, and ≥3 types was also estimated. To assess for confounding, 
associations between factors listed in Table 1 and any-HPV, any-β, and type-specific HPV seroprevalence 
were examined among controls; associations between these factors and EGL development were assessed 
among the seronegative groups (unexposed) for any-HPV, any-β, and type-specific HPV. Also, factors 
associated with the cutaneous HPV seroprevalence, reported previously for the same population (Chapter 
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2), were considered for inclusion in the multivariate modeling. The final multivariate model included 
country, age, education, circumcision status, number of lifetime female sex partners, and number of lifetime 
male sex partners. Using these adjustment factors and logistic regression, separate models were estimated 
for associations between seropositivity to any-HPV type, any-β HPV type, and each specific HPV type, and 
EGL development. Interaction with seropositivity to nine mucosal HPV vaccine types (6, 11, 16, 18, 31, 
33, 45, 52 and 58.) was also assessed. Additionally, it was hypothesized that cutaneous HPV seropositivity 
could possibly be associated with condyloma that have definite HPV 6/11 etiology. Therefore, stratified 
associations were evaluated in the condyloma group by tissue DNA positivity to HPV 6/11 and antibody 
status to HPV 6/11. All analyses were performed in SAS 9.3.  
 
RESULTS  
The characteristics of the 163 incident EGL cases and 352 controls are shown in Table 3.1. Among 
48 men diagnosed with other EGL cases, statistically significant differences (p<0.05) by country, race, 
ethnicity, education, marital status, and circumcision were observed when compared to controls. Men from 
Brazil and Mexico, the “other” race group, Hispanics, men with ≤12 years of education, and uncircumcised 
men were more likely to have other EGLs diagnoses compared with controls. In total, 109 men were 
diagnosed with condyloma (n=62) or suggestive of condyloma (n=47). Significant differences by the 
number of recent female sex partners among those reporting ever having a female sex partner were observed 
for the combined group of condyloma where men with ≥2 recent female sex partners were more likely to 
have condyloma compared to controls. Six men were diagnosed with PeIN.  Significant differences between 
PeIN and controls were not observed for any of the socio-demographic and behavioral characteristics 
evaluated.  
Table 3.2 presents seropositivity of type-specific and grouped cutaneous HPV by case-control 
status. Approximately, 58.3% and 37.5% of men in the other EGL cases group, 71.6% and 46.8% in the 
combined condyloma, 66.8% and 50.0% in the PeIN, and 71.9% and 38.4% in the control group were 
seropositive for any-HPV and any-β HPV, respectively. The most commonly occurring type-specific HPV 
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were ɤ-HPV 4, µ-HPV 1, and β-HPV 8. Approximately 25.0% of men in the other EGL cases group, 31.2% 
in the combined condyloma, 50.0% in the PeIN, and 31.0% in the control group were seropositive for ɤ-
HPV 4. Approximately 14.6% and 22.9% of men in the other EGL cases group, 25.7% and 22.9% in the 
combined condyloma, and 33.3% and 33.3% in the PeIN, and 31.3% and 19.6% in the control group were 
seropositive for µ-HPV 1 and β-HPV 8, respectively. Seropositivity to only one HPV type ranged from 
(16.7%) to (35.5%), to two HPV types from (10.4%) to (20.2%), and to ≥3 HPV types from (22.0%) to 
(33.3%) across different pathologic diagnoses.  
The univariate and multivariate associations of grouped and type-specific cutaneous HPV 
seropositivity and each of three case outcomes (all EGL cases, combined condyloma, and other EGL cases) 
are presented in Table 3.3. No association was observed between any-HPV, any-β, and type-specific HPV 
seropositivity and ‘all EGL’ cases in either the univariate or the multivariate analyses, except for µ-HPV 1. 
Seropositivity to µ-HPV 1 was inversely associated with ‘all EGL’ cases in the unadjusted model (odds 
ratio [OR] 0.65; 95% confidence interval [CI]: 0.42–0.99).  Similarly, no association was observed between 
any-HPV, any-β, and type-specific HPV seropositivity and ‘combined condyloma’ and ‘other EGL’ cases 
in either the univariate or the multivariate analyses, except for µ-HPV 1. Seropositivity to µ-HPV 1 was 
inversely associated with other EGL cases (OR 0.38; 95% CI: 0.16 – 0.86) in unadjusted analyses, but failed 
to reach statistical significance in the adjusted models. 
In multivariate analyses a non-significant pattern of elevated risk was observed for any-β HPV and 
α-HPV type 27 seropositivity in all categories of EGLs compared to controls [(AOR 1.46; 95%CI: 0.95–
2.24) and (AOR 1.43; 95% CI: 0.75–2.75) for all EGL cases, [(AOR 1.53; 95% CI: 0.95–2.47) and (AOR 
1.24; 95% CI: 0.58–2.62) for combined condyloma] and [(AOR 1.23; 95% CI: 0.59–2.56) and (AOR 2.31; 
95% CI: 0.88–6.05) for other EGLs cases], respectively. No significant association was observed when the 
association between grouped and type-specific cutaneous HPV seropositivity was examined with separate 
categories of condyloma, and suggestive of condyloma compared to controls (Table A2.4 in Appendices). 
Furthermore, no significant association was observed between grouped and type-specific cutaneous HPV 
seropositivity and condyloma when condyloma were stratified by tissue HPV 6/11 DNA positivity or 
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antibody status to HPV 6 /11 (Table A2.5 in Appendices). Out of the 109 combined condyloma cases 
examined in this study, 71 (65.1%) were tissues positive for HPV 6/11 DNA, and 21 (19.3%) men with 
condyloma were also seropositive for HPV 6/11. No significant interaction by seropositivity to ≥1 nine 
vaccine type HPV was observed (Table A2.6 in Appendices); therefore, the interaction terms were removed 
from the final models.  
 
DISCUSSION  
This is the first study to examine the association between cutaneous HPV seropositivity and EGLs 
in a prospective, multi-national cohort of men. Overall, the seroprevalence of grouped and type-specific 
HPV was similar across different EGL categories and controls with the most frequent types being ɤ-HPV 
4, µ-HPV 1, and β-HPV 8. We did not observe an association between any-HPV, any-β HPV, and type-
specific HPV seropositivity and different pathological diagnoses of EGLs [i) other EGL cases, ii) combined 
condyloma, and iii) all EGLs cases]. However, a non-significant pattern of elevated risk was observed for 
any-β HPV and α-HPV type 27 seropositivity in all categories of EGLs compared to controls. In contrast, 
a non-significant pattern of reduced risk was observed for µ-HPV 1 seropositivity in all categories of EGLs. 
The null findings in this study suggest that cutaneous HPV is not associated with EGLs in contrast 
to previous studies of other cutaneous lesions. Reasons for these differences may include anatomic location 
of the lesions (i.e. UV exposed versus unexposed), immune status of the participants, and different high-
risk groups of populations as previously reported.92 The first evidence of the cutaneous HPV association 
with the development of skin lesions was observed among immunosuppressed individuals.93,94 Patients with 
a rare genetic disorder, epidermodysplasia verruciformis (EV) developed HPV-associated keratotic skin 
lesions primarily on sun-exposed skin with potential for malignant transformation.92 Later, the role of 
cutaneous HPV pathogenesis was assessed in organ-transplant recipients who were at high risk for skin 
warts, mainly on the sun-exposed areas that could carry potential for malignant transformation.95,96 
Although the precise role of cutaneous HPV in the development of squamous cell carcinoma (SCC) is 
debated, a number of epidemiologic studies have examined the association between grouped and type-
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specific cutaneous HPV seropositivity and SCC,18,19,48-50,57,97,98 and several studies have reported the 
presence of antibodies against ≥1 genus β HPV types to be associated with the risk of SCC.19,49,50 The null 
association in our study is in contrast with the positive associations reported for cutaneous HPV 
seropositivity and SCC of the skin.  
It is hypothesized that cutaneous HPV infection might modify the effect of UV-induced DNA 
damage and apoptosis leading to accumulation of mutations and cancer initiation.99 If UV exposure is 
necessary for cutaneous HPV carcinogenicity, lesions on the genital skin do not have significant UV 
exposure; therefore, development of EGLs may not be associated with exposure to cutaneous HPV 
infections.  
Different studies have reported a variety of individual types of cutaneous HPV to be associated 
with the SCC of the skin.18,19,48,57 Some of this variation in the type-specific associations across studies may 
be explained in part due to differences in the assays used, study population, age distribution, and cut-points 
used for seropositivity. However, it is also suggested that unlike mucosal HPV type 16 which is consistently 
causally associated with various forms of cancers, cutaneous HPV may act as a group of similar viruses 
with possible oncogenic properties.48 Contrary to skin cancer studies20,48,50 that have reported grouped 
cutaneous HPV association with SCC of the skin particularly for beta genotypes, in our study, seropositivity 
to grouped cutaneous HPV was not associated with subsequent risk of EGLs. 
Cutaneous HPV DNA is abundantly found on skin surfaces and persists in hair follicles of healthy 
individuals.100 This ubiquity may largely reflect viral colonization. Also, prevalence based on DNA 
detection varies considerably between various types of specimens collected from skin, e.g. skin swab vs. 
biopsy, making prevalence based on DNA detection a less precise measure. Serologic studies measuring 
antibodies against type-specific L1 major capsid protein of HPV provide evidence of host immune response 
to previous or recent infection and indicate cumulative exposure to HPV over time. Prevalence based on 
serology is also not dependent on the anatomic site of HPV infection. However, there are two important 
limitations to HPV serology studies. All infected individuals do not develop antibodies against HPV 
infection and antibodies may wane over time. Also, in this study we included only 14 types of cutaneous 
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HPV, out of which 10 were from genus beta. In contrast, studies on skin cancer generally have included 
more cutaneous HPV types from genus beta.19,48,101 This difference may partially explain the grouped 
cutaneous HPV associations observed in the studies on skin cancer.    
In this work a non-significant pattern of reduced risk of EGLs for some HPV types was observed. 
Previously a few studies have also reported a protective effect for some cutaneous HPV types against skin 
lesions. For example, Masini et al.98  reported a protective effect for β-HPV 15 seropositivity against SCC 
of the skin (OR 0.40; 95% CI: 0.20–0.90). In a recent study by Pierce-Campbell et al. in the same HIM 
Study population, men with condyloma were significantly less likely to have beta-HPV 24 and 47 detected 
on the surface of the lesion than controls were to have beta-HPV 24 and 47 on the normal genital skin (OR: 
0.09, 95% CI: 0.01–0.60 and OR: 0.20, 95% CI: 0.02–0.87, respectively). (Pierce Campbell et al. under 
review).  
High seroprevalence estimates in both cases and controls in the current study may suggest that 
cutaneous HPV are ubiquitous on skin and that cutaneous HPV might be a commensal component of the 
microbiological flora of the skin.61,62 It is also possible that cutaneous HPV might be competing against less 
prevalent and high risk mucosal HPV types and some types might be involved in a protective role in the 
skin flora. There is a growing body of literature suggesting that non-oncogenic HPV might be stimulating 
or inhibiting a co-existing oncogenic HPV through interference or immune cross-reaction.102,103 However, 
all these proposed hypotheses need rigorous investigations before meaningful conclusions can be drawn.  
We also examined the association of grouped and type-specific cutaneous HPV seropositivity and 
condyloma with definite HPV etiology, categorizing condyloma by tissue DNA positivity to HPV 6/11, 
and antibody status to HPV 6 /11, but no association was observed.   
The current study is an extension of our previous work25(Campbell et al. under review) examining 
the role of cutaneous HPV in the development of external genital lesions in men. Biopsy-confirmed incident 
EGLs, prospective evaluation of the association, and the use of a previously validated55,101 highly sensitive 
assay to measure antibodies against L1 cutaneous HPV major capsid protein, are the strengths of this study. 
Also, important cutaneous HPV types were included in this study based on previous reports of their 
 31 
 
associations with SCC,19,48 and recently their detection on the surface of EGLs.25 There are also some 
limitations to this study. The small sample size of the PeIN (n=6) limited our ability to further conduct 
subgroup and type-specific analyses for PeIN. Antibodies against cutaneous HPV are considered a marker 
of lifetime exposure to HPV, however, baseline serostatus in our study may have been affected by the 
seroconversion rate or waning of antibodies over time. Data on the serodynamics of cutaneous HPV do not 
exist to allow us to evaluate the effect of differential seroconversion rates and waning of antibodies over 
time in EGL cases and controls. Also, the anatomic site of HPV infection cannot be determined, a limitation 
relevant to all serological studies. 
Our findings show that cutaneous HPV are not associated with the development of EGLs. Further 
research is needed to understand the natural history and seroepidemiology of HPV infections and their role 
in the development of skin lesions among men, utilizing longitudinal study designs with repeated measures.   
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Table 3.1. Association between demographic, lifestyle and sexual behavior factors and external genital lesions 
(EGLs) and controls 
Characteristics 
EGLs Other 
than 
Conlyloma, Suggestive 
of Condyloma 
and PeINb 
(N=48) 
Condyloma 
and 
Suggestive of 
Condyloma 
(N=109) 
PeINe 
(N=6) 
Control 
(N=352) 
 n (%) p n % p n % p n % 
Country            
  U.S. 1 2.1 <0.001 32 29.4 0.193 1 16.7 0.275 137 38.9 
  Brazil 19 39.6  45 41.3  4 66.7  124 35.2 
  Mexico 28 58.3  32 29.4  1 16.7  91 25.9 
Age, Years            
  18-30 13 27.1 0.264 50 45.9 0.235 3 50.0 0.496 135 38.4 
  31-44 26 54.2  45 41.3  3 50.0  151 42.9 
  45-73 9 18.8  14 12.8  0 0.0  66 18.8 
Race            
  White 11 22.9 <0.001 60 55.0 0.160 4 66.7 0.135 182 51.7 
  Black 9 18.8  15 13.8  1 16.7  65 18.5 
  Asian 0 0.0  1 0.9  0 0.0  15 4.3 
  Native Hawaiian/Pacific Islanders 0 0.0  1 0.9  0 0.0  0 0.0 
  American Indian, Alaska Native 1 2.1  2 1.8  1 16.7  3 0.9 
  Others 27 56.3  29 26.6  0 0.0  79 22.4 
  Not reported 0 0.0  1 0.9  0 0.0  8 2.3 
Ethnicity            
  Hispanic 34 70.8 0.002 46 42.2 0.922 1 16.7 0.478 142 40.3 
  Non-Hispanic 13 27.1  63 57.8  5 83.3  207 58.8 
  Not reported 1 2.1  0 0.0  0 0.0  3 0.9 
Education, Years            
  ≤12 27 56.3 0.028 49 45.0 0.416 4 66.7 0.681 148 42.0 
  13-15 6 12.5  27 24.8  1 16.7  99 28.1 
  ≥16 12 25.0  33 30.3  1 16.7  98 27.8 
  Not reported 3 6.3  0 0.0  0 0.0  7 2.0 
Marital Status            
  Single/never married 9 18.8 0.003 53 48.6 0.076 2 33.3 0.264 139 39.5 
  Married 23 47.9  28 25.7  2 33.3  132 37.5 
  Cohabitating, living together 14 29.2  15 13.8  0 0.0  48 13.6 
  Divorced/separated/widowed 2 4.2  12 11.0  2 33.3  33 9.4 
  Not reported 0 0.0  1 0.9  0 0.0  0 0.0 
Smoking Status            
  Current 12 25.0 0.979 35 32.1 0.253 2 33.3 0.061 85 24.1 
  Former 7 14.6  14 12.8  3 50.0  49 13.9 
  Never 29 60.4  60 55.0  1 16.7  218 61.9 
Alcohol, No. of Drinks/Month            
  0 13 27.1 0.637 17 15.6 0.061 2 33.3 0.762 87 24.7 
  1–30 27 56.3  51 46.8  3 50.0  171 48.6 
  31-60 4 8.3  12 11.0  1 16.7  38 10.8 
  ≥61 4 8.3  29 26.6  0 0.0  54 15.3 
  Not reported 0 0.0  0 0.0  0 0.0  2 0.6 
Circumcision            
  No 40 83.3 0.001 69 63.3 0.347 5 83.3 0.407 205 58.2 
  Yes 8 16.7  40 36.7  1 16.7  147 41.8 
Sexual Orientation            
  MSW 40 83.3 0.489 94 86.2 0.385 6 100.0 0.470 310 88.1 
  MSM 5 10.4  10 9.2  0 0.0  29 8.2 
  MSWM 2 4.2  5 4.6  0 0.0  8 2.3 
  Missing 1 2.1  0 0.0  0 0.0  5 1.4 
No. of Female LTP            
  0 3 6.3 0.334 10 9.2 0.618 0 0.0 0.464 36 10.2 
  1-3 5 10.4  14 12.8  0 0.0  57 16.2 
  4-18 27 56.3  44 40.4  2 33.3  146 41.5 
  ≥19 11 22.9  35 32.1  4 66.7  103 29.3 
  Not reported 2 4.2  6 5.5  0 0.0  10 2.8 
Continued on next page 
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Table 3.1. (Continued)  
Characteristics  
EGLs Other 
than 
Conlyloma, Suggestive 
of Condyloma 
and PeINb 
(N=48) 
Condyloma 
and 
Suggestive of 
Condyloma 
(N=109) 
PeINe 
(N=6) 
Control 
(N=352) 
 n (%) p n % p n % p n % 
No. of Male Anal LTP            
  0 41 85.4 0.726 91 83.5 0.162 6 100.0 0.764 295 83.8 
  1-3 1 2.1  3 2.8  0 0.0  11 3.1 
  ≥4 3 6.3  9 8.3  0 0.0  13 3.7 
Not reported 3 6.3  6 5.5  0 0.0  33 9.4 
Recent Female Sex Partner, #a            
  0 6 12.5 0.696 14 12.8 0.043 0 0.0 0.443 46 14.6 
  1 25 52.1  39 35.9  3 50.0  170 53.8 
  ≥2 14 29.2  44 40.4  3 50.0  94 29.8 
  Not reported 3 6.3  12 11.0  0 0.0  6 1.9 
Recent Male Sex Partners, # a            
  0 42 87.5 0.332 91 83.5 0.343 6 100.0 0.836 308 88.5 
  1 3 6.3  4 3.7  0 0.0  8 2.3 
  ≥2 1 2.1  6 5.5  0 0.0  9 2.6 
Not reported 2 4.2  8 7.3  0 0.0  23 6.6 
P = p-values compares respective EGL category with the last column (control group). P-values were calculated using Chi-square and Fisher exact 
tests, significant p-values are highlighted in bold.   
EGLs = external genital lesions; PeIN = penile intraepithelial neoplasia; LTP = lifetime sex partners 
a. Number of female sex partners in the past 6 months among those reporting ever having a female sex partner; number of male sex partners in 
the past 6 months among those reporting ever having a male sex partner. 
b. This category is also referred to as ‘other EGL cases’ included different other diagnoses i.e. molluscum contagiosum, intradermal nevus, 
fibroepithelial polyp (skin tag), chronic balanitis, genital melanotic macule, psoriasiform dermatitis, lichenoid tissue reaction, and acute 
mucositis. 
c. Condyloma: A lesion with koilocytes, papillomatosis, hypergranulosis, parakeratosis and dilated blood vessels.  
d. Suggestive of condyloma: A lesion without koilocytes but with one or two of the other features associated with a condyloma. These lesions 
were most likely early condyloma that did not show complete histological features of a fully developed condyloma.  
e. PeIN: A lesion with pre-neoplastic or neoplastic cells. 
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Table 3.2. Grouped and type-specific cutaneous HPV seropositivity by case-control status 
HPV type 
EGLsa 
Other than 
Condyloma, 
Suggestive of 
Condyloma 
and PeIN (N=48) 
Condyloma and 
Suggestive of 
Condyloma 
(N=109)b,c 
PeINd 
(N=6) 
 
 
Controls 
(N=352) 
 
 n % n % n % n % 
Any-HPV         
  Seropositive 28 58.3 78 71.6 4 66.8 253 71.9 
Any β HPV         
  Seropositive 18 37.5 51 46.8 3 50.0 135 38.4 
α-HPV 27         
  Seropositive 8 16.7 13 11.9 0 0.0 34 9.7 
γ-HPV 4         
  Seropositive 12 25.0 34 31.2 3 50.0 109 31.0 
µ-HPV 1         
  Seropositive 7 14.6 28 25.7 2 33.3 110 31.3 
ν-HPV 41         
  Seropositive 4 8.3 10 9.2 1 16.7 42 11.9 
β-HPV 5         
  Seropositive 3 6.3 9 8.3 1 16.7 32 9.1 
β-HPV 8         
  Seropositive 11 22.9 25 22.9 2 33.3 69 19.6 
β-HPV 12         
  Seropositive 4 8.3 5 4.6 1 16.7 20 5.7 
β-HPV 14         
  Seropositive 3 6.3 2 1.8 1 16.7 17 4.8 
β-HPV 17         
  Seropositive 6 12.5 20 18.4 2 33.3 55 15.6 
β-HPV 22         
  Seropositive 3 6.3 9 8.3 1 16.7 21 6.0 
β-HPV 23         
  Seropositive 4 8.3 15 13.8 0 0.0 36 10.2 
β-HPV 24         
  Seropositive 1 2.1 5 4.6 1 16.7 17 4.8 
β-HPV 38         
  Seropositive 8 16.7 14 12.8 0 0.0 46 13.1 
β-HPV 47         
  Seropositive 4 8.3 13 11.9 1 16.7 51 14.5 
Seropositivity to  
1, 2, ≥ 3 HPV types 
        
  Seropositive to 1 HPV 12 25.0 32 29.4 1 16.7 125 35.5 
  Seropositive to 2 HPV 5 10.4 22 20.2 1 16.7 57 16.2 
  Seropositive to ≥ 3 HPV 11 22.9 24 22.0 2 33.3 71 20.2 
EGLs = external genital lesions; PeIN = penile intraepithelial neoplasia  
a. This category is also referred to as ‘other EGL cases’ included different other diagnoses i.e. molluscum contagiosum, intradermal nevus, 
fibroepithelial polyp (skin tag), chronic balanitis, genital melanotic macule, psoriasiform dermatitis, lichenoid tissue reaction, and acute 
mucositis. 
b. Condyloma: A lesion with koilocytes, papillomatosis, hypergranulosis, parakeratosis and dilated blood vessels.  
c. Suggestive of condyloma: A lesion without koilocytes but with one or two of the other features associated with a condyloma. These lesions 
were most likely early condyloma that did not show complete histological features of a fully developed condyloma.  
d. PeIN: A lesion with pre-neoplastic or neoplastic cells. 
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Table 3.3. Association between grouped and type-specific cutaneous HPV seropositivity and EGLsa  
HPV type 
EGLs Other than 
Condyloma Suggestive of 
Condyloma and PeINb 
Condyloma 
and Suggestive of 
Condylomac 
All EGL 
Casesd 
 OR AORe  95% CI OR AORe  95% CI OR AORe  95% CI 
Any-HPV       
Negative 1.00 1.00 1.00 1.00 1.00 1.00 
Positive 0.55  0.63 ( 0.30 - 1.32) 0.98 1.03 ( 0.61 - 1.72) 0.81 0.91 ( 0.58 - 1.42) 
Any β HPV       
Negative 1.00 1.00 1.00 1.00 1.00 1.00 
Positive 0.96 1.23 ( 0.59 - 2.56) 1.41 1.53 ( 0.95 - 2.47) 1.27 1.46 ( 0.95 - 2.24) 
α-HPV 27       
Negative 1.00 1.00 1.00 1.00 1.00 1.00 
Positive 1.87 2.31 ( 0.88 - 6.05) 1.27 1.24 ( 0.58 - 2.62) 1.38 1.43 ( 0.75 - 2.75) 
γ-HPV 4       
Negative 1.00 1.00 1.00 1.00 1.00 1.00 
Positive 0.74 0.69 ( 0.31 - 1.54) 1.01 1.04 ( 0.63 - 1.72) 0.96 1.00 ( 0.64 - 1.57) 
µ-HPV 1       
Negative 1.00 1.00 1.00 1.00 1.00 1.00 
Positive 0.38 0.62 ( 0.23 - 1.65) 0.76  0.79 ( 0.46 - 1.37) 0.65 0.78 ( 0.48 - 1.28) 
ν-HPV 41       
Negative 1.00 1.00 1.00 1.00 1.00 1.00 
Positive 0.67 0.78 ( 0.25 - 2.47) 0.75 0.67 ( 0.31 - 1.45) 0.75 0.74 ( 0.38 - 1.44) 
β-HPV 5       
Negative 1.00 1.00 1.00 1.00 1.00 1.00 
Positive 0.67 1.01 ( 0.27 - 3.79) 0.90 1.02 ( 0.45 - 2.3) 0.87 1.02 ( 0.49 - 2.11) 
β-HPV 8       
Negative 1.00 1.00 1.00 1.00 1.00 1.00 
Positive 1.22 1.50 ( 0.64 - 3.50) 1.22 1.55 ( 0.88 - 2.76) 1.25 1.62 ( 0.98 - 2.69) 
β-HPV 12       
Negative 1.00 1.00 1.00 1.00 1.00 1.00 
Positive 1.51 1.41 ( 0.40 - 4.97) 0.80 0.60 ( 0.19 - 1.92) 1.08 0.90 ( 0.37 - 2.18) 
β-HPV 14       
Negative 1.00 1.00 1.00 1.00 1.00 1.00 
Positive 1.31 1.60 ( 0.38 - 6.72) 0.37 0.19 ( 0.02 - 1.53) 0.75 0.64 ( 0.21 - 1.94) 
β-HPV 17       
Negative 1.00 1.00 1.00 1.00 1.00 1.00 
Positive 0.77 0.80 ( 0.28 - 2.30) 1.21 1.20 ( 0.65 - 2.23) 1.12  1.12 ( 0.64 - 1.94) 
β-HPV 22       
Negative 1.00 1.00 1.00 1.00 1.00 1.00 
Positive 1.05 1.52 ( 0.37 - 6.13) 1.42 1.50 ( 0.61 - 3.68) 1.37 1.50 ( 0.67 - 3.35) 
β-HPV 23       
Negative 1.00 1.00 1.00 1.00 1.00 1.00 
Positive 0.80 1.14 ( 0.35 - 3.74) 1.40 1.27 ( 0.63 - 2.57) 1.16 1.10 ( 0.57 - 2.12) 
β-HPV 24       
Negative 1.00 1.00 1.00 1.00 1.00 1.00 
Positive 0.42 0.46 ( 0.05 - 4.14) 0.95 0.96 ( 0.32 - 2.86) 0.88 0.91 ( 0.34 - 2.44) 
β-HPV 38       
Negative 1.00 1.00 1.00 1.00 1.00 1.00 
Positive 1.33 1.82 ( 0.71 - 4.69) 0.98 0.82 ( 0.40 - 1.66) 1.04 0.96 ( 0.52 - 1.76) 
β-HPV 47       
Negative 1.00 1.00 1.00 1.00 1.00 1.00 
Positive 0.54 0.66 ( 0.20 - 2.14) 0.80 0.88 ( 0.44 - 1.79) 0.73 0.85 ( 0.45 - 1.61) 
Seropositivity to 1, 2, ≥ 3 HPV       
Negative 1.00 1.00 1.00 1.00 1.00 1. 
Positive to 1 HPV 0.48 0.50 (0.21 - 1.22) 0.82 0.82 (0.45 – 1.51) 0.67 0.71 (0.42 – 1.20) 
Positive to 2 HPV 0.43 0.33 (0.08 - 1.30) 1.23 1.37 (0.70 – 2.75) 0.92 1.08 (0.56 – 2.03) 
Positive to ≥ 3 HPV 0.77 1.23 (0.47 - 3.21) 1.08 1.12 (0.57 – 2.23) 0.97 1.21 (0.67 – 2.17) 
EGLs = external genital lesions; PeIN = penile intraepithelial neoplasia; OR = odds ratios unadjusted; AOR = adjusted odds ratios 
a. Due to fewer cases unadjusted and adjusted models were not estimated for PeIN. b. This category is also referred as ‘other EGL cases’ included 
different other diagnoses i.e. molluscum contagiosum, intradermal nevus, fibroepithelial polyp (skin tag), chronic balanitis, genital melanotic 
macule, psoriasiform dermatitis, lichenoid tissue reaction, and acute mucositis. c.This category included condyloma and suggestive of condyloma. 
Condyloma: A lesion with koilocytes, papillomatosis, hypergranulosis, parakeratosis and dilated blood vessels. Suggestive of condyloma: A 
lesion without koilocytes but with one or two of the other features associated with a condyloma. These lesions were most likely early condylomas 
that did not show complete histological features of a fully developed condyloma. d. This category included all pathological diagnoses of EGLs  
e. Odds ratios were adjusted for Country of residence, age, education, circumcision, female lifetime sex partners, and male li fetime sex partners. 
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CHAPTER FOUR: 
 
MANUSCRIPT 3: SEROPREVALENCE AND ASSOCIATED FACTORS OF NINE VACCINE 
TYPE HUMAN PAPILLOMAVIRUSES (HPV) AMONG MEN IN THE MULTINATIONAL HIM 
STUDY 
 
ABSTRACT 
Human papillomavirus (HPV) is one of the most common sexually transmitted infections 
worldwide. Recently a 9-valent HPV (9vHPV) prophylactic vaccine was licensed. Seroprevalence prior to 
vaccine dissemination is needed for monitoring vaccine effectiveness over time. Few studies have assessed 
the seroprevalence of 9vHPV types in men. This study investigated the seroprevalence of 9vHPV vaccine 
types and associated risk factors among men residing in Brazil, Mexico, and the United States. Six hundred 
men were randomly selected from the HPV Infection in Men (HIM) Study. Archived serum specimens 
collected at enrollment were tested for antibodies against nine HPV types (6, 11, 16, 18, 31, 33, 45, 52 and 
58) using a GST L1-based multiplex serologic assay. Socio-demographic, lifestyle and sexual behavior data 
at enrollment were collected through a questionnaire. Binomial proportions were used to estimate 
seroprevalence and logistic regression was used to examine factors associated with seropositivity. 
Overall, 28.3% of men were seropositive for at least one of the 9vHPV vaccine types, 14.0% for at 
least one of the seven high-risk types (16, 18, 31, 33, 45, 52 and 58) and 11.2% for at least one of the five 
high-risk types (31, 33, 45, 52 and 58) not included in the quadrivalent HPV vaccine, and 17.4% for at least 
one of the low-risk types (6/11). In multivariate analyses, compared to men with no anal sex lifetime 
partners, men with ≥2 partners were more likely to be seropositive for grouped HPV [(9vHPV: adjusted 
odds ratio (AOR) 2.52; 95% confidence interval (CI) 1.40-4.54), (high-risk HPV: AOR 2.18; 95%CI: 1.05-
4.50) and (low-risk HPV: AOR 2.12; 95%CI: 1.12-4.03)], and individual HPV types 6, 16, 33 and 58 with 
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AORs ranging from 2.19 to 7.36. Compared to men aged 18-30 years, men older than 30 years were 
significantly more likely to be seropositive for any high-risk HPV, in addition to individual types 18 and 
45; and compared to never smokers, current smokers were more likely to be seropositive to 9vHPV, low-
risk HPV and HPV 6. In contrast, married men were less likely to be seropositive to any high-risk HPV and 
individual HPV types 18 and 31 when compared to single men. In conclusion, these data indicate that 
exposure to the nine HPV types included in the 9vHPV vaccine is common in men and that seropositivity 
to 9vHPV vaccine types is associated with older age and the lifetime number of anal sex partners.  
 
INTRODUCTION 
Human papillomavirus (HPV) is one of the most common sexually transmitted infections (STI) 
worldwide. Nearly all sexually active adults will be infected with one or more HPV types at some point in 
their lives.10,27 More than 40 HPV types are known to infect the ano-genital region, of which at least 13 are 
classified as oncogenic.27,104 HPV infection is often asymptomatic and transient; however, a small 
proportion of infections persist and cause benign and malignant diseases in men and women.4,105 Oncogenic 
HPV is a necessary cause of cervical cancer and nearly all cervical, approximately 50% of vulvar, and 65% 
of vaginal cancers, are caused by oncogenic HPV.10,14 HPV also causes approximately 40-50% of penile, 
85% of anal, 60-70% of oropharyngeal, and 10% of laryngeal cancers.27,28,106-108 Non-oncogenic HPV types 
cause genital warts and other benign lesions of epithelial tissues.11 
In the United States (U.S.), the bivalent and 4-valent HPV vaccines are recommended for routine 
vaccination for girls at age 11 or 12 years, females age 13 through 26 years, and males age 13 through 21 
years if they have not yet received the HPV vaccine.35 Recently, the Advisory Committee on Immunization 
Practices (ACIP) added the 9-valent HPV vaccine (9vHPV) to the vaccine recommendations.36 Information 
on the natural history of HPV infection and serology in men prior to vaccine dissemination is needed to 
monitor the effectiveness of the vaccine over time.  
Although a number of studies have reported seroprevalences of HPV types 6, 11, 16 and 18 in men 
from different countries,37-42 few have examined other HPV types (e.g. 31, 33, 45, 52 and 58) included in 
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the 9vHPV vaccine in the general population. One study included only men who have sex with men 
(MSM),109 another study included men only from the U.S. with an age range of 14-59 years,110 and two 
studies using the same study population in the Netherlands examined only the seven high-risk types in the 
9vHPV vaccine.111,112 Previously, we reported seroprevalences for the 4-valent HPV vaccine types (6, 11, 
16 and 18).39 In this study, we extended our analysis to estimate the seroprevalence of 9vHPV vaccine types 
and investigated factors associated with the seropositivity in men from three countries (Brazil, Mexico, and 
the U.S.) across a broad age range to report data across the entire adult lifespan and old age.  
 
METHODS 
 
Study Population 
Study participants included a sub-cohort of 600 men randomly selected from the HPV Infection in 
Men (HIM) Study. Simple random sampling method was used to select the sub-set because performing 
serology testing for the entire parent cohort was not viable and cost-effective. The HIM Study uses a 
prospective cohort design to examine the natural history of HPV infections among men in three countries. 
Detailed descriptions of the study population and procedures have been published elsewhere.53,54 Briefly, 
over 4000 men aged 18-70 years at baseline were recruited from Tampa, Florida, Sao Paulo, Brazil, and 
Cuernavaca, Mexico. Eligibility criteria included no previous history of penile cancer, anal cancer, ano-
genital warts and HIV; no current history or treatment for STIs; no current discharges from the penis or 
burning sensation during urination; and no history of prior or current participation in HPV vaccine traials. 
Participants were followed every six months for a median of four years.  At baseline and each study visit, 
participants completed a computer-assisted self-interviewed questionnaire, provided blood and urine 
specimens, and underwent a clinical examination. A total of 3,695 HIM Study participants who provided 
serum specimens and completed the questionnaire at baseline were eligible to be included in the current 
study. This study was approved by the Institutional Review Boards of the University of South Florida 
(Tampa, FL, the U.S.), the Ludwig Institute for Cancer Research (Sao Paulo, Brazil), the Centro de 
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Referencia e Treinamento em Doencas Sexualmente Transmissiveis e AIDS (Sao Paulo, Brazil), and the 
Instituto Nacional de Salud Publica de Mexico (Cuernavaca, Mexico).  
 
Specimens and Data Collection 
At the baseline visit, the HIM Study participants provided detailed information on 
sociodemographic characteristics, smoking habits, alcohol consumption, medical history, and an extensive 
sexual behaviors history. Archived baseline serum specimens from 600 participants were tested for 
seroreactivity to L1 major capsid proteins of the 9vHPV vaccine types (6, 11, 16, 18, 31, 33, 45, 52 and 
58). The antibody detection method was based on a glutathione S-transferase (GST) capture enzyme-linked 
immunosorbent assay (ELISA), in combination with fluorescent bead technology previously described.55,56 
To define seropositivity for each of the 9vHPV vaccine types, type-specific cut-off values measured in 
median fluorescence intensity [MFI] units were applied, as previously described.56 
 
Statistical Analysis  
Type-specific seroprevalence was calculated as the proportion of men who tested positive for a 
given HPV type. Four additional categories of HPV (i.e. 9vHPV, high-risk HPV, 5-additional HPV, and 
low-risk HPV) were also used as dependent variables in the analyses. ‘9vHPV’ seroprevalence was defined 
as the proportion of men who were seropositive for at least one of the nine vaccine types. ‘High-risk HPV’ 
included men who were seropositive for at least one of the seven oncogenic types (i.e. 16, 18, 31, 33, 45, 
52 and 58), ‘five additional HPV’ included men who were seropositive for at least one of the five oncogenic 
types not included in the quadrivalent HPV vaccine (i.e. 31, 33, 45, 52 and 58), and ‘low-risk HPV’ included 
men who were seropositive for HPV types 6 or 11. Two subjects with inadequate serology results were 
excluded from all analyses resulting in a final sample size of 598 men. Baseline sociodemographic and 
behavioral factors listed in Table 1 were compared between seropositive and seronegative men with high- 
and low-risk HPV, and with the full HIM Study cohort (>4000 men) using Chi-square tests.  Seroprevalence 
estimates were calculated for each HPV type, by country and age group, and compared using Chi-square 
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and Fisher’s exact tests. The Holm–Bonferroni correction was used to adjust for multiple comparisons when 
comparing seroprevalence estimates across countries. To examine associations between individual and 
grouped HPV seropositivity and potential risk factors, logistic regression was used and odds ratios (ORs) 
and their 95% confidence intervals (CI) were estimated. Factors listed in Table 1 were considered for 
inclusion in multivariate logistic regression models. Variables were selected using backward stepwise 
elimination with significance at p≤0.1. Country and age were forced into the model due to the study design. 
To assess the individual contribution of each variable retained in the model at p≤0.1, the likelihood ratio 
test at p<0.05 was performed. The final multivariate models for 9vHPV and low-risk HPV included country, 
age, smoking status, and the number of male anal sex lifetime partners (LTP). The final model for high-risk 
HPV included country, age, marital status, and the number of male anal sex LTP. Multivariate models for 
individual high-risk HPV types 16, 18, 31, 33, 45, 52 and 58 were adjusted for the same factors as the 
grouped high-risk HPV model, and multivariate models for individual low-risk HPV types 6 and 11 were 
adjusted for the same factors as the grouped low-risk HPV model. All analyses were performed in SAS 9.3. 
 
RESULTS 
This study included 184 participants from the U.S., 200 from Brazil, and 214 from Mexico. 
Participant characteristics by seropositivity to high- and low-risk HPV are presented in Table 4.1. 
Significant differences by age, sexual orientation, lifetime number of anal sex partners (LTP), and recent 
male anal sex partners were observed for seropositivity to high-risk HPV (p<0.05). Mid-adult men (35-44 
years) and older men (45-73 years), men who have sex with men (MSM), men who have sex with men and 
women (MSMW), men with ≥2 lifetime male anal sex partners (LTP), and men with ≥2 recent anal sex 
partners were more likely to be seropositive for high-risk HPV (p<0.05). Significant differences in 
seropositivity to low-risk HPV were observed by country, circumcision status, sexual orientation, and 
number of male anal sex LTP (p<0.05). Participants in the randomly selected sub-cohort (n=600) were 
similar (P>0.05) to the full HIM cohort (>4,000 men) on all baseline sociodemographic and sexual 
behavioral characteristics listed in Table 1 (Table A2.1 in Appendices).  
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Grouped and individual type HPV seroprevalence estimates are presented in Table 4.2. Overall, 
28.3% of men were seropositive for ≥1 9vHPV type, 14.0% for ≥1 high-risk HPV types, 11.2% for ≥1 of 
the five additional types, and 17.4% for low-risk HPV types 6 and/or 11. Type-specific seropositivity for 
five individual HPV types was as follows: HPV 31 (4.5%), HPV 33 (1.7%), HPV 45 (3.7%), HPV 52 
(2.5%), and HPV 58 (4.7%).  Seropositivity for 9vHPV was statistically significantly different by country 
[Brazil (36.5%), Mexico (28.5%) and U.S. (19.0%); overall p<0.001] and remained significant only for 
Brazil vs. U.S. (p<0.001) after pair wise comparisons. No significant differences in the seroprevalence of 
grouped high-risk HPV types was observed by country [Brazil (14.5%), Mexico (16.8%) and U.S. (10.3%); 
overall p=0.173].  Seroprevalence of the five additional types also did not vary significantly by country 
[Brazil (10.5%) and Mexico (13.6) and U.S. (9.2%); overall p=0.368]. Seropositivity to low-risk HPV was 
statistically significantly different by country [Brazil (27.5%), Mexico (14.0%) and U.S. (10.3%); overall 
p<0.001] and remained significant for Brazil vs. U.S. (p<0.001) and Brazil vs. Mexico (p<0.001) after pair 
wise comparisons. Seroprevalence of individual HPV types 6 and 16 significantly differed by country 
[Brazil (25.5%) and (5.5%), Mexico (13.6%) and (1.9%) and U.S. (9.2%) and (1.6%), respectively; overall 
p-values<0.05]. After pair wise comparisons, significant difference remained for Brazil vs. U.S. (p<0.001) 
and Brazil vs. Mexico (p=0.004) only for HPV 6. Seroprevalence was highest for HPV 6 in all three 
countries [Brazil (25.5%), Mexico (13.6%) and U.S. (9.2%)].  Figures 4.1A and B show grouped and type-
specific HPV seroprevalence by age group. A significant positive trend (p trend <0.05) for seropositivity with 
increasing age was observed for grouped high-risk HPV, grouped five additional types, and some individual 
HPV types (18, 45 and 58). 
Factors associated with seropositivity of grouped and specific individual HPV types are presented 
in Tables 4.3A-C. In multivariable analyses, adjusting for all other variables in the table, number of anal 
sex lifetime partners, was significantly associated with seropositivity for grouped and specific individual 
HPV types (6, 16, 33, and 58). Compared to men with no reported anal sex, men with ≥2 anal sex LTP were 
more likely to be seropositive for grouped HPV [(9vHPV: adjusted odds ratio (AOR) 2.52; 95%CI: 1.40-
4.54), (high-risk HPV: AOR 2.18; 95%CI: 1.05-4.50) and (low-risk HPV: AOR 2.12; 95%CI: 1.12-4.03)] 
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respectively. Similarly, men with ≥2 anal sex LTP were significantly more likely to be seropositive for 
individual HPV types 6, 16, 33 and 58, with AORs ranging from 2.19 to 7.36. Increasing age was 
significantly positively associated with seropositivity for high-risk HPV and HPV types 18 and 45. 
Compared to men aged 18-30 years, men aged 31-44 years and men aged 45-73 were more likely to be 
seropositive for high-risk HPV [(AOR 1.95; 95%CI: 1.03-3.70) and (AOR 2.75; 95%CI: 1.23-6.15), 
respectively] and HPV 18 [(AOR 4.60; 95%CI: 1.24-17.10) and (AOR 14.47; 95%CI: 3.24-64.68) 
respectively]. Compared to men aged 18-30 years, men aged 45-73 years were more likely to be seropositive 
for HPV 45 (AOR 5.43; 95%CI: 1.27-23.25). Country was significantly associated with seropositivity for 
grouped and individual HPV types. Compared to men from the U.S., men from Brazil were more likely to 
be seropositive to 9vHPV (AOR 2.18; 95%CI: 1.31-3.60), low-risk HPV (AOR 3.13; 95%CI: 1.71-5.75), 
HPV 6 (AOR 3.15; 95% CI: 1.67-5.93), HPV 11 (AOR 3.43; 95%CI: 1.04-11.35), and less likely to be 
seropositive to HPV 58 (AOR 0.12; 95%CI: 0.03-0.53). Similarly, compared to men from the U.S., men 
from Mexico were more likely to be seropositive for 9vHPV (AOR 1.66; 95%CI: 1.02-2.71), high-risk 
HPV (AOR 2.24; 95%CI: 1.15-4.40) and HPV 18 (AOR 7.91; 95%CI: 1.51-41.34). Compared to never 
smokers, current smokers were more likely to be seropositive to 9v-HPV, low-risk HPV and HPV 6. In 
contrast, compared to men who reported being single/never married, married/cohabiting men were less 
likely to be seropositive to high-risk HPV, HPV types 18 and 31 (Table 4.3A-C). 
 
DISCUSSION  
Previously, we reported seroprevalence of the 4-valent HPV vaccine types (6, 11, 16 and 18).39 In 
this study, we extended our analysis to include five additional HPV types (31, 33, 45, 52 and 58) in the 
9vHPV vaccine. Additionally, we investigated factors associated with 9vHPV seropositivity in 598 men 
recruited from Brazil, Mexico and the U.S. across a broad age range (18-73 years).  
Over 28.3% of men were seropositive for ≥1 9vHPV vaccine types, and 11.2% for ≥ 1 of the five 
additional high-risk types. Type specific seropositivity for five additional types was as follows: [HPV 31 
(4.5%), 33 (1.7%), 45 (3.7%), 52 (2.5%), and 58 (4.7%)]. Age, lifetime number of male anal sex partners, 
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and smoking were positively associated with seropositivity of grouped and individual HPV types. A recent 
study110 used competitive Luminex Immunoassay (cLIA) and estimated seroprevalence of 9vHPV vaccine 
types among men using the National Health and Nutrition Examination Survey (NHANES) data. The 
seroprevalence estimates for 9vHPV, and 5-additional types in our study were higher than the NHANES 
study [(28.3% vs. 19.4%) and (11.2% vs. 6.6%) respectively]. The type-specific seroprevalence estimates 
of the five additional types were also slightly higher in our study [HPV 31 (4.5% vs. 2.3%), 33 (1.7% vs. 
1.6%), 45 (3.7% vs. 0.7%), 52 (2.5% vs. 1.3%), and 58 (4.7% vs. 1.5%). Another study112 estimated the 
seroprevalence of five additional types in the Netherlands using virus-like particles (VLP) based serologic 
assay and reported slightly higher seroprevalence estimates than our study for HPV types 33 (1.7% vs. 
6.0%), 45 (3.7% vs. 6.8%) and 52 (2.5% vs.5.2%); and slightly lower estimates for types 31 (4.5% vs. 
2.5%) and 58 (4.7% vs. 3.7%). Some of this variation could be partially explained by the differences in 
serologic assays used, study population, and age distribution across studies.  
Seroprevalence estimates of grouped and individual 4-valent HPV vaccine types in our study were 
considerably lower than the estimates we had previously reported using VLP-based serologic assay.39 
Important demographic and sexual behavior confounders such as age, marital status, education, and lifetime 
number of anal sex partners were similar in both current and previous studies, except for country of 
residence. Compared to previous study, current study had slightly fewer men from the U.S. (31% vs. 37%) 
and marginally higher from Brazil (33 vs. 30%). Since men from U.S. are less likely, and men from Brazil 
are more likely, to be seropositive for 4-valent HPV types as reported in both studies, this difference in the 
sample distribution by country of residence is not likely to underestimate the seroprevalence estimates in 
the current study compared to our previous reports. We believe that this variation is due to differences in 
the serologic assays used in our current and previous study, and that the GST L1-based multiplex serologic 
assay underestimated seroprevalence estimates for 4vHPV types in the current study. Nevertheless, both 
studies have consistently reported that men with multiple lifetime number of anal sex partner, older age, 
single men, and Brazilians are more likely to be seropositive for 4-valent HPV types.  
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 The positive association of increasing age and high-risk HPV in this study is consistent with 
previous serology studies in men,37,39,113,114 and this may reflect the fact that exposure to HPV and antibodies 
as a response accumulate over time. The positive association of the increasing number of male anal sex 
LTP with the seropositivity of HPV is also consistent with previous studies,39,115 and is likely to be explained 
by i) the increased probability of exposure to HPV types due to multiple sex partners, ii) the highest DNA 
prevalence of HPV infection and persistence in the anal canal of MSM, and iii) the anatomic site-specific 
immune response. Studies have shown that HPV infection is common in the anal canal, and its prevalence 
is higher among MSM than men who have sex with women (MSW).115-117 Recently, emerging evidence 
showed that HPV infection persists longer in the anal canal of MSM118 which may explain the highest 
incidence of HPV-related anal cancers in MSM.119 Also, it is suggested that the viral antigen is more 
efficiently detected by the immune system in the mucosal epithelium. Therefore, mucosal epithelium (e.g. 
anal canal) is more likely to induce immune response to HPV infections compared to keratinized epithelium 
(e.g. penile skin).119-121 Therefore, MSM are more likely to have incident, prevalent, and persistent HPV 
infections, and potentially may induce greater immune response because of the anatomic location of their 
infection compared to other sub-groups (e.g. MSW) resulting in high seroprevalence. Current smokers were 
more likely to be seropositive to low-risk HPV (AOR 1.96; 95%CI: 1.17-3.29). Syrjanen et al.122 and Dunne 
et al.37 also reported a two-fold increased risk of low-risk HPV (6/11) seropositivity for current male 
smokers. However, Liu et al.110 did not find an association between smoking and low-risk HPV. In contrast, 
married/cohabiting men were less likely to be seropositive to high-risk HPV compared to single men. 
Similar associations have also been reported by other studies previously.112,123,124 This association is likely 
to be partially explained that single men might have more opportunity of meeting new sex partners than 
married men, therefore, they have a high probability of exposure to different HPV types.  
 Inclusion of men from three countries across a broad range of ages, detailed information on 
demographic and sexual history, and the estimation of prevalence based on type-specific antibodies against 
L1 HPV capsid protein in a single laboratory with one protocol are the strengths of this study. Some 
limitations should be considered when interpreting the results. This study was a cross-sectional analysis 
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which utilized serology and risk factor data collected at baseline. HPV prevalence based on antibody 
response may be affected by waning of antibodies over time and by the seroconversion rate since all infected 
individuals do not produce an immune response to HPV infections; therefore, prevalence and cumulative 
exposure of HPV might be underestimated. Seropositivity in our study was measured by GST-based 
multiplex serologic assay and may not be comparable to estimates measured using other assays. Risk factor 
data was self-reported. Due to social desirability and recall biases lifetime number of sex partners may be 
under- or over-reported. However, the use of computer-assisted self-interviews for sexual behavior data 
may have minimized the social desirability bias. Despite these limitations, this study provides important 
data on the distribution of 9-valent HPV vaccine types in a sample of men from three countries.  
In summary, more than a quarter of men were seropositive for at least one of the nine vaccine type 
HPV, and MSM were two and half times more likely to be seropositivity to ≥1 HPV types, indicating the 
need for HPV immunization in men, and particularly among MSM.  
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Table 4.1. Participant characteristics by seropositivity to high-risk and low-risk types in 9vHPV vaccine  
 
High-risk HPV 
(16, 18, 31, 33, 45, 52, 58) 
Low-risk HPV 
(6, 11) 
 Seropositive Seropositive  
Characteristic  n % p-valuea n % p-valuea 
Country       
  U.S.    19 10.3 0.173 19 10.3 <0.001 
  Brazil 29 14.5  55 27.5  
  Mexico 36 16.8  30 14.0  
Age, Years       
  18-30 26 10.0 0.018 46 17.8 0.976 
  31-44 40 15.6  44 17.2  
  45-73 18 21.7  14 16.9  
Race       
  White                            44 16.4 0.248 56 20.8 0.229 
  Black                            6 7.7  11 14.1  
  Asian                            2 11.8  2 11.8  
  American Indian/Alaska Native    0 0.0  3 33.3  
  Other                            30 13.8  32 14.7  
Ethnicity       
  Hispanic     42 14.9 0.535 45 16.0 0.383 
  Non-Hispanic 40 13.1  57 18.7  
Education, Years       
  ≤12        45 15.7 0.104 54 18.8 0.572 
  13-15        14 8.8  28 17.6  
  ≥16        23 15.4  22 14.8  
Marital Status       
  Single/never married       35 13.5 0.140 52 20.1 0.232 
  Married/cohabitating       35 12.6  44 15.8  
  Divorced/separated/widowed 13 22.4  7 12.1  
  Not reported               1 33.3  1 33.3  
Smoking Status       
  Never   47 13.9 0.909 50 14.7 0.104 
  Former  15 13.3  21 18.6  
  Current 22 15.1  33 22.6  
Alcohol, No. Drinks/Month       
  0           18 12.8 0.818 31 22.0 0.124 
  1–30        41 14.7  40 14.3  
  31-60       10 17.2  14 24.1  
  ≥61        14 12.7  18 16.4  
Circumcision       
  No  57 14.7 0.561 77 19.8 0.034 
  Yes 27 12.9  27 12.9  
Sexual Orientation       
  MSW          67 12.8 0.011 79 15.1 0.001 
  MSM          12 23.5  17 33.3  
  MSWM         5 33.3  7 46.7  
No. of Female LTP       
  0           7 11.7 0.663 15 25.0 0.372 
  1-3         21 16.7  20 15.9  
  4-18        32 13.0  45 18.3  
  ≥19        15 11.9  19 15.1  
No. of Male Anal Sex LTP       
  0            67 13.2 0.003 76 15.0 0.001 
  1            0 0.0  7 25.0  
  ≥2    15 25.9  20 34.5  
Recent Female Sex Partners, #b       
  0            22 19.1 0.096 14 12.2 0.111 
  1            26 10.8  36 14.9  
  ≥2          24 14.8  34 21.0  
Recent Male Anal Sex Partners, #b       
 0  7 12.7 0.021 14 25.4 0.256 
 1  1 7.7  6 46.2  
 ≥2  8 38.1  8 38.1  
a Chi-square and Fisher’s exact tests were used to calculate p-values. significant p-value is marked in bold 
b. Number of female/male sex partners in the past 6 months among those reporting ever having a female/male sex partner 
Note: LTP = lifetime partners, MSW=men who have sex with women;  MSM=men who have sex with men;  MSWM=men who have sex with 
women and men 
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Table 4.2. Grouped and type-specific seroprevalence of 9vHPV types among men from Brazil, Mexico and the 
U.S. 
 
Overall 
(N=598) 
U.S. 
(N=184) 
Brazil 
(N=200) 
Mexico 
(N=214) 
 
HPV Type % % % % P-valuee 
HPV 6 16.2 9.2 25.5 13.6 <0.001 
HPV 11 3.8 2.2 6.0 3.3 0.129 
HPV 16 3.0 1.6 5.5 1.9 0.041 
HPV 18 3.5 1.1 4.0 5.1 0.082 
HPV 31 4.5 3.8 4.0 5.6 0.628 
HPV 33 1.7 1.6 2.0 1.4 0.892 
HPV 45 3.7 1.6 5.0 4.2 0.189 
HPV 52 2.5 3.3 1.5 2.8 0.513 
HPV 58 4.7 6.5 2.0 5.6 0.081 
9vHPVa 28.3 19.0 36.5 28.5 0.001 
High-risk (16, 18, 31, 33, 45, 52, 58)b 14.0 10.3 14.5 16.8 0.173 
Five additional types (31, 33, 45, 52, 58) 11.2 9.2 10.5 13.6 0.368 
Low-risk (6, 11)c 17.4 10.3 27.5 14.0 <0.001 
4vHPV types (6, 11, 16, 18)d 21.2 12.5 32.0 18.7 <0.001 
 
a. 9vHPV category included nine vaccine types (6, 11, 16, 18, 31, 33, 45, 52, and 58). ‘9vHPV’ variable was created, if a man was seropositive 
for one or more of the 9vHPV vaccine types then the ‘9vHPV’ variable was seropositive otherwise seronegative. 
b. High-risk category included seropositivity to at least one of the seven types of HPV (16, 18, 31, 33, 45, 52, and 58).   
c. Low-risk category included seropositivity to at least one of the two types of HPV (6 and 11). 
d. 4vHPV category included seropositivity to at least one of the four types of HPV (6, 11, 16, and 18). 
e. P-values were calculated by Chi-square and Fisher exact tests. Significant p-value is marked in bold.  
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Table 4.3A. Factors independently associated with seropositivity of nine vaccine type HPV in men from Brazil, Mexico and the U.S. 
 9vHPVa High Risk HPVb Low Risk HPVc HPV 6 
Characteristics  
OR 
(95%CI) 
AOR 
(95%CI)e 
OR 
(95%CI) 
AOR 
(95%CI) e 
OR 
(95%CI) 
AOR 
(95%CI) e 
OR 
(95%CI) 
AOR 
(95%CI)e 
Country         
  U.S. 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
  Brazil 2.45 2.18 (1.31 - 3.60) 1.47 1.17 (0.59 - 2.35) 3.29 3.13 (1.71 - 5.75) 3.36 3.15 (1.67 - 5.93) 
  Mexico 1.70 1.66 (1.02 - 2.71) 1.76 2.24 (1.15 - 4.40) 1.42 1.39 (0.74 - 2.62) 1.54 1.48 (0.77 - 2.86) 
Age, Years         
  18-30 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
  31-44 1.12 0.95 (0.63 - 1.43) 1.66 1.95 (1.03 - 3.70) 0.96 0.78 (0.48 - 1.26) 0.99 0.79 (0.48 - 1.30) 
  45-73 1.62 1.43 (0.81 - 2.51) 2.48 2.75 (1.23 - 6.15) 0.94 0.83 (0.41 - 1.68) 1.05 0.92 (0.45 - 1.89) 
Marital Status         
  Single or never married                 -- -- 1.00 1.00 -- -- -- -- 
  Married/cohabitating                          -- -- 1.02 0.50 (0.26 - 0.99) -- -- -- -- 
  Divorced/separated/widowed -- -- 1.15 1.18 (0.52 - 2.70) -- -- -- -- 
Smoking Status         
  Never 1.00 1.00 -- -- 1.00 1.00 1.00 1.00 
  Current 1.51 1.57 (1.01 - 2.44) -- -- 1.69 1.96 (1.17 - 3.29) 1.83 2.12 (1.25 - 3.61) 
  Former  1.14 1.14 (0.69 - 1.89) -- -- 1.32 1.52 (0.84 - 2.77) 1.41 1.58 (0.85 - 2.91) 
No. of Male Anal Sex LTP         
   0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   1 0.97 0.78 (0.32 - 1.92) NE NE 1.89 1.37 (0.54 - 3.44) 2.08 1.52 (0.6 - 3.83) 
  ≥2 3.11 2.52 (1.40 - 4.54) 2.29 2.18 (1.05 - 4.50) 2.98 2.12 (1.12 - 4.03) 3.04 2.19 (1.14 - 4.21) 
OR = unadjusted odds ratio;  AOR = adjusted odds ratio; CI = 95% confidence interval;  LTP = lifetime partners 
‘--‘ variable not included in the final adjusted model  
a.  This category included seropositivity to ≥1 of the nine vaccine types (6, 11, 16, 18, 31, 33, 45, 52, 58)  
b.  This category included seropositivity to ≥ 1of the high-risk types in the vaccine (16, 18, 31, 33, 45, 52, 58) 
c.  This category included seropositivity to ≥ 1 of the low-risk types in the vaccine (16, 18) 
e.  Final adjusted models were estimated using backward stepwise elimination method with a significance level of p-value ≤ 0.1 for retention. Odds ratios were adjusted for all other variables in the 
column.  
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Table 4.3B. Factors independently associated with seropositivity of nine vaccine type HPV in men from Brazil, Mexico and the U.S. 
 HPV 11 HPV 16 HPV 18 HPV 31 
Characteristics 
OR 
(95%CI) 
AOR 
(95%CI)e 
OR 
(95%CI) 
AOR 
(95%CI)e 
OR 
(95%CI) 
AOR 
(95%CI)e 
OR 
(95%CI) 
AOR 
(95%CI)e 
Country         
U.S. 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Brazil 2.87 3.43 (1.04 - 11.35) 3.51 1.71 (0.4 - 7.39) 3.79 3.22 (0.61 - 16.97) 1.05 1.08 (0.34 - 3.42) 
Mexico 1.52 1.66 (0.47 - 5.91) 1.15 1.43 (0.29 - 7.10) 4.93 7.91 (1.51 - 41.34) 1.50 2.65 (0.93 - 7.58) 
Age, Years         
18-30 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
31-44 0.73 0.62 (0.24 - 1.60) 1.71 1.52 (0.42 - 5.42) 2.59 4.60 (1.24 - 17.1) 0.71 1.08 (0.39 - 2.98) 
45-73 1.14 0.98 (0.29 - 3.35) 1.04 0.59 (0.08 - 4.26) 5.87 14.47 (3.24 - 64.68) 0.66 1.04 (0.24 - 4.52) 
Marital Status         
Single or never married -- -- 1.00 1.00 1.00 1.00 1.00 1.00 
Married/cohabitating -- -- 0.76 0.66 (0.17 - 2.56) 0.89 0.17 (0.05 - 0.56) 0.60 0.32 (0.10 - 0.99) 
Divorced/separated/widowed -- -- 1.31 3.58 (0.84 - 15.19) 0.37 0.11 (0.01 - 1.00) 0.37 0.82 (0.20 - 3.42) 
Smoking Status         
Never 1.00 1.00 -- -- -- -- -- -- 
Current 1.50 1.73 (0.65 - 4.65) -- -- -- -- -- -- 
Former 1.38 1.57 (0.51 - 4.84) -- -- -- -- -- -- 
No. of Male Anal Sex LTP         
0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
1 NE NE NE NE NE NE NE NE 
≥2 1.90 1.34 (0.41 - 4.41) 8.85 7.33 (2.22 - 24.17) 0.50 2.48 (0.78 - 7.93) 1.63 1.72 (0.51 - 5.88) 
OR = unadjusted odds ratio;  AOR = adjusted odds ratio;   CI = 95% confidence interval;  LTP = lifetime partners 
‘--‘ variable not included in the final adjusted model  
e. Final adjusted models were estimated using backward stepwise elimination method with a significance level of p-value ≤ 0.1 for retention. Odds ratios were adjusted for all other variables in the 
column. 
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Table 4.3C. Factors independently associated with seropositivity of nine vaccine type HPV in men from Brazil, Mexico and the U.S. 
 HPV 33 HPV 45 HPV 52 HPV 58 
Characteristics 
OR 
(95%CI) 
AOR 
(95%CI)e 
OR 
(95%CI) 
AOR 
(95%CI)e 
OR 
(95%CI) 
AOR 
(95%CI)e 
OR 
(95%CI) 
AOR 
(95%CI)e 
Country         
U.S. 1.00 1.00 1.00 1.00 1.00 1.00 1.00  
Brazil 1.23 0.8 (0.14 - 4.60) 3.17 2.52 (0.62 - 10.28) 0.45 0.30 (0.06 - 1.51) 0.29 0.12 (0.03 - 0.53) 
Mexico 0.86  1.47 (0.26 - 8.26) 2.65 3.05 (0.72 - 12.87) 0.86 0.99 (0.27 - 3.67) 0.85 0.87 (0.33 - 2.29) 
Age, Years         
18-30 1.00 1.00 1.00 1.00 1.00 1.00 1.00  
31-44 0.81 0.83 (0.17 - 4.03) 2.28 3.14 (0.94 - 10.51) 0.84 0.63 (0.15 - 2.57) 1.68 1.82 (0.61 - 5.44) 
45-73 0.62 0.48 (0.04 - 6.05) 3.96 5.43 (1.27 - 23.25) 2.14 1.22 (0.25 - 5.90) 2.89 2.90 (0.81 - 10.47) 
Marital Status         
Single or never married 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Married/cohabitating 0.20 0.36 (0.06 - 2.35) 1.00 0.38 (0.12 - 1.17) 0.69 1.35 (0.29 - 6.21) 0.98 0.83 (0.26 - 2.62) 
Divorced/separated/widowed 1.04 2.05 (0.29 - 14.39) 0.37 0.18 (0.02 - 1.57) 0.76 4.72 (0.90 - 24.77) 1.93 1.80 (0.47 - 6.81) 
Smoking Status         
Never -- -- -- -- -- -- -- -- 
Current -- -- -- -- -- -- -- -- 
Former -- -- -- -- -- -- -- -- 
No. of Male Anal Sex LTP         
0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
1 NE NE NE NE NE NE NE NE 
≥2 6.19 7.36 (1.56 - 34.77) 2.90 1.9 (0.59 - 6.14) 2.25 4.03 (0.89 - 18.28) 1.99 4.49 (1.36 - 14.8) 
OR = unadjusted odds ratio;  AOR = adjusted odds ratio;   CI = 95% confidence interval;  LTP = lifetime partners 
‘--‘ variable not included in the final adjusted model  
e. Final adjusted models were estimated using backward stepwise elimination method with a significance level of p-value ≤ 0.1 for retention. Odds ratios were adjusted for all other variables in the 
column. 
 
 
 
 
 
 
 
51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1A. Grouped HPV seroprevalence of nine vaccine types by age group   
Figure 4.1A shows seropositivity for 9vHPV, high-risk, five additional types, low-risk, and 4vHPV categories by three age groups (18-30 years, 31-44 years, and 
45-73 years).  9vHPV category included nine vaccine types (6, 11, 16, 18, 31, 33, 45, 52 and 58). ‘9vHPV’ variable was created, if a man was seropositive for one 
or more of the nine vaccine types then ‘9vHPV’ was seropositive otherwise seronegative. 4vHPV category included seropositivity to at least one of the four types 
of HPV (6, 11, 16 and 18). High risk category included seropositivity to at least one of the seven types of HPV (16, 18, 31, 33, 45, 52 and 58).  Low risk category 
included seropositivity to at least one of the two types of HPV (6 and 11). Significant p-value <0.05 is marked with ‘*’. P-value was obtained from Cochran-
Armitage Trend Test. Ptrend <0.05 for high-risk and five additional types categories. 
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 Figure 4.1B. Type-specific seroprevalence of nine HPV vaccine types by age group  
Figure 4.1B shows seropositivity for type-specific HPV. Significant p-value <0.05 is marked with ‘*’. P-value was obtained from Cochran-Armitage Trend Test. 
Ptrend <0.05 for HPV types 18, 45 and 58. 
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CHAPTER FIVE: 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
This study estimated the seroprevalence of 14 cutaneous HPV, β types (5, 8, 12, 14, 17, 22, 23, 24, 
38 and 47), α type 27, γ type 4, µ type 1, and ν type 41, and 9vHPV vaccine types (6, 11, 16, 18, 33, 45, 52 
and 58) and investigated factors associated with the seropositivity in a random sample of 600 men residing 
in Brazil, Mexico, and the U.S. enrolled in the prospective HIM Study. It also investigated association 
between seropositivity to cutaneous HPV types and the risk of external genital lesions (EGLs) comparing 
163 incident EGL cases to 352 EGL-free controls nested in the HIM cohort. This was one of the few studies 
to estimate seroprevalence of cutaneous HPV and 9vHPV types and evaluate association between cutaneous 
HPV seropositivity and the risk of EGLs prospectively in men across a broad range of age from three 
countries. 
Approximately 65.4% of men were seropositive for ≥1 cutaneous HPV types, and 39.0% for ≥1 β-
HPV types. The most commonly occurring type-specific HPV were ɤ-HPV 4, µ-HPV 1, and β-HPV 8. 
Compared to men with ≤12 years of education, men with ≥16 years of education, and compared to men 
aged 18-30 years, men aged 31-44 years, were 1.75 times and 1.72 times more likely to be seropositive to 
≥1 cutaneous HPV types, respectively. Country of residence was significantly associated with β-HPV types 
(5, 12, 14, 24 and 47), older age was significantly positively associated with β-HPV types (8, 14, 22, 38 
and 47), circumcision status was significantly positively associated with β-HPV types (5, 14, 24 and 47) 
and γ-HPV type 4, and lifetime number of male anal sex partners were significantly positively associated 
with HPV types (23, 24 and 17). These data show that exposure to cutaneous HPV is common among men 
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and that prevalence estimates based on antibodies against L1 major capsid HPV protein represent 
cumulative exposure to cutaneous HPV over time which may rise with increasing age. 
Several studies have reported a positive association between cutaneous HPV seropositivity and skin 
cancer, and a variety of cutaneous HPV types are detectable in the genital epithelial lesions. However, it 
remains unclear whether these viruses are causally associated with the diseases. This study also investigated 
association between seropositivity to cutaneous HPV types and the risk of development of EGLs among 
men from three countries. Incident EGL cases were ascertained through visual inspection, verified through 
biopsy and pathological examination, and categorized into condyloma, suggestive of condyloma, penile 
intraepithelial neoplasia (PeIN), and other EGL cases. Controls included men who did not develop any EGL 
in the entire follow up period. No statistically significant association was observed between grouped and 
type-specific cutaneous HPV seropositivity and development of EGLs across all pathological diagnoses. 
Overall, the seroprevalences of grouped and type-specific HPV were similar across different EGL 
categories and controls with the most frequent types being ɤ type 4, µ type 1 and β type 8. Our data show 
that exposure to cutaneous HPV is common, and exposure to cutaneous HPV is not likely to increase the 
risk of EGLs among men. 
Recently, the 9-vHPV vaccine was approved for use in for both in men and women living in the 
U.S. In addition to the four HPV types (6, 11, 16 and 18) targeted previously in the quadrivalent HPV 
vaccines, the 9vHPV vaccine also prevents against five additional high-risk HPV types (31, 33, 45, 52 and 
58). Measuring seropositivity before vaccine introduction and dissemination provides baseline data on 
exposure and is essential for monitoring the effectiveness of vaccines over time. This study also estimated 
seroprevalence of 9vHPV types and investigated factors associated with the seropositivity in a random 
sample of 600 men enrolled in the HIM cohort. Approximately 28.3% of men were seropositive for ≥1 
9vHPV types, 14.0% for ≥1 seven high-risk HPV, 11.2% for ≥1 five additional high-risk, and 17.4% for 
≥1 low-risk HPV types (6/11). Compared to men with no partners, men with ≥2 lifetime anal sex partners 
were two times significantly more likely to be seropositive for grouped 9vHPV, high-risk, and low risk 
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HPV, and individual types (6, 16, 33, and 58) with odds ratios ranging from 2.19 to 7.36. Compared to men 
aged 18-30 years, men aged >30 years were two times significantly more likely to be seropositivity for 
grouped high-risk HPV, and compared to never, current smokers were nearly two times more likely to be 
seropositivity for low-risk HPV. In contrast, compared to single men, married men were two times less 
likely to be seropositive for grouped high-risk HPV. Our data show that exposure to 9vHPV vaccine types 
is common among men. Older men and men who have sex with men are at highest risk.  
Inclusion of men from three countries across a broad range of age, detailed information on 
demographic and sexual history, the estimation of prevalence based on antibodies against L1 HPV capsid 
protein in a single laboratory simultaneously by multiplex serology, biopsy-confirmed incident EGL cases, 
and the prospective evaluation of the association are major strengths of this study. However, this study has 
limitations that should be considered when interpreting the results. Antibodies against L1 HPV capsid 
protein are considered a marker of cumulative exposure to HPV infections. However, all infected men with 
HPV do not induce antibody response and that the antibodies may decline over time. Therefore, prevalence 
and cumulative exposure of HPV in our study might be underestimated. Due to lack of information on 
serodynamics of cutaneous HPV, the impact of seroconversion, clearance of infection, and waning of 
antibodies over time could not be assessed. Also, the anatomic site of HPV infection cannot be determined. 
These are limitations relevant to all serological studies. Seropositivity in our study was measured by GST-
based multiplex serologic assay and these estimates may not be comparable to estimates measured by other 
HPV serologic assays. The limited number of PeIN cases restricted our ability to conduct sub-group 
analyses for PeIN. Despite these limitations, this study provides important data and contributes to the 
understanding of the distribution and associated factors of cutaneous HPV and 9vHPV. Furthermore, it 
provides evidence on the etiologic role of exposure to cutaneous HPV in development of EGLs. 
This study was one of the few to estimate seroprevalence of cutaneous HPV and 9vHPV types in 
men across a broad range of age from three different countries and examined the etiologic role of exposure 
to cutaneous HPV and the risk of EGLs. To validate these results, future large prospective studies of 
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cutaneous HPV with repeated measures are recommended to evaluate the etiologic role of cutaneous HPV 
in the development of skin lesions including skin cancer, and benign and malignant diseases of the genitalia. 
Research on HPV is rapidly evolving and new types and strains are discovered on a regular basis, future 
studies should include newly discovered and less explored types and sub-types of HPV as well. It is also 
recommended that more than one measure of HPV exposure should be used and that the impact of 
seroconversion rate along with the decay of antibodies over time be assessed. Until the current international 
efforts to standardize HPV serologic assays yield some fruitful results, it is also recommended that future 
studies utilize more than one serologic assays so that the results could be compared and contrasted to 
previous literature utilizing different assays. Also, future studies should focus on identifying viral 
mechanism and pathway of pathogenesis for cutaneous HPV infections which is currently unknown at large. 
Finally, future research should focus on summarizing and consolidating results from studies on HPV 
epidemiology, serology, and natural history to inform public health policy and practice and vaccine 
development efforts.  
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APPENDIX 1. LITERATURE REVIEW 
 
 
A1.1. HUMAN PAPILLOMAVIRUS (HPV) VIRAL STRUCTURE AND PROTEINS  
The HPV genome is a double-stranded circular DNA which is approximately 8 kb (7200-8000 base-pair) 
long (Figure 1).1  HPV DNA can be divided into early (E), late (L) and long control (LCR, non-coding) regions.1 
These regions are separated by two (early and late) polyadenylation (pA) sites.1  The early region constitutes more 
than 50% of the total viral genome and includes six open reading frames (ORFs) that encodes  E1, E2, E4, E5, E6 and 
E7 viral proteins.2  The late region, located downstream of the early region, forms 40% of the viral genome, and has 
L1 and L2 ORFs which encodes major (L1) and minor (L2) viral capsid proteins.  LRC forms 10% of the viral genome, 
and it is a non-protein coding region which regulates the process of viral replication2  
The E1 viral protein is required for DNA replication.  It binds with the origin of replication located in the 
LCR region, functions as helicase, and prepares viral genome for replication3 Also, the E1 protein recruits other 
replication proteins such as DNA polymerase from the host cell.2  E2 viral protein assists E1 to bind with the origin 
of replication, but its primary function is regulation of the transcription process.4 Also, E2 has a negative regulatory 
mechanism with E6 and E7 viral oncogenes.5  Active E2 inhibits the expression of E6 and E7 and overexpresses p53 
gene of cell which results in apoptosis. Whereas inactivated E2 overexpresses E6 and E7 oncoproteins resulting in 
cellular transformation and genetic destabilization.5,6 E4 viral protein is mainly found in the cytoplasm of the host 
cells and is expressed in the late phases of the infection.  It facilitates viral release to the environment.7  The E4 may 
also play a role in the host cell cycle by arresting the G2 phase.7  E6 and E7, viral oncoproteins, are of particular 
interest because of their role in the HPV related malignant transformation of human cells.  The major role of E6 is 
degrading tumor suppressor protein, p53, in the host cells which in turn results in the DNA destabilization.  The E6 
protein also alters several other cellular pathways and disturbs the cell cycle and the cell maturation process.8,9 The 
E7 oncoprotein degrades the tumor suppressor protein, retinoblastoma (pRb), of the host cells.  Together E6 and E7 
prevent cell death by inhibiting apoptosis, promoting cell-cycle progression, and immortalizing keratinocytes so that 
the virus can continue to replicate.8,9 L1 and L2 are capsid proteins, both are about 500 amino acids long.  HPV virons 
contain about 10 times more L1 protein than L2.  This is why it is called a major capsid protein.10 
 
\ 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.1. Human papillomavirus genome structure  
This figure illustrates the genomic structure of HPV. The virus has three regions: Long control (LCR), early (E) and 
late (L) regions. LCR is a non-coding regulatory region. The E-region encodes E1, E2, E4, E5, E6 and E7 early 
proteins; and the L-region encodes L1 and L2 HPV capsid proteins.6  
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A1.2. CLASSIFICATION OF HPV 
The Papillomaviridae family (also known papillomaviruses [PV]) includes highly diverse DNA viruses 
which infect mucosal and cutaneous epithelium of humans and other vertebrates.11  PV are classified into 29 genera, 
which include over 200 types.12  More than 120 types of PV are isolated from human cells hence called human 
papillomaviruses (HPV) and are classified into five genera: Alpha, Beta, Gamma, Mu, and Nu.12,13  By convention, a 
new type of HPV is recognized if it is ≥10% different in the L1 open reading frame (ORF) region from the already 
sequenced types. About 60-70% of the nucleotides identity in the L1 region is shared by viruses that are placed in a 
particular genus.14 L1 ORF is a highly conserved region of the HPV genome and from 2 to 10% variation in the 
nucleotides in the L1 region creates a sub-type, and variation in less than 1% creates a new variant.12  Due to shortfalls 
in the classic, and immunological-based classifications of HPV, the genome-based approach is widely used.11,12 
Bernard et al. has presented an expanded classification for PV using L1 nucleotide sequence, which contains 
29 genera and 189 types. Out of these, 120 types are isolated from humans, 64 from the non-human mammals, 3 from 
birds and 2 from reptiles. Greek letters were used to designate genera (Figure A1.2).11,12 The International Agency for 
Research on Cancer (IARC) expert group has classified mucosal HPV based on their carcinogenic potential into 
groups: 1A (high-risk), 2A (probable) and 2B (possible) cause for cancer. The high-risk group includes HPV 16, 18, 
31, 33, 35, 45, 52, and 58, more constantly found in the cervical cancer; and HPV-39, 51, 56, and 59, less constantly 
found in the cervical cancer. Among the high-risk group, HPV 16 is the most important cause of cancer.15 Due to 
limited evidence in humans and strong mechanistic evidence for cervical cancer, HPV 68 was classified as 2A; and 
due to limited evidence in humans, HPV 26, 30, 34, 53, 66, 67, 69, 70, 73, 82, 85, and 97 were classified as 2B or 
probable cause of cancer. HPV 6 and 11 were classified as group 3 (not carcinogens) due to inadequate 
epidemiological evidence and lack of carcinogenic mechanism. Beta HPV types 5 and 8 were classified as 2B 
(probable) and other gamma types were classified as group 3 (Table A1.1).15 
 
 
 
Figure A1.2. Phylogenetic tree of 189 papillomavirus types based on L1 nucleotide sequence* 
Greek letters represent genus and within each genus there are species ([groups] i.e. α1, α2, α3…α14), and the numbers 
at the end of each branch represent types. *Adopted from Bernard et al.12 
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Table A1.1. The IARC classification of HPV* 
Group   HPV types Comments 
Alpha HPV types 
1 16 
Most potent HPV type, known to cause cancer at 
several sites 
1 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 Sufficient evidence for cervical cancer 
2A 68 
Limited evidence in humans and strong 
mechanistic evidence for cervical cancer  
2B 26, 53, 66, 67, 70, 73, 82 Limited evidence in humans for cervical cancer 
2B 30, 34, 69, 85, 97 
Classified by phylogenetic analogy to HPV types 
with sufficient or limited evidence in humans. 
3 6, 11  
Beta HPV types 
2B 5 and 8 
Limited evidence for skin cancer in patients with 
epidermodysplasia verrcuiformis 
3 Other beta and gamma types  
*Adopted from A review of human carcinogens – Part B: biological agents 15 
A.1.3. HPV LIFE CYCLE AND PATHOGENESIS 
Unlike most viruses that produce their progeny from the infected cell directly, HPV relies on the mitosis and 
differentiation of the basal epithelial cells to produce its progeny. Understanding of the HPV lifecycle is mainly 
derived from research on HPV 16. However, with slight modifications, life cycle model of HPV 16 can be applied to 
other HPV types as well.17 Skin to skin contact is the primary route of transmission, and sexual behavior greatly 
influences the incidence and prevalence of HPV infections.18   Virus finds its way to basal epithelial cell via micro-
abrasions and micro-traumas on the skin. It is not fully understood how the virus binds with the surface of basal cells. 
However, L1 and L2 capsid proteins, alpha-6 integrin cellular receptors, and heparan sulfate proteoglycans/heparin 
sulfate may play a role in the process of binding.19  The virus enters basal epithelial cells through endocytosis, and the 
capsid is disassembled by the cellular endosome/lysosome. The L2 viral protein transfers the viral genome to nuclei 
of keratinocytes,20 and with the help of early viral proteins (E1 and E2), the virus maintains its episomal form and 
replicates in synchrony with the host DNA.17 As the infected host cells differentiate, late viral promoters are activated 
which facilitate viral packaging and release.17,20 Usually the expression of L1 and L2 viral proteins takes place in the 
granular layer the viral assembly in the cornified layer of the skin.7,20 Viruses are constantly released to the 
environment as the keratinocytes age and die.17  
 
A.1.4. PREVALENCE OF CUTANEOUS HPV  
Normal human skin hosts a diverse array of microbiota.  Recent developments in meta-genomic techniques 
have revealed that a diverse array of viruses including cutaneous HPV, particularly beta and gamma genera represent 
a significant part of the skin flora.21 Cutaneous HPV is also widely distributed in eyebrow hairs,22 and external genital 
lesions (EGLs).23 Until recently, about 51 β-HPV types and 80 γ -HPV types have been identified and sequenced.24 
Details of the types and sequence data can be found on (http://www.hpvcenter.se/html/refclones.html).  
Hampras et al.25 followed 209 men enrolled in the HIM study, a prospective study of the natural history of 
HPV infections in men, for a median of 12.6 months and measured DNA for 25 types of β cutaneous HPV and 16 
types of γ cutaneous HPV in  skin swabs and eyebrow hairs. They reported a prevalence of 67.3% for any β-HPV in 
the skin swabs, and 56.5% in the eyebrow hairs, and 15.9% for any γ-HPV in the skin swabs and 26.8% in  the eyebrow 
hairs. In this study, the prevalence of ‘any-HPV’ was associated with older age in both types of specimens, (skin 
swabs, OR = 2.3; 95% CI: 1.2 – 4.6) and (eyebrow hairs, OR= 3.0; 95% CI: 1.2 – 7.0) for men over age 44  years 
compared with those age 18-33 years old , respectively.  
One study16 estimated seroprevalence of 36 cutaneous HPV among 411 patients recruited from a skin cancer 
screening clinic in Tampa Florida and reported a seroprevalence of 96% in men for ≥1 HPV types. Seroprevalence of 
γ-HPV type 4 was (46%), µ-HPV type 1 (37%) and β-HPV type 1 (31%). Another skin cancer case-control study26 
measured serum antibodies against major capsid L1 protein of cutaneous HPV type(s) within genera beta (β), gamma 
(γ), mu (µ) and nu (ν) among healthy controls and patient with squamous cell carcinoma (SCC). The study reported 
the following seroprevalence estimates for the control group: 33.3% for any β1-HPV (types: 5, 8, 20, 24, 36); 47.7% 
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for any β2-HPV (types: 9, 15, 17, 23, 38, 107); 33.7% for any β3-HPV (types: 49, 75, 76); 16.7% for any β4-HPV (type 
92); and 15.0% for any β5-HPV (type 96). Seroprevalence of γ-HPV type 4 was 34.3%, and the seroprevalence of µ-
HPV type 1 and ν-HPV type 41 were 32.0% and 11.3% respectively. Another study27 estimated seroprevalence of 
cutaneous HPV in a hospital-based case-control study. Cases were non-melanoma skin cancer patients and controls 
were patients with benign skin lesions. The study reported an overall seroprevalence of 42% for any β-HPV among 
the controls. Type-specific seroprevalence of antibodies against the major capsid L1 protein were reported as follows:  
β-HPV type 20 (14%), β-HPV type 5 (15.0%), β-HPV type 36 (7.0%), β-HPV type 8 (26.0%),  β-HPV type 24 
(11.0%), β-HPV type 15 (12.0%), β-HPV type 9 (12.0%), β-HPV type 38 (18.0%) and ν-HPV type 1 (18.0%).  
One case series23of 69 men included pathologically confirmed EGL patients and reported DNA prevalence 
of 61.1% for 25 β-HPV (types: 5, 8, 12, 14, 19, 20, 21, 24, 25, 36, 47, 93, 9, 15, 17, 22, 23, 37, 38, 80, 49, 75, 76, 92 
and 96) detected on the surfaces of EGLs with the most common types being 38 (16.7%), 5 (15.3%), and 12 (12.5%). 
Another study24 estimated DNA prevalence of 43 β-HPV types and 30 γ-HPV types in anal samples obtained from 66 
HIV-positive men sex with men (MSM), and 153 HIV-negative MSM. Among HIV-positive MSM, the study reported 
DNA prevalence of β-HPV (65.6%) and γ-HPV (68.2%), and among HIV negative MSM β-HPV (59.1%) and γ-HPV 
(57.7%) respectively. The study also reported a significantly higher DNA prevalence of β-HPV type 1, β-HPV type 
3, γ-HPV type 6, and γ-HPV type 7 among HIV positive MSM compared to HIV negative MSM. One study assessed 
DNA prevalence of HPV types (5, 8, 9, 12, 14, 15, 17, 19-25, 36-38, 47 and 49) among 26 renal transplant patients 
and 22 healthy individuals in hairs plucked from eyebrows, scalp, arms and legs. The study reported a DNA prevalence 
of 92% for ≥1 HPV types among the renal transplant patients, and 45% among the healthy individuals.28 
Very few studies have assessed the prevalence and persistence of cutaneous HPV among healthy 
individuals.22,29 One study22 assessed prevalence and persistence of 25 types β-HPV among 23 immuno-competent 
individuals over a period of two years and collected eight consecutive hair samples plucked from eyebrows. The study 
reported the baseline DNA prevalence to at least one β-HPV (61%) which increased to (96%) during the follow-ups 
with the most common type being β-HPV type 23. Type-specific β-HPV DNA was persistent for six months or longer 
in 74% cases.  
Antonsson et al.30 examined skin swab specimens obtained from newborns and infants, their mothers and 
environmental samples for cutaneous HPV DNA. On the day of birth, two of 16 babies, and on the second day of life, 
8 of 16 babies, tested positive for cutaneous HPV DNA. They reported that cutaneous HPV DNA was detected in over 
50% of the samples obtained from 1-month, 1-year and 4-year old children. Similarly, about 77% of the samples 
obtained from the mothers and 18% of the environmental samples (mother’s bed-side table in the maternity ward) 
tested positive for cutaneous HPV DNA. The finding that HPV DNA is already present in the early life shows that it 
is environmentally ubiquitous. Another multinational study31 assessed for cutaneous HPV DNA in the skin swabs 
obtained from women in five countries and reported the following prevalence estimates: Bangladesh 68%, Japan 54%, 
Ethiopia 52%, Zambia 42% and Sweden 70%. HPV 5 was the most commonly detected type.  
In summary, the prevalences of cutaneous HPV differ across studies depending on whether the estimates are 
based on DNA detection or serum antibodies, whether the population is healthy or sick, older or younger. Table A1.2 
shows a comparison for various cutaneous HPV types across four studies. It can be seen that estimates are also different 
based on the site of sample collection (e.g. eyebrow specimens or skin swabs) and the population being investigated.  
Different studies have included different sets of cutaneous HPV with the most common being beta types 5, 8, 9, 20 
and 38. Also, statistical methods and reported measures varied across studies. Some studies reported prevalence 
estimates based on genus (e.g. β-HPV, γ-HPV), while other studies reported positivity to one type, two types, three 
types and so on. The prevalence estimates to at least one HPV (‘any-HPV’) increased when the number of the types 
in the study increased, whereas the prevalence estimates decreased when concurrent seropositivity was measured for 
more than one type (i.e., positive for 2 types or 3 types).  
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Table A1.2. DNA distribution and antibodies prevalence of various cutaneous HPV types  
HPV types 
Innacone et al.16,a Iannacone at al.26 Andersson et al.27 Pierce-Campbell et al23,b Hampras et al.25 
Seroprevalence 
(%) 
Seroprevalence 
(%) 
Seroprevalence 
(%) 
DNA 
Prevalence (%) 
DNA 
Prevalence (%) 
Screening Clinic 
Patients  
Controls SCC SCC BCC Controls Condyloma PeIN Eyebrow Skin 
HPV 27 (α) 18.0 11.0 16.8 - - - - - - - 
HPV 5 (β) 14.0 12.7 20.2 19.0 13.0 13.0 21.0 0.0 7.7 17.3 
HPV 8 (β) 31.0 23.0 36.0 29.0 23.0 26.0 17.9 0.0 6.7 4.5 
HPV 9 (β) 24.0 25.0 29.5 21.0 8.0 12.0 7.1 16.7 5.7 6.4 
HPV 12 (β) - - - - - - 10.7 0.0 9.6 19.9 
HPV 14 (β) - - - - - - 17.9 0.0 2.4 3.8 
HPV 17 (β) 25.0 25.7 35.3 - - - 10.7 16.7 6.2 10.3 
HPV 20 (β) 21.0 21.0 29.5 13.0 13.0 13.0 0.0 0.0 4.8 3.2 
HPV 22 (β) - - - - - - 14.3 0.0 8.1 6.4 
HPV 23 (β) 19.0 - - - - - 14.3 0.0 13.4 8.3 
HPV 24 (β) 20.0 12.3 20.8 17.0 9.0 11.0 7.1 0.0 - - 
HPV 38 (β) 20.0 24.7 24.3 25.0 16.0 18.0 21.4 16.7 15.3 14.1 
HPV 47 (β) - - - - - - 10.7 0.0 3.3 5.8 
HPV 4 (γ) 46.0 34.3 43.4 - - - - - 6.2 13.4 
HPV 1 (µ) 37.0 32.0 38.2 21.0 19.0 18.0 - - - - 
HPV 41 (ŋ) 14.0 11.3 12.1 - - - - - - - 
a. Patients were recruited from a skin cancer screening clinic in Tampa Florida  
b.A case series of 69 subjects, 28 condyloma and 6 PeIN cases. 
 
 
A.1.5. CUTANEOUS HPV AND NON-MELANOMA SKIN CANCER 
Emerging evidence suggests that cutaneous HPV is associated with the risk for non-melanoma skin cancer. 
Before this association is further described, a brief note is presented on skin cancer. Normal skin consists of three 
layers, the epidermis, dermis and the sub-cutaneous layer.32 The epidermis is the top layer of the skin and consists of 
three main types of cells: squamous cells, which are constantly shed and replaced; basal cells, which constantly divide 
and replace the shed squamous cells; and melanocytes which give color to skin. The dermis is the middle layer of skin 
that contains hair follicles, sweat glands, blood vessels, nerves and collagen fibers. The sub-cutaneous layer is the 
deepest layer and is composed mainly of fat cells.32,33 Skin cancer is the most common type of cancer among 
Caucasians worldwide. There are three main types of skin cancer: a) basal cell carcinomas (BCC), squamous cell 
carcinomas (SCC), and c) melanomas. The most common type of skin cancers are BCC and SCC, and together they 
are also called non-melanoma skin cancer (NMSC).34 NMSC are mainly found on the sun-exposed parts of the body 
such as the head and neck. NMSCs are strongly related with sun exposure.35,36 The other less common form of skin 
cancer is melanoma which originates from melanocytes.37 Melanoma can be found anywhere on the body, most 
commonly on the chest and the back in men and on the legs in women.37  Annually, around 5 million skin cancer 
patients are treated in the United States. In 2006, an estimated 3.5 million new cases of skin cancer were diagnosed in 
2.2 million people.38  The lifetime risk for skin cancer for Americans is one in five,39,40 Around 2.8 million patients 
with BCC and another 0.7 million with SCC are diagnosed annually in the U.S.40 In the past few decades, SCC 
incidence has doubled.41 Close to 90% of NMSC and 85% of melanomas are associated with UV radiation from sun 
exposure.42,43 In 2002, nearly 374,000 cases of NMSC were diagnosed and the age-standardized rate per 100 000 
persons for NMSC in Australia was 1170 (BCC 884, SCC 387).44 
Epidemiologic evidence examining the association of UV and skin cancer can be summarized as follows. 
Studies have reported a negative correlation between latitude of residence and incidence and mortality of NMSC and 
melanoma.45 Animal models have shown that skin cancer could be produced by exposing mice to UV radiation.46 
Patients with genetic disorders who cannot repair UV-induced DNA damage adequately have higher incidence rates 
of skin cancers.46 UV-carcinogenesis is a complex multistage process that involves cancer initiation, promotion and 
 
 
72 
 
 
progression. DNA damage is induced by UV radiation, which is promoted by UV-induced immunosuppression and 
other host and environmentally related factors to pre-cancerous and cancerous lesions.47,48  
A number of studies have assessed the association between cutaneous HPV and skin cancer.26,49-52  One 
study26 examined the association between cutaneous HPV (genera: α, β, γ, µ and ν) and SCC comparing 173 SCC 
cases to 300 controls in a clinic-based case-control study conducted in Tampa, Florida. Serum antibodies against L1 
capsid protein were tested for genera alpha (2, 3, 7, 10, 27, 57, and 77); beta (5, 8, 9, 15, 17, 20, 23, 24, 36, 38, 49, 75, 
76, 92, 96, and 107); gamma (4, 48, 50, 65, 88, 95, 101, and 103); mu (1); and nu (41). The study found that serum 
antibodies against any HPV in genus-beta was positively associated with increased risk of SCC (OR = 1.93; 95% CI: 
1.23–3.02). Type-specific associations for β-HPV type 8 was (OR= 1.80; 95% CI: 1.14–2.84), for β-HPV type 17 
(OR=1.59; 95% CI: 1.02–2.49), and for α-HPV 10 (OR= 2.24; 95% CI: 1.04–4.85).  
A multicenter case-control study,49 compared 689 SCC patients with 845 controls recruited from the 
Netherlands, Italy and Australia. Serum antibodies against L1 capsid protein and DNA in eyebrow specimens were 
tested for 15 HPV types of genus beta (types: 5, 8, 9, 15, 17, 20, 23, 24, 36, 38, 49, 75, 76, 92, and 93). The study 
reported that any-beta HPV DNA was associated with an increased risk for SCC in the Netherlands (OR = 2.8; 95% 
CI: 1.3-5.8) and Italy (OR= 1.7; 95%CI: 0.79-3.6), but not in Australia (OR = 0.91; 95% CI: 0.53-1.6). In addition, 
serum antibodies against any β-HPV were positively associated with SCC in Australia (OR= 2.2; 95% CI: 1.4-3.3), 
the Netherlands (OR = 2.0; 95% CI: 1.2-3.4) and Italy (OR= 1.6, 95% CI: 0.94- 2.7). A stronger association between 
UV susceptibility and SCC among β-HPV seropositive individuals also was reported, supporting the possible 
interaction between cutaneous HPV and UV exposure  
Another case-control study,50  investigated the association between the presence of DNA of β-cutaneous HPV 
types 5, 8, 15, 20, 24 and 38 in eyebrow hairs and the risk for SCC in 155 immunocompetent SCC patients and 371 
controls. The study reported age- and sex- adjusted odds ratios of 1.70 (95% CI: 1.10-2.70) for increased risk for SCC 
among people who tested positive to at least one of these types of HPV.  Neale et al.51 hypothesized that higher viral 
load of β-cutaneous HPV might be responsible for the increased risk of SCC. They conducted a study examining the 
association between eight β-cutaneous HPV (types: 5, 8, 15, 20, 23, 24, 36 and 38) viral load measured in eyebrow 
hair follicles and the risk of SCC in a hospital-based case-control study comparing 448 immunocompetent SCC cases 
with 464 controls from Italy and Australia, and 179 organ transplant recipients (OTR) SCC cases with 318 controls  
Compared with the lowest tertile, participants in the highest tertile of cumulative β-cutaneous HPV viral load were at 
a significantly higher risk for SCC in Australia and the in OTR group.  
In a population-based case control study conducted in the U.S., Karagas et al.52 compared 663 SCC and 898 
BCC cases with 805 controls. Serum antibodies against L1 capsid protein were tested for 16 β-cutaneous HPV (types: 
5, 8, 9, 15, 17, 20, 23, 24, 36, 38, 49, 75, 76, 92, 96 and 107). Seropositivity to β-cutaneous HPV was positively 
associated with SCC but not with BCC. Also, a dose-response association was reported where the odds ratios increased 
with increasing numbers of seropositivity to β-cutaneous types (P for trend = 0.003). Age, sex, education, smoking 
and skin sensitivity adjusted odds ratios were as follows: For one type β-cutaneous HPV positive: 0.99 (95% CI: 0.74–
1.33); for 2-3 types positive: 1.44 (95% CI: 1.03 – 2.01); for 4-8 types positive 1.51 (95% CI: 1.03 – 2.20); and for 
more than 8 types positive 1.71 (95% CI: 1.12 – 2.62).  These data suggest that unlike mucosal HPV types, cutaneous 
HPV might work in a group in the carcinogenesis of SCC. 
In summary, the literature is consistent in showing that cutaneous HPV is positively associated with the risk 
for SCC of the skin. The association remains present after controlling for age and other NMSC risk factors, and is 
consistently reported for cutaneous HPV in genus beta, particularly for HPV 5, 8 and 10. Studies show that this 
association is more pronounced in ORT and immunocompromised patients who are at increased risk for both 
cutaneous HPV infections and SCC. Although the exact mechanism of this association is not fully understood, an 
interaction between UV exposure and cutaneous HPV infections might be responsible. It is also suggested that 
cutaneous HPV might work as group of viruses in carcinogenesis of SCC, unlike the mucosal HPV types where the 
majority of the cancers are caused by two types (HPV 16 and 18). However, the temporality of this association has 
not yet been established as the only prospective study of the association is on-going and has not yet reported data.  
 
A.1.6. RELATIONSHIP OF HPV, PENILE CANCER, PeIN, AND GENITAL WARTS 
In this section, we begin with a brief description of the anatomy and histology of the penis, penile cancer, its 
incidence prevalence and potential risk factors for penile cancer.  Subsequently, a description of the distribution of 
mucosal HPV in penile cancer/penile intraepithelial neoplasia (PeIN) and genital warts will be presented. Finally, the 
section will be concluded with cutaneous HPV distribution in penile cancer/PeIN and genital warts. 
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The human penis is an intromittent organ of the male reproductive system which also serves as a urinal duct. 
The penis is made of three parts, root (radix), body (corpus) and glans. The root consists of the median urethral bulb 
and crura which attaches the penis to the fasciae and pubic rami in the perineum. The body includes three masses of 
erectile tissues, two on both sides are corpora cavernosa, and below them is corpus spongiosum through which the 
urethra passes. At birth, the glans is covered by foreskin or prepuce which is often removed in infants through 
circumcision.53,54 The body and glans are covered by a thin stratified squamous epithelium, loosely connected to the 
deeper parts of the body of the penis, and is non-keratinized at glance before circumcision.55  The skin of the penis is 
an extension of the lower abdominal-wall skin. It covers the body of the penis and joins the smooth and hairless skin 
of the glans penis at the corona. The subcutaneous tissues of the penile skin are rich in smooth muscles, also called 
Dartos Facial, which continues into the perineum and fuses with the perineal fasciae.53,54 
Over 95% of penile cancers are of the squamous cell carcinoma (SCC) type.56 SCC can develop anywhere 
on the penis, but the most common sites are the glans and foreskin. Generally, SCC of the penis grows slowly over 
many years. Before the development of a fully invasive penile cancer, pre-malignant changes occur in the skin cells 
of the penis.56 Cancerous cells restricted to the penile skin that have not spread to any deeper tissues, are called 
carcinoma in situ or penile intraepithelial neoplasia (PeIN).56 Penile cancer is relatively rare in developed countries 
comprising only 1% of all cancers in men.57 The age-standardized incidence of penile cancer in Europe and the U.S. 
is about 1 per 100,000 men.57 However, penile carcinoma is relatively common in developing countries comprising 
up to 10% of all malignancies in men,58 and the incidence ranges from 3 per 100,000 men in India to 8.3 per 100,000 
men in Brazil. Penile cancer incidence rates in Uganda are higher where the cumulative incidence approaches 1% by 
age 75.58 Over 25% of penile cancer metastases are usually to the inguinal lymph nodes.56 
Recent studies show that incidence rates of penile cancer are on the rise in some European countries.59 The 
epidemiology of penile cancer is mainly drawn from case-reports and case-series, and very few population-based 
studies exist on this disease. In a population-based study, Hernandez et al.60 used SEER and the ‘National Program 
for Cancer Registries’ data from 1998–2003 to estimate the incidence of invasive penile cancer in the U.S. During this 
time period, a total of 4967 cases of histologically confirmed invasive SCC of the penis were diagnosed. The annual 
incidence rate was estimated at 0.81 per 100,000 men. They also reported that the annual incidence increased steadily 
with age (RR = 8.03; 95% CI: 7.25 – 8.89, for 50-59 years vs. <50, and RR=18.48; 95% CI: 16.81-20.33, for 60-69 
years vs. <50). Whites and African-Americans did not have significantly different incidence rates. Pacific Islanders 
had lower incidence rates (RR= 0.45; 95% CI: 0.35 – 0.58, vs. Whites), and Hispanics had higher incidence rates 
(RR=1.72; 95%CI: 1.56 – 1.88, vs. non-Hispanics). Similarly, the incidence rate was 16% higher in those counties 
where ≥ 25% of the population was living at the poverty level compared to those counties where ≤10% of the 
population was living at the poverty level. The incidence rates were also higher in areas where fewer men had 
completed high-school.60  
The single most important and preventable cause of penile cancer is HPV. It is estimated that over 50% of 
the penile cancer is caused by HPV with the main types being HPV 16 (in 60% cases) and HPV 18 (in 15% cases).57 
HPV causes two types of genital lesions in men, condyloma (genital warts) and PeIN (penile intraepithelial 
neoplasia).61 History of condyloma is associated with a 3-5 fold increased risk of penile cancer.62 Dillner et al.63 
conducted a systematic review to describe the etiology of SCC of the penis and found that between 70 and 100% of 
PeIN cases were positive for HPV DNA, and over 50% of the invasive penile cancer tumors were positive for HPV 
DNA. The review also reported that more sensitive methods of HPV sequencing (i.e., PCR), compared to less sensitive 
methods (i.e., Southern Blot Hybridization assays), had higher rates of HPV detection in PeIN (5-48% vs. 17-82%). 
HPV 16 was the most frequently detected type.63 Other risk factors for SCC of the penis are: i) phimosis (non-
retractable foreskin);64 ii) lack of circumcision, found associated in ecologic data; iii) smoking, consistently 
independently associated in a dose-response manner (3-fold risk for current vs. never smokers);65, iv) number of 
lifetime partners, with a 3-fold increased risk for ≥ 30 lifetime partners;60 and v) history of condyloma, associated with 
a 3-5 fold increased risk.63,65 Based on SCC histology, HPV prevalence is higher in purely basaloid forms (75%) of 
the penile cancer, and basaloid and/or warty forms (47%) as compared to the keratinizing form of  penile cancer 
(11%).63 Over 94% of the HPV-positive penile carcinomas are located on the glans or coronal sulcus.60   
The role of circumcision in the prevention of penile cancer is somewhat controversial. Some studies suggest 
it is protective, others suggest that this association is confounded by other risk factors, such as sexual behavior. A 
systematic review66 of eight studies assessed the association between male circumcision and penile cancer. Three 
studies in the review found a protective effect for childhood/adolescent circumcision (summary OR = 0.33; 95% CI: 
0.13-0.83), two studies did not find any association after adjusting for phimosis, and the remaining three studies 
reported an increased risk of adult circumcision and SCC of the penis (summary OR=2.71; 95% CI: 0.93-7.94; 3 
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studies). The review concluded that circumcision is only protective if performed during childhood. Also, it is possible 
that circumcision corrects the problem of phimosis, which is an independent risk factor penile cancer. 
Another systematic review67 assessed HPV DNA distribution in invasive penile carcinoma. The review 
included 30 studies from different countries. A total of 1266 biopsy-confirmed penile carcinoma cases were included 
in the analysis. HPV DNA distribution was confirmed through PCR. The review reported that any-HPV prevalence in 
the penile SCC was (47.9%) with the highest prevalence in basaloid/warty histologic type (66.3%). Type-specific 
prevalence was (30.8%) for HPV 16, (6.7%) for HPV 6 and (6.6%) for HPV 18. In a retrospective cohort study of 216 
men with invasive penile carcinoma diagnosed between 1984 and 2008 in Sweden, Kirrander et al.68 estimated the 
overall and type-specific prevalence of HPV. Using real-time PCR, they detected HPV DNA in (82.9%) of tumor 
specimens. The majority of the tumors were infected with one type of HPV (70.4%), two types of HPV (25.7%) and 
three types of HPV (3.9%). Some studies have also assessed anti-HPV antibodies among penile cancer patients. 
Heideman et al.69 compared 83 penile SCC patients with 83 age-matched controls and found that penile SCC patients 
were 6.7 times more likely to be seropositive for antibodies against L1 capsid protein for ‘any HPV’, and 11 times 
more likely to be seropositive for antibodies against E6 and E7 viral proteins for ‘any HPV,’ (OR = 6.7; 95% CI: 2.4 
- 19) and (OR = 11; 95% CI: 3.6 – 34) respectively.  
HPV is also associated with precursors of penile cancer, namely penile intraepithelial neoplasia(PeIN).61,71 
PeIN requires careful medical attention as from 1 to 30% of PeINs can progress to invasive penile cancer.72 Based on 
the etiology, PeIN can be classified into HPV-related and HPV-unrelated.19 Microscopically, PeIN is subdivided into 
differentiated and undifferentiated PeIN. The undifferentitated type is then sudivided into basaloid, warty, and warty-
basaloid.71 Figure A1.3 shows pre-malignant penile lesions. Between 70 and 100% of the PeIN are positive for HPV 
with the highest prevalence found among basaloid, warty, and wart-basaloid forms.72 Very few studies have assessed 
the HPV distribution in PeIN. One study73 estimated the prevalence of HPV DNA in genital lesions among men and 
compared two different methods, i) swabbing the surface of the lesions, and ii) tissue biopsies. It reported the following 
prevalence estimates for different types of HPV in 10 PeIN cases: Any HPV (100% both methods); HPV 6 (30% 
biopsy, 20% swab); HPV 11 (30% biopsy, 20% swab); HPV 16 (60% both methods); and HPV 18 (10% both 
methods).  Another study74 assessed HPV distribution in eight cases of Erythorplaisa of Queyart, a rare type of PeIN, 
and detected cutaneous HPV DNA in 100% of cases.  HPV 16 DNA was detected in 88% of the cases, and DNA of 
HPV 39 and 51 were detected in 50% of the cases. One study75 conducted in France used a Southern Blot method and 
reported the following HPV prevalence for different grades of PeIN. PeIN-I (43 cases): any HPV (83.7%), HPV 6 
(33.3%), HPV 16 (38.9%) and HPV 18 (8.3%). PeIN-II (18 cases): any HPV (94.4%), HPV 6 (11.8%), HPV 16 
(58.8%) and HPV 18 (11.8%). PeIN-III (4 cases): any HPV (100%) and HPV 16 (100%).  
 
 
 
 
 
 
 
 
 
 
Figure A1.3.  Pre-malignant or in situ lesions of the penis* 
A, pseudoepitheliomatous micaceous balanitis. B, Erythroplasia of Queyrat. C, Bowenoid papulosis. *Adopted from 
Ferrandiz-Pulido et al. 72 
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Genital warts is a common STI in the U.S. and each year around one million new cases of genital warts are 
diagnosed.76 Prevalence of genital warts decreases with increasing age and the highest prevalence among men is 
recorded at ages 25-29 years.77 The ever prevalence of genital warts in the United States is estimated at 5.6% 78  Even 
though, genital warts are benign lesions, they cause considerable psychological discomfort to patients 79 The annual 
medical cost of genital warts in the U.S is estimated at $200 million 80 The duration between HPV exposure and the 
first clinical manifestation for a genital wart ranges between 3 weeks and 8 months81, and about 20-30% of genital 
warts regress over time without any treatment,82 however, the recurrence rate is also very high Sexual behavior is the 
most important risk factor for genital warts. Although genital warts are benign lesions mainly caused by HPV 6 and 
11, men with a history of genital warts are 3-5 times more likely to develop SCC of the penis compared with men 
without a history of genital warts.60,63,66 This association could be explained partially due to the common source of 
exposure (i.e., sexual contact) for both high-risk and low risk HPV. People with a history of genital warts often engage 
in sexual behaviors that increase their risk of acquiring high-risk HPV as well. In a large prospective cohort of men, 
Anic et al. 83 estimated the incidence of genital warts at 2.35 cases per 1,000 person-years, and the distribution of HPV 
DNA in genital warts was as follows: HPV 6 (43.8%), HPV 11 (10.7%) and HPV 16 (9.8%). They concluded that 
HPV 6 and 11 are the most common types of HPV detected in genital warts among men83 In another study, Chang 
and colleagues 84 assessed the HPV DNA distribution in genital warts in China, and reported a prevalence of (78.1%) 
for low-risk HPV, (41.3%), for HPV 6 (37.6%) for HPV 11 and (10.4%) for HPV 16  
In summary, some studies have assessed HPV DNA in invasive penile tumors. Few studies have examined 
HPV DNA distribution in PeIN and genital warts. In comparison to penile SCC, HPV DNA prevalence in PeIN is 
nearly doubled (70-100% vs. 50-60%). In part, this discrepancy can be explained by the notion that HPV-negative 
invasive penile cancers may arise from other cancer precursors. The majority of HPV prevalence estimates, both in 
invasive penile cancer and in PeIN, are drawn from case series and case reports. Case series are weak epidemiologic 
study designs and due to absence of a control group, they are inconclusive regarding the etiologic role of HPV in these 
lesions. Some studies were conducted 10-20 years ago. These studies may have provided underestimates of HPV 
prevalence in penile SCC because of the use of less sensitive DNA detection methods. Prospective data in this area 
are lacking. Prevalence of HPV DNA in PeIN/cancer varies in different populations and geographical areas. Some 
possible explanations for this variation could be that different populations have different sexual behaviors and other 
risk factors and that the use of different detection methods by different studies impede their comparison. Also, 
compared to PCR, Southern Blot tends to underestimate the prevalence. Very few sero-epidemiologic studies have 
assessed antibodies against HPV proteins in serum of PeIN or penile SCC patients. Although limited by the 
seroconversion rate and waning of antibodies over time, measurement of antibodies against L1 major capsid protein 
of HPV provides markers of cumulative exposure to HPV infection over time. Serologic studies could provide useful 
data on PeIN and penile cancer epidemiology There exists some limited literature assessing mucosal HPV distributions 
in penile SCC and PeIN. However, literature assessing the distribution of cutaneous HPV in penile cancer and/or PeIN 
is almost non-existent.  
 
A1.7. HPV INFECTION IN MEN (THE HIM STUDY)  
The HIM Study was a prospective study of the natural history of HPV infections in men which started in 2005 
with over 4,000 participants recruited from South Florida, U.S., São Paulo, Brazil, and Cuernavaca, Mexico.85, 86  
Participants who met following criteria were recruited to the study: i) ages between 18 and 70 years, ii) residents of 
one of the three study sites, iii) did not have plans to relocate to another place in the following 4 years, iv) were willing 
to participate in the follow-up visits every 6 months for up to 4 years, v) no previous history of penile or anal cancers, 
vi) no previous history of HIV or AIDS , vii) no current history of discharges from penis or burning sensation during 
urination and were not receiving any treatment for any sexually transmitted infections, viii) no history of imprisonment 
or homelessness in the past 6 months, ix) no history of participation in the HPV vaccine studies. Study participants 
were recruited from the general population, universities, and organized healthcare systems in three age groups: 18–30 
years, 31– 44 years and 45–70 years. In Brazil, the study was advertised through radio, television and newspapers, 
and participants were recruited from a STI clinic in Sao Paulo. In Mexico, members of a large health plan working in 
factories and military residing in Cuernavaca and Morelos were recruited. In the U.S., participants were recruited 
through brochures, flyers, posters, and advertisement in the local media from the University of South Florida and 
residence of the local communities in Greater Tampa Bay area. 85, 86 
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APPENDIX 2. SUPPLEMENT TABLES AND FIGURES 
 
 
Table A2.1. Baseline characteristics of randomly selected men compared to the entire HIM cohort   
 
Full cohort 
(n=4290) 
Sub-cohort 
(n=600) 
 
Characteristic n % n % p-valuea 
Country      
  U.S. 1426 33.24 186 31.00 0.404 
  Brazil 1442 33.61 200 33.33  
  Mexico 1422 33.15 214 35.67  
Age, years      
  18-30 2040 47.5 260 43.3 0.104 
  31-44 1646 38.3 256 42.7  
  >45 613 14.3 84 14.0  
Race      
  White 1886 44.72 271 45.70 0.529 
  Black 669 15.86 78 13.15  
  Asian 119 2.82 17 2.87  
  Native Hawaiian or Other Pacific Islander 3 0.07 0 0.0  
  American Indian, Alaska Native 81 1.92 9 1.52  
  Other 1459 34.60 218 36.76  
Ethnicity       
  Hispanic  1926 47.15 282 47.88 0.740 
  Non-Hispanic  2159 52.85 307 52.12  
Education, years       
   ≤12        2105 49.27 287 48.07 0.339 
   13-15        1207 28.25 160 26.80  
   ≥16        960 22.47 150 25.13  
Marital Status      
  Single, never married 1934 45.24 260 43.55 0.886 
  Married 1454 34.01 212 35.51  
  Cohabiting, living together 511 11.95 67 11.22  
  Divorced/separated 362 8.47 56 9.38  
  Widowed 14 0.33 2 0.34  
Smoking Status       
  Current 1038 24.20 147 24.50 0.984 
  Former  806 18.79 113 18.83  
  Never 2446 57.02 340 56.67  
Circumcision       
  No 2687 63.75 389 64.83 0.605 
  Yes 1528 36.25 211 35.17  
Sexual Orientation       
  MSW 3565 88.11 526 88.85 0.800 
  MSM 121 8.90 51 8.61  
  MSWM 360 2.99 15 2.53  
Alcohol Consumption, # drinks/month*      
  Mean (SD) 33.94  (65.15) 36.41  (69.47) 0.694 
  Median (range) 9.00  (0-480)  8.00  (0-468)  
  0           1024 24.17 141 23.90 0.790 
  1–30        1939 45.77 281 47.63  
  31-60       463 10.93 58 9.83  
  ≥61        810 19.12 110 18.64  
Number of Female Sex Lifetime Partners      
  Mean (SD) 17.06  (45.46) 19.61  (50.31) 0.417 
  Median (range) 8.00  (0-1000) 8.00  (0-700)  
  0 83 2.05 60 10.71 <0.001 
  1-3 967 23.84 126 22.50  
  4-18 1779 43.86 247 44.11  
  ≥19 1227 30.25 127 22.68  
(Continued on next page) 
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Table A2.1. (Continued)  
 
Full cohort 
(n=4290) 
Sub-cohort 
(n=600) 
 
Characteristics n % n % p-valuea 
Number of Male Sex Lifetime Partners       
  Mean (SD) 3.54 (44.31) 4.00 (42.46) 0.6450 
  Median (Range) 0.00 (0-2000) 0.00 (0-750)  
  0 3309 85.59 508 85.38 0.5630 
  1 155 4.01 29 4.87  
  ≥2 402 10.40 58 9.75  
a. For categorical variables Chi-square and for continuous variables Wilcoxon rank-sum test were used to calculate p-values. 
Significant p-value is marked in bold 
 
 
 
 
Table A2.2. Type-specific cutaneous HPV seroprevalence among men residing in the U.S., Brazil, and 
Mexicoa,b    
 
Overall  
Seroprevalence (N=598) 
U.S. 
Seroprevalence (N=184) 
Brazil 
Seroprevalence (N=200) 
Mexico 
Seroprevalence (N=214) 
Type of 
HPV 
n (%) 95% CI n (%) 95% CI n (%) 95%CI n (%) 95% CI 
Any HPV 391(65.4) [61.6-69.2] 121(65.8) [58.8-72.7] 140(70.0) [63.6-76.4] 130(60.7) [54.2-67.3] 
Any β 233(39.0) [35.0-42.9] 72(39.1) [32.0-46.2] 97(48.5) [41.5-55.5] 64(29.9) [23.7-36.1] 
β-HPV 5 46(7.7) [5.6-9.8] 12(6.5) [2.9-10.1] 30(15.0) [10.0-20.0] 4 (1.9) [0.0-3.7] 
β-HPV 8 122(20.4) [17.2-23.6] 39(21.2) [15.2-27.2] 59(29.5) [23.1-35.9] 24(11.2) [7.0-15.5] 
β-HPV 12 36(6.0) [4.1-7.9] 6(3.3) [0.7-5.9] 26(13.0) [8.3-17.7] 4(1.9) [0.0-3.7] 
β-HPV 14 34 (5.7) [3.8-7.5] 7(3.8) [1.0- 6.6] 22(11.0) [6.6-15.4] 5(2.3) [0.3-4.4] 
β-HPV 17 78(13.0) [10.3-15.8] 20(10.9) [6.3-15.4] 39(19.5) [14.0-25.0] 19(8.9) [5.0-12.7] 
β-HPV 22 41(6.9) [4.8-8.9] 12 (6.5) [2.9-10.1] 22(11.0) [6.6-15.4] 7(3.3) [0.9-5.7] 
β-HPV 23 73(12.2) [9.6-14.8] 22(12.0) [7.2-16.7] 39(19.5) [14.0-25.0] 12(5.6) [2.5-8.7] 
β-HPV 24 46(7.7) [5.6-9.8] 13(7.1) [3.3-10.8] 25(12.5) [7.9-17.1] 8(3.7) [1.2-6.3] 
β-HPV 38 83(13.9) [11.1-16.7] 26(14.1) [9.1-19.2] 42(21.0) [15.3-26.7] 15(7.0) [3.6-10.5] 
β-HPV 47 74(12.4) [9.7-15.0] 24(13.0) [8.1-18.0] 33(16.5) [11.3-21.7] 17(7.9) [4.3-11.6] 
α-HPV 27 53(8.9) [6.6-11.1] 17(9.2) [5.0-13.5] 23(11.5) [7.0-16.0] 13(6.1) [2.8-9.3] 
γ-HPV 4 185(30.9) [27.2-34.7] 61(33.2) [26.3-40.0] 75(37.5) [30.7-44.3] 49(22.9) [17.2-28.6] 
µ-HPV 1 171(28.6) [25.0-32.2] 69(37.5) [30.4-44.6] 69(34.5) [27.9-41.1] 33(15.4) [10.5-20.3] 
ν-HPV 41 56(9.4) [7.0-11.7] 14(7.6) [3.7-11.5] 24(12.0) [7.5-16.5] 18(8.4) [4.7-12.2] 
a. 600 subjects were randomly selected at baseline from HIM study to participant in the cutaneous HPV seroprevalence study. 
Seroprevalence data for 2 subjects were not available therefore they were excluded from analysis. 
b. Confidence limits were calculated using Wald (linear) confidence limits method. 
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Table A2.3. Factors independently associated with α, β, ν cutaneous HPV seroprevalence among men residing in the U.S., Brazil, and Mexicoa 
 α-HPV 27 ν-HPV 41 β-HPV 5 β-HPV 12 β-HPV 14 
Characteristics  OR AOR (95%CI) OR AOR (95%CI) OR AOR (95%CI) OR AOR (95%CI) OR AOR (95%CI) 
Country            
   U.S. 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   Brazil 1.28 1.54 (0.57 - 4.12) 1.66 1.02 (0.37 - 2.81) 2.53 4.14 (1.49 -11.49) 4.43 10.0 (2.86 - 34.93) 3.13 7.14 (2.18 - 23.4) 
   Mexico 0.64 0.46 (0.10 - 2.07) 1.12 0.53 (0.14 - 2.06) 0.27 0.35 (0.04 - 2.94) 0.57 0.21 (0.03 - 1.58) 0.60 0.40 (0.04 - 4.23) 
Age, Years           
  18-30 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
  31-44 1.29 1.27 (0.62 - 2.62) 1.06 0.89 (0.45 - 1.75) 1.68 2.09 (0.91 - 4.79) 2.66 2.64 (0.99 - 7.05) 2.37 3.83 (1.32 - 11.11) 
  45-73 1.27 1.02 (0.37 - 2.83) 1.25 0.96 (0.39 - 2.41) 1.50 1.52 (0.49 - 4.72) 3.35 2.72 (0.82 - 9.10) 3.35 5.59 (1.63 - 19.18) 
Race           
  White                               1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
  Black                               0.40 0.43 (0.14 - 1.31) 0.33 0.38 (0.11 - 1.32) 1.00 0.77 (0.31 - 1.96) 0.53 0.56 (0.17 - 1.84) 1.04 0.93 (0.31 - 2.83) 
  Asian/Am. Indian/ 
Alaska Native 
0.62 0.76 (0.16 - 3.61) 1.50 0.84 (0.18 - 3.94) 0.31 0 (NE) 0.39 0.00 (NE) 1.04 1.60 (0.31 - 8.33) 
  Other 0.55 1.37 (0.34 - 5.60) 0.84 1.18 (0.33 - 4.20) 0.18 1.17 (0.17 - 7.89) 0.28 5.19 (0.89 - 30.43) 0.35 2.60 (0.30 - 22.69) 
Education           
   ≤12        1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   13-15        0.94 0.80 (0.34 - 1.93) 1.11 1.02 (0.45 - 2.32) 0.99 1.09 (0.44 - 2.70) 1.27 1.78 (0.64 - 5.00) 2.23 3.86 (1.39 - 10.67) 
   ≥16        2.08 1.87 (0.91 - 3.86) 1.68 1.80 (0.89 - 3.63) 1.49 1.48 (0.64 - 3.41) 2.19 2.08 (0.82 - 5.25) 1.81 1.93 (0.68 - 5.50) 
Circumcision           
  No  1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
  Yes 1.25 1.30 (0.56 - 3.01) 0.59 0.56 (0.23 - 1.34) 1.63 2.66 (1.14 - 6.18) 1.20 2.40 (0.98 - 5.88) 1.32 2.63 (1.01 - 6.88) 
No. of Female LTP           
  0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
  1-3 0.65 0.78 (0.29 - 2.09) 0.61 0.61 (0.19 - 1.93) 0.85 1.20 (0.35 - 4.16) 0.79 1.21 (0.24 - 6.07) 1.46 2.06 (0.47 - 9.07) 
  4-18         0.39 0.41 (0.16 - 1.08) 1.20 1.17 (0.43 - 3.18) 0.87 0.80 (0.25 - 2.53) 1.41 1.36 (0.33 - 5.66) 1.23 1.13 (0.28 - 4.64) 
  ≥19       0.60 0.47 (0.16 - 1.34) 0.69 0.59 (0.18 - 1.93) 1.05 0.50 (0.14 - 1.75) 1.46 0.70 (0.15 - 3.24) 0.79 0.41 (0.08 - 2.04) 
No. of Male Anal LTP           
   0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
   1 0.44 0.46 (0.06 - 3.72) 0.79 0.77 (0.17 - 3.55) 1.78 1.47 (0.36 - 5.94) 0.71 0.45 (0.05 - 3.76) 0.00 0.00 (NE) 
  ≥2 3.13 1.87 (0.80 - 4.35) 1.64 1.30 (0.51 - 3.31) 3.09 1.43 (0.57 - 3.55) 3.54 1.45 (0.54 - 3.84) 3.54 1.65 (0.60 - 4.56) 
Note: OR= unadjusted OR; AOR = adjusted odds ratio; CI = confidence interval; Am.=American LTP = lifetime sex partners; signi ficant results are marked in bold 
a. Final model was selected through backward stepwise elimination with significance level of p≤0.1 for retention in the model. Country, age, race, marital status, education, smoking alcohol consumption, 
circumcision, # of female LTP, and # of male LTP were loaded to the model while forcing country and age (design factors) to stay in the model 
b. 'Any-HPV' category included men seropositive for at least one HPV genotype, and 'Any β HPV' category included men seropositive for  at least one β HPV types. 
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Table A2.3. (Continued)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 β-HPV 22 β-HPV 24 
Characteristics OR AOR (95%CI) OR AOR (95%CI) 
Country      
   U.S. 1.00 1.00 1.00 1.00 
   Brazil 1.77 1.49 (0.50 - 4.45) 1.88 3.96 (1.44 - 10.89) 
   Mexico 0.48 0.11 (0.02 - 0.58) 0.51 0.87 (0.12 - 6.14) 
Age, Years     
  18-30 1.00 1.00 1.00 1.00 
  31-44 2.34 2.56 (1.06 - 6.20) 1.61 1.46 (0.66 - 3.21) 
  45-73 3.03 3.36 (1.16 - 9.75) 1.74 1.47 (0.52 - 4.15) 
Race     
  White                               1.00 1.00 1.00 1.00 
  Black                               1.28 1.16 (0.45 - 3.04) 1.95 1.87 (0.79 - 4.41) 
  Asian/American Indian/Alaska Native 0.45 0.65 (0.08 - 5.57) 0.89 1.58 (0.33 - 7.65) 
  Other 0.54 3.67 (0.82 - 16.43) 0.46 1.61 (0.26 - 10.17) 
Education     
   ≤12        1.00 1.00 1.00 1.00 
   13-15        1.02 1.10 (0.42 - 2.85) 1.38 1.55 (0.63 - 3.84) 
   ≥16        2.04 1.72 (0.74 - 3.96) 2.33 2.43 (1.08 - 5.48) 
Circumcision     
  No  1.00 1.00 1.00 1.00 
  Yes 0.86 0.77 (0.30 - 1.97) 1.79 2.43 (1.09 - 5.42) 
No. of Female LTP     
  0 1.00 1.00 1.00 1.00 
  1-3 0.61 0.99 (0.30 - 3.31) 0.45 0.59 (0.18 - 1.94) 
  4-18         0.63 0.79 (0.26 - 2.39) 0.67 0.73 (0.26 - 2.04) 
  ≥19       0.78 0.52 (0.15 - 1.76) 0.65 0.46 (0.15 - 1.46) 
No. of Male Anal LTP     
   0 1.00 1.00 1.00 1.00 
   1 0.00 0.00 NE) 1.18 1.22 (0.25 - 5.90) 
  ≥2 4.46 2.32 (0.96 - 5.57) 4.44 2.55 (1.07 - 6.05) 
Note: OR= unadjusted OR; AOR = adjusted odds ratio; CI = confidence interval; LTP = lifetime sex partners; 
significant results are marked in bold 
a. Final model was selected through backward stepwise elimination with significance level of p≤0.1 for retention 
in the model. Country, age, race, marital status, education, smoking alcohol consumption, circumcision, # of 
female LTP, and # of male LTP were loaded to the model while forcing country and age (design factors) to stay 
in the model 
b. 'Any-HPV' category included men seropositive for at least one HPV genotype, and 'Any β HPV' category 
included men seropositive for at least one β HPV types. 
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Table A2.4. Association between grouped and type-specific cutaneous HPV seropositivity and separate 
categories of condyloma and suggestive of condyloma 
 
Condylomaa 
Suggestive of  
Condylomab 
HPV type OR 95% CI OR 95% CI 
Any-HPV   
  Seronegative 1.00 1.00 
  Seropositive 1.47 ( 0.77 - 2.84) 0.63 ( 0.33 - 1.19) 
Any β HPV   
  Seronegative 1.00 1.00 
  Seropositive 1.71 ( 1.00 - 2.95) 1.09 ( 0.59 - 2.03) 
α-HPV 27   
  Seronegative 1.00 1.00 
  Seropositive 1.39 ( 0.61 - 3.15) 1.11 ( 0.41 – 3.00) 
γ-HPV 4   
  Seronegative 1.00 1.00 
  Seropositive 1.23 ( 0.70 - 2.16) 0.76 ( 0.38 - 1.53) 
µ-HPV 1   
  Seronegative 1.00 1.00 
  Seropositive 0.97 ( 0.54 - 1.75) 0.52 ( 0.24 - 1.11) 
η-HPV 41   
  Seronegative 1.00 1.00 
  Seropositive 0.79 ( 0.32 - 1.95) 0.69 ( 0.23 - 2.01) 
β-HPV 5   
  Seronegative 1.00 1.00 
  Seropositive 0.88 ( 0.33 - 2.35) 0.93 ( 0.31 - 2.76) 
β-HPV 8   
  Seronegative 1.00 1.00 
  Seropositive 0.98 ( 0.50 - 1.95) 1.57 ( 0.79 - 3.13) 
β-HPV 12   
  Seronegative 1.00 1.00 
  Seropositive 0.84 ( 0.24 - 2.93) 0.74 ( 0.17 - 3.26) 
β-HPV 14   
  Seronegative 1.00 1.00 
  Seropositive 0.66 ( 0.15 - 2.92) 0.00 ( NE) 
β-HPV 17   
  Seronegative 1.00 1.00 
  Seropositive 1.16 ( 0.57 - 2.37) 1.28 ( 0.59 - 2.79) 
β-HPV 22   
  Seronegative 1.00 1.00 
  Seropositive 1.09 ( 0.36 - 3.28) 1.88 ( 0.67 - 5.24) 
β-HPV 23   
  Seronegative 1.00 1.00 
  Seropositive 1.12 ( 0.47 - 2.64) 1.8 ( 0.78 - 4.15) 
β-HPV 24   
  Seronegative 1.00 1.00 
  Seropositive 1.00 ( 0.28 - 3.53) 0.88 ( 0.20 - 3.92) 
β-HPV 38   
  Seronegative 1.00 1.00 
  Seropositive 0.85 ( 0.36 - 1.97) 1.16 ( 0.49 - 2.75) 
β-HPV 47   
  Seronegative 1.00 1.00 
  Seropositive 1.13 ( 0.54 - 2.38) 0.4 ( 0.12 - 1.34) 
Seropositivity to 1, 2, ≥3 HPV   
  Seronegative  1.00 1.00 
  Seropositive to 1 HPV 1.40 ( 0.68 - 2.91) 0.40 ( 0.17 - 0.92) 
  Seropositive to 2 HPV 1.87 ( 0.82 - 4.26) 0.77 ( 0.32 - 1.89) 
  Seropositive to ≥ 3 HPV 1.29  0.55 - 2.99) 0.93 ( 0.42 - 2.05) 
a. Condyloma: A lesion with koilocytes, papillomatosis, hypergranulosis, parakeratosis and dilated blood vessels. There were 
62 cases of condyloma and 352 controls. Odds ratios (OR) are unadjusted.  
b. Suggestive of condyloma: A lesion without koilocytes but with one or two of the other features associated with a 
condyloma. These lesions were most likely early condyloma that did not show complete histological features of a fully 
developed condyloma. There were 47 cases of suggestive of condyloma and 352 controls. Odds ratios (OR) are unadjusted.  
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Table A2.5. Association between cutaneous HPV seropositivity and condyloma stratified by HPV 6 or 11 
tissue DNA positivity and seropositivity to HPV 6/11.  
 
Condyloma 
Tissue DNA Positive for HPV 6/11 
Condyloma 
Seropositivity to  HPV 6/11 
HPV type OR (95%CI)a OR (95%CI)b 
Any-HPV    
  Seronegative  1.00 1.00 
  Seropositive  0.69 ( 0.28 - 1.70) 1.34 ( 0.45 - 4.05) 
Any-β   
  Seronegative 1.00 1.00 
  Seropositive  0.70 ( 0.32 - 1.54) 2.14 ( 0.81 - 5.68) 
α-HPV 27   
  Seronegative 1.00 1.00 
  Seropositive 1.23 ( 0.35 - 4.31) 1.30 ( 0.32 - 5.21) 
γ-HPV 4   
  Seronegative 1.00 1.00 
  Seropositive  0.67 ( 0.29 - 1.55) 0.64 ( 0.21 - 1.91) 
µ-HPV1   
  Seronegative 1.00 1.00 
  Seropositive  0.95 ( 0.39 - 2.33) 0.88 ( 0.29 - 2.68) 
ν-HPV 41   
  Seronegative 1.00 1.00 
  Seropositive 0.78 ( 0.21 - 2.97) 0.44 ( 0.05 - 3.67) 
β-HPV 5   
  Seronegative 1.00 1.00 
  Seropositive  1.08 ( 0.25 - 4.57) 2.28 ( 0.52 - 9.97) 
β-HPV 8   
  Seronegative 1.00 1.00 
  Seropositive 0.75 ( 0.30 - 1.88) 1.06 ( 0.35 - 3.26) 
β-HPV 12   
  Seronegative 1.00 1.00 
  Seropositive  0.12 ( 0.01 - 1.13) 1.05 ( 0.11 - 9.91) 
β-HPV 14   
  Seronegative 1.00 1.00 
  Seronegative 0.53 ( 0.03 - 8.69) 0.0 (NE) 
β-HPV 17   
  Seronegative 1.00 1.00 
  Seropositive  0.99 ( 0.36 - 2.74) 1.52 ( 0.48 - 4.79) 
β-HPV 22   
  Seronegative 1.00 1.00 
  Seropositive 0.64 ( 0.16 - 2.56) 2.28 ( 0.52 - 9.97) 
β-HPV 23   
  Seronegative 1.00 1.00 
  Seropositive 0.77 ( 0.25 - 2.37) 1.65 ( 0.47 - 5.80) 
β-HPV 24   
  Seronegative 1.00 1.00 
  Seropositive 0.12 ( 0.01 - 1.13) 2.98 ( 0.47 - 19.1) 
β-HPV 38   
  Seronegative 1.00 1.00 
  Seropositive  0.17 ( 0.05 - 0.58) 1.84 ( 0.51 - 6.55) 
β-HPV 47   
  Seronegative 1.00 1.00 
  Seropositive  1.23 ( 0.35 - 4.31) 1.63 ( 0.36 - 15.70) 
Seropositivity to 1, 2, ≥3 types    
  Seronegative 1.00 1.00 
  Seropositive to 1 types 1.46 ( 0.47 - 4.58) 1.46 ( 0.41 - 5.20) 
  Seropositive to 2 types 0.41 ( 0.13 - 1.28) 0.82 ( 0.17 - 3.86) 
  Seropositive to ≥ 3 types 0.48 ( 0.16 - 1.48) 1.73 ( 0.46 - 6.56) 
a. Condyloma were stratified by tissue D NA positivity to HPV 6/11. Condyloma negative for DNA of 6/11 were the reference group. Out of 
109 condyloma, 71 (65.14%) were positive for DNA of HPV 6/11. Odds ratios (OR) are unadjusted. 
b. Condyloma were stratified by serostatus to HPV 6/11. Seronegative for HPV 6/11 were the reference group. Out of 109 men with condyloma 
21 (19.27%) were seropositive for HPV 6/11. Odds ratios (OR) are unadjusted.  
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Table A2.6. Association between grouped and type-specific cutaneous HPV seropositivity and external genital 
lesions and controls examining interaction with seropositivity to 9-valent HPV vaccine types  
 
EGLsa 
Other than Condyloma, 
Suggestive of Condyloma 
and PeIN 
Condyloma  
And Suggestive  
of Condylomab 
All EGL 
Casesc 
Variable Beta 
Chi- 
square 
P-valuef Beta 
Chi- 
square 
P-valuef Beta 
Chi- 
square 
P-valuef 
Any-HPVd -0.849 4.998 0.025 -0.014 0.003 0.960 -0.286 1.422 0.233 
9vHPVe -0.301 0.248 0.619 0.029 0.004 0.950 -0.143 0.128 0.721 
Any-HPV*9vHPV 0.785 1.161 0.281 -0.010 0.000 0.986 0.276 0.346 0.556 
          
Any-β HPV -0.275 0.439 0.508 0.452 2.863 0.091 0.250 1.138 0.286 
9vHPV -0.085 0.034 0.854 0.140 0.176 0.675 0.021 0.005 0.943 
Any-β HPV *9vHPV 0.584 0.734 0.392 -0.334 0.483 0.487 -0.033 0.006 0.938 
          
α-HPV 27 0.857 2.473 0.116 0.403 0.816 0.366 0.503 1.724 0.189 
9vHPV 0.214 0.354 0.552 0.058 0.051 0.822 0.078 0.122 0.727 
α-HPV 27 *9vHPV -0.607 0.472 0.492 -0.410 0.331 0.565 -0.445 0.537 0.464 
          
γ-HPV 4  -0.779 2.360 0.124 0.010 0.001 0.973 -0.110 0.185 0.667 
9vHPV -0.133 0.105 0.746 0.021 0.005 0.942 -0.019 0.006 0.940 
γ-HPV 4 *9vHPV 1.094 2.170 0.141 -0.002 0.000 0.996 0.187 0.184 0.668 
          
µ-HPV1   -1.859 6.252 0.120 -0.180 0.373 0.541 -0.461 2.946 0.086 
9vHPV -0.084 0.049 0.825 0.113 0.163 0.687 0.041 0.029 0.864 
µ-HPV 1*9vHPV 1.721 3.343 0.067 -0.308 0.323 0.570 0.066 0.020 0.888 
          
η-HPV 41  -0.651 0.739 0.390 -0.083 0.038 0.845 -0.170 0.205 0.650 
9vHPV 0.116 0.112 0.738 0.093 0.137 0.711 0.082 0.142 0.706 
η-HPV 41*9vHPV 0.577 0.271 0.602 -0.786 0.777 0.378 -0.400 0.323 0.570 
          
β-HPV 5  -0.949 0.826 0.363 -0.405 0.511 0.475 -0.396 0.673 0.412 
9vHPV 0.113 0.107 0.744 -0.037 0.021 0.885 -0.004 0.000 0.985 
β-HPV 5*9vHPV 0.960 0.527 0.468 0.639 0.634 0.426 0.537 0.593 0.441 
          
β-HPV 8  -0.129 0.063 0.801 0.235 0.515 0.473 0.193 0.448 0.503 
9vHPV -0.045 0.013 0.910 0.032 0.014 0.906 0.004 0.000 0.986 
β-HPV 8*9vHPV 0.730 0.914 0.339 -0.105 0.035 0.851 0.071 0.022 0.881 
          
β-HPV 12  -12.207 0.001 0.971 -0.721 0.873 0.350 -0.711 1.195 0.274 
9vHPV -0.110 0.095 0.758 -0.033 0.017 0.896 -0.069 0.101 0.750 
β-HPV 12*9vHPV 13.748 0.002 0.967 1.057 1.003 0.317 1.535 3.173 0.075 
          
β-HPV 14  -0.037 0.001 0.973 -13.464 0.001 0.980 -0.619 0.601 0.438 
9vHPV 0.117 0.116 0.733 0.015 0.004 0.950 0.031 0.022 0.883 
β-HPV 14*9vHPV 0.458 0.113 0.737 13.090 0.001 0.980 0.544 0.287 0.592 
          
β-HPV 17  -0.610 0.648 0.421 0.520 2.013 0.156 0.296 0.764 0.382 
9vHPV 0.134 0.133 0.715 0.165 0.378 0.539 0.113 0.235 0.628 
β-HPV 17*9vHPV 0.523 0.286 0.593 -0.821 1.848 0.174 -0.437 0.699 0.403 
          
β-HPV 22  -0.368 0.120 0.729 0.609 1.344 0.246 0.491 1.052 0.305 
9vHPV 0.115 0.112 0.738 0.063 0.063 0.802 0.063 0.084 0.771 
β-HPV 22*9vHPV 0.673 0.251 0.617 -0.660 0.579 0.447 -0.437 0.340 0.560 
          
β-HPV 23  -0.764 0.531 0.466 0.783 3.367 0.067 0.443 1.170 0.279 
9vHPV 0.131 0.136 0.712 0.142 0.302 0.582 0.112 0.254 0.614 
β-HPV 23*9vHPV 0.745 0.353 0.552 -1.059 2.337 0.126 -0.654 1.132 0.287 
          
β-HPV 24  -12.186 0.001 0.977 0.205 0.088 0.766 0.092 0.022 0.883 
9vHPV 0.154 0.212 0.645 0.056 0.051 0.821 0.071 0.112 0.738 
β-HPV 24*9vHPV 11.845 0.001 0.978 -0.579 0.296 0.586 -0.476 0.262 0.608 
(Continued on next page) 
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Table A2.6. (Continued)          
 
EGLsa 
Other than Condyloma, 
Suggestive of Condyloma 
and PeIN 
Condyloma and 
Suggestive of Condylomab 
All EGL 
Casesc 
Variable Beta 
Chi- 
square 
P-valuef Beta 
Chi- 
square 
P-valuef Beta 
Chi- 
square 
P-valuef 
β-HPV 38  0.497 0.879 0.349 0.176 0.182 0.669 0.228 0.412 0.521 
9vHPV 0.241 0.445 0.505 0.099 0.147 0.701 0.114 0.260 0.610 
β-HPV 38*9vHPV -0.577 0.444 0.505 -0.513 0.564 0.452 -0.500 0.747 0.388 
          
β-HPV 47  -0.729 0.931 0.335 -0.478 1.044 0.307 -0.468 1.381 0.240 
9vHPV 0.187 0.288 0.591 -0.041 0.025 0.875 0.018 0.007 0.935 
β-HPV 47*9vHPV 0.170 0.024 0.877 0.552 0.663 0.415 0.338 0.323 0.570 
          
Seroactivity to 1 HPV -0.688 2.531 0.112 -0.262 0.606 0.436 -0.466 2.708 0.100 
Seroactivity to 2 HPV -1.412 3.314 0.069 0.304 0.633 0.426 -0.103 0.090 0.764 
Seroactivity to ≥ 3 HPV -0.843 2.037 0.154 0.115 0.091 0.763 -0.126 0.146 0.702 
9vHPV -0.301 0.248 0.619 0.029 0.004 0.951 -0.143 0.128 0.721 
Seroactivity to 1 HPV*9vHPV -0.283 0.079 0.778 0.208 0.105 0.745 0.268 0.231 0.631 
Seroactivity to 2 HPV *9vHPV 1.399 1.532 0.216 -0.317 0.189 0.663 0.089 0.020 0.888 
Seroactivity to ≥3 HPV *9vHPV 1.290 2.034 0.154 -0.111 0.027 0.870 0.301 0.273 0.601 
a. This category is also referred to as ‘other EGL cases’ included different other diagnoses i.e. molluscum contagiosum, intradermal nevus, 
fibroepithelial polyp (skin tag), chronic balanitis, genital melanotic macule, psoriasiform dermatitis, lichenoid tissue reaction, and acute 
mucositis.  
b. Condyloma: A lesion with koilocytes, papillomatosis, hypergranulosis, parakeratosis and dilated blood vessels. Suggestive of condyloma: A 
lesion without koilocytes but with one or two of the other features associated with a condyloma. These lesions were most likely early condyloma 
that did not show complete histological features of a fully developed condyloma.  
c. This category included all pathological diagnoses of EGLs. 
d. Any-HPV variable included seropositivity to at lease of the 14 cutaneous HPV, β types: 5, 8, 12, 14, 17, 22, 23, 24, 38, and 47, α type 27, γ 
type 4, µ type 1, and ν type 41 assessed in this study. 
e. 9vHPV variable included seropositivity to at least of the 9-valent HPV (9vHPV) vaccine types: 6, 11, 16, 18, 31, 33, 45, 52, and 58.  
f. Logistic regression was used to obtain Wald Chi-square and p-values. Reference categories included seronegative for each HPV types and 
control group. P-values for interaction terms are shaded and significant p-values are highlighted in bold.  
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Figure A2.1. Seroprevalence of grouped and type-specific cutaneous HPV at baseline of men residing in the 
U.S. Brazil and Mexico 
Any-HPV variable was created if a persons tested positive for ≥1 of the 14 cutaneous HPV types included in this 
study, he was considered seropositive for any-HPV. Any-β variable was created if a person tested positive for ≥ 1 of 
the 10 beta HPV types included in this study, he was considered seropositive for any-β HPV. P-value is from Chi-
square test. Except for ‘any-HPV’ category, seroprevalence significantly differed (p<0.05) by country in all other 
categories. * Denotes significant p-value. 
 
 
 
 
 
 
 
 
 
 
65.8
39.1
6.5
21.2
70
48.5
15
29.5
60.7
29.9
1.9
11.2
0
10
20
30
40
50
60
70
80
Any HPV Any β β-HPV 5 β-HPV 8
Se
ro
p
re
va
le
n
ce
 %
USA
Brazil
Mexico
*
*
*
 
 
89 
 
 
Figure A2.2. Seroprevalence of type-specific cutaneous HPV at baseline of men residing in the U.S. Brazil and 
Mexico 
P-values is from Chi-square test. Seroprevalence for all individual HPV types significantly differed (p<0.05) by 
country. * Denotes significant p-value. 
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Figure A2.3. Seroprevalence of type-specific cutaneous HPV at baseline of men residing in the U.S. Brazil and 
Mexico 
P-values is from Chi-square test. Seroprevalence for all individual HPV types significantly differed (p<0.05) by 
country. * Denotes significant p-value. 
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Figure A2.4. Seroprevalence of type-specific cutaneous HPV at baseline of men residing in the U.S. Brazil and 
Mexico 
P-values is from Chi-square test. Seroprevalence for γ-HPV 4 and µ-HPV 1 significantly differed (p<0.05) by country. 
* Denotes significant p-value. 
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